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The Adenosine A1 receptor (A1AR) and metabotropic glutamate subtype 5 (mGluR5) 
receptor are class A G protein-coupled receptors (GPCRs) which have been implicated 
in disease pathologies such as neurodegenerative disorders, inflammation, cardiovascular 
and pain disorders. Fluorescent ligands are invaluable tools for probing and 
understanding the expression, localisation and receptor-ligand interactions of A1AR and 
mGluR5. However, the development of fluorescent ligands with high affinity and 
selectivity for these receptors has been challenging. The development of covalent, 
clickable ligands for the A1AR and mGluR5 is an attractive concept whereby a ligand 
first covalently binds to the receptor via a chemoreactive group of the ligand and can then 
undergo a click reaction with a fluorophore, thus labelling the receptor.  
Two series of A1AR ligands were designed based on the xanthine scaffold with a 
bicyclic-ring at the C8 position which was guided by docking studies using the A1AR 
crystal structure. A covalent arm consisting a fluorosulfonyl group was placed at the 
xanthine N1 position. Corresponding sulfonic acid derivatives were also synthesised as 
reversible analogues. An azide or terminal alkyne ‘click’ handle connected via linker of 
varying length and type was installed from the bicyclic-ring, for ‘clicking’ with a 
fluorophore with a complementary clickable partner in situ by the azide-alkyne Huisgen 
cycloaddition to form a 1,2,3-triazole.  
Out of the 14 ligands biologically evaluated, the highest affinity covalent 
clickable A1AR ligand was 3.6 ((hA1AR pKi = 8.81 ± 0.24 (1.6 nM), chapter 3) 
containing a hexyne clickable linker, which was also found to act as A1AR antagonist. 
Covalent clickable ligands in chapter 2 and 3 were shown to bind irreversibly to hA1AR. 
Covalent clickable ligand 3.6 was docked in the A1AR crystal structure with the 
chemoreactive fluorosulfonyl group covalently binding to residue Y271. Assays of 
ligand 3.6 and other closely related analogues at other AR subtypes showed moderate 
hA1AR selectivity, which was suggested to be due to the covalent interaction of the 
fluorosulfonyl group with Y271 which is conserved in A1AR, A2AAR and A3AR. 
Covalent clickable A1AR ligands consisting of the clickable azide (2.24 and 3.1) and 
alkyne (3.6) linkers were ‘clicked’ with a Cy5.5 fluorophore consisting a complementary 
clickable group and demonstrated covalent binding and imaging capability.  
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A library of compounds were designed based on the mGluR5 negative allosteric 
modulator (NAM) 4-(3-(6-methylpyridin-2-yl)prop-2-yn-1-ylidene)piperidin-1-
yl)(phenyl)methanone (4.10). Molecular docking was carried out to investigate suitable 
sites for the introduction of a clickable linker and a chemoreactive group. Literature 
compounds (4.10 and 4.12) and non-covalent ligands consisting of a clickable alkyne 
(4.24) or azide (4.25) linker were successfully synthesised. These ligands will be sent for 
pharmacological evaluation in due course. Incorporation of the fluorosulfonyl group into 
the series of mGluR5 ligands was attempted using PdCl2(Amphos)2 catalyst, DABSO and 
NFSI. However, these reactions were found to only work for compounds without an 
alkyne or azide functional group. A different synthetic strategy avoiding the use of a 
palladium catalyst has been suggested for future work to synthesise the fluorosulfonyl 
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Chapter 1 Introduction 
 
1.1 G Protein-Coupled Receptors (GPCR) 
G protein-coupled receptors (GPCRs) are the largest family of human membrane proteins 
consisting of about 800 distinct genes.1 GPCRs are further divided systematically into two 
overlapping classifications: classifications A-F, T and O2 according to their sequence 
homology and functional similarities or the 6 classifications based on GRAFS families3 as 
shown briefly in table 1. All GPCRs are comprised of seven transmembrane (TM) α-helices, 
three extracellular loops, three intracellular loops, an amino terminus and a carboxyl 
terminus (Figure 1.1).4 GPCRs govern a wide range of physiological processes in which they 
mediate most cellular responses to hormones and neurotransmitters as well as being involved 
in vision, olfaction and taste.5 Aberrant GPCR signalling can elicit a diversity of disease. 
Therefore, researchers often study the change in GPCR signalling to understand about 
disease pathologies. GPCRs are exploited as drug targets where approximately 34% of all 
drugs approved by the US Food and Drug Administration (FDA) are targeted at GPCRs.6  
 













C Glutamate 22 
D - - 
E - - 
F Frizzled 11 
T Taste 2 25 






Figure 1.1 General structure of a GPCR (Image taken from Latorraca et al. (2017) 
(Permission on appendix 1,  https://pubs.acs.org/doi/full/10.1021/acs.chemrev.6b00177 - 
further permissions related to the material excerpted should be directed to the ACS)4 
    
1.1.1 Discovery of GPCRs 
The understanding of GPCR structure is crucial for the creation of drugs and the lack of 3-
dimensional structures of GPCRs makes it a great challenge. Before the X-ray 
crystallography era, circular dichroism (CD) experiments were commonly used to study 
protein structures. CD studies eventually led to the first suggestion of the 7-transmembrane 
helices in the structure of rhodopsin8, which is now categorised as a Class A GPCR. In 1993, 
the breakthrough in GPCR characterisation was made when a low resolution two-
dimensional crystal projection map of rhodopsin was produced.9  The first crystal structure 
of bovine rhodopsin were obtained in 200010 which was rapidly followed by the high 
resolution structure11. Several reasons including the structural instability12, solubility of 
protein and unsuitably large size of protein-complex for nuclear magnetic resonance make 
the structure determination of GPCRs challenging.13 The use X-ray crystallography 
techniques such as lipidic cubic phase enabled crystallisation14, thermal stabilisation through 
mutagenesis15 and serial femtosecond crystallography16 resulted in the exponential 
generation of GPCR structures.  
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 GPCRs were initially studied in their inactive states by the stabilisation of antagonists 
or inverse agonists. The analysis of high conformational plasticity and heterogeneity of an 
activated GPCR state via crystallisation was challenging. However, rhodopsin (opsin) was 
successfully stabilised to provide the first insight into active-state crystal structures in 
2008.17, 18 The rhodopsin receptor in the inactive state is comprised of an apoprotein (opsin) 
and a chromophore 11-cis-retinal which are bound to  Lys 296 via a protonated Schiff base 
linkage. Photon absorption by the chromophore 11-cis-retinal then led to the isomerisation 
to the trans-isomer of retinal. This process led to the deprotonation of retinylidene Schiff 
base linkage and generated the active G-protein-binding metarhodopsin II state.19, 20 The 
active-state crystal structures of adenosine A2A receptor (A2AAR)
21, 22 and β2 adrenergic 
receptor (β2AR)
23, 24 were later stabilised and solved. Additionally, the revolution in cryo-
electron microscopy (cryo-EM) in 2017 set the stage to determining active GPCR crystal 
structures.25 Years after the first discovery of GPCRs, more than 370 crystal structures of a 
total of 70 individual receptors have been solved.26 This includes crystal structures in human 
GPCR classes A, B, C and F while none are yet to be produced in class A orphan and B1 
Adhesion GPCRs.26 As of 2020, at least one crystal structure is available for 46 of the 103 
GPCRs that are targeted by approved drugs.26 
 
1.1.2 GPCR signalling 
The successful structure elucidation of many GPCRs has revealed important information 
related to the arrangement of TM domains, location of orthosteric, allosteric, bitopic and 
biased ligand binding sites, homo- or heterooligomerisation of receptors and structural 
rearrangements involved in conformational changes upon GPCR activation or 
inactivation.27, 28 As more 3-dimentional information of GPCRs was obtained, interaction at 
the molecular level was also elucidated. For instance, the oligomeric complex structures of 
β2AR coupled to Gs-protein
23 and β-arrestin 129, A2AAR complexed with mini-Gs protein
30 
and glucagon-like peptide 1 receptor (GLP-1R) in complex with Gs-protein
31 were studied 
and the functional importance of these receptors was able to be better understood.  
 With the ligand binding sites of receptors being uncovered, ligand binding strategies 
can be developed and further inform about the function of receptors. GPCRs are essential 
tools for the cell to transduce both extracellular and intracellular signal to produce cellular 
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responses. GPCRs can be activated by binding of both naturally produced (endogenous) or 
externally administered (exogenous) ligands. Small molecule ligands, one type of chemical 
tool to study GPCR, can be divided into agonists, partial agonists, antagonists, inverse 
agonists and allosteric modulators. A full agonist activates a GPCR and produces its 
maximum response. Upon binding of an agonist, specific conformational changes occur 
within the TM domain of a receptor will subsequently change the conformation of the 
intracellular region. This activation of GPCRs initiates complex ligand-specific signalling 
cascades either by coupling to a G protein or via a G protein-independent process (G protein-
coupled receptor kinase-mediated phosphorylation and arrestin coupling).  
 G proteins are a heterotrimeric complex which is divided into α-, β- and γ-subunits. 
The α-subunit is further divided into 4 different subfamilies. Despite the large collection of 
GPCR genes found in the human genome, only 4 major G protein families (Gs, Gi, Gq and 
G12/13) have been categorised based on sequence homologies (Table 2).
32 
 
Table 2 Gα-subunits of G proteins classified into 4 main groups 
G-protein family α-subunit 
Gi-family 








Gq αq, α11, α14, α15, α16 
G12/13-family 





In one signalling pathway, the activation of GPCR activates the heterotrimeric G 
protein to bind with the receptor (Figure 1.2). This activated receptor induces a 
conformational change in the α-subunit, causing the guanosine diphosphate (GDP) originally 
bound to the α-subunit to dissociate. Guanosine triphosphate (GTP), which is abundant in 
the cytosol, can readily bind in the place of the GDP. The binding of GTP causes a further 
conformational change on the G protein, activating the G protein and dissociating the α-
subunit from the βγ-subunit. These subunits can individually regulate the activities in the 
target cell which will relay signal for other components in the signalling cascade. The GTP-
bound α-subunit modulates adenylyl cyclase which governs cyclic adenosine 
monophosphate production (cAMP). Eventually, the α-subunit hydrolyses the bound GTP 
to GDP which inactivates the subunit. The inactivated α-subunit reforms with the βγ-subunit 
complex which turns off other downstream events.33, 34 The other GPCR signalling pathways 
are not described in depth in this Thesis. In Chapters 2 and 3, only the cAMP G protein-




Figure 1.2 A general schematic diagram of ligand mediated GPCR signalling (Image taken 
from Stateczny et al. 2016)35 (Permission in appendix 2). 1) The inactive state of a GPCR, 
2) Agonist ligand binding to GPCR induces conformational changes and GTP readily 
displacing GDP and 3) The dissociation of the α-subunit of G protein from the βγ-subunit 




Partial agonists stimulate the receptor to a maximum level that is less than the 
maximal activation of the endogenous agonist. An antagonist competes with the agonist for 
the binding site and inhibits the binding and action of the agonist without changing the 
dynamic conformational equilibrium of the receptor. An inverse agonist induces a 
pharmacological response opposite to that of the agonist. Allosteric modulator, upon binding 
to an allosteric site of a receptor without the presence of an agonist does not affect the 
response of the system while intensifying (or reduces) the response of a receptor-bound 
primary agonists. Allosteric ligands are ligands that bind at the allosteric site and exert its 
effects without the orthosteric ligand present.  
 
1.2 Adenosine receptors 
1.2.1 Adenosine receptor discovery and classification  
Adenosine receptors (ARs) are class A GPCRs that are activated by the endogenous ligand, 
adenosine. There are 4 AR subtypes which are the adenosine A1 (A1AR), adenosine A2A 
(A2AAR), adenosine A2B (A2BAR) and adenosine A3 (A3AR) receptors. The existence of AR 
was first suggested by Gubareff and Sleator36 by the effect of caffeine blocking the actions 
of adenosine in heart tissue. Following that, studies of adenosine analogues on the 
cardiovascular effect carried out by Cobbin et al.37 strongly suggested the presence of a 
receptor specifically for adenosine and their analogues. It was Calker and co-workers who 
demonstrated the presence of two effects mediated by adenosine through two different types 
of receptor that led to the identification of A1AR and A2AR
a.38 Considerable efforts on 
purifying A1AR and A2AR were made but insufficient for protein sequencing. In 1989, 
Libert et al.39 finally identified several novel members of the GPCR family through screening 
of the canine thyroid library. These receptors were then identified as A1AR
40 and A2AAR
41. 
The encoding of subtype A2BAR
42 and A3AR
43-46 followed shortly after. There are a number 
of A2AAR crystal structures published from 2008.
47, 48 In addition, three A1AR crystal 





a rA2AR referred to the historical adenosine A2 receptor before the identification of subtype A2AAR and A2BAR 
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1.2.2 Adenosine A1 receptor 
1.2.2.1 Adenosine A1 receptor expression and signalling 
The A1AR is highly expressed in the brain (cortex, hippocampus, and cerebellum), spinal 
cord, eye, adrenal gland and atria while being moderately present in the skeletal muscle, 
liver, kidney and adipose tissue.52 It is also found in low level in the lungs and pancreas.52 
A1AR was subdivided from other AR subtypes based on its inhibitory effect on adenyl 
cyclase.38 It couples to Gi protein and follows with series of diverse signalling pathways such 
as the activation of K+ channels, inactivation Ca2+ channels and activation of phospholipase 
C (PLC) leading to the increase in levels of calcium and inositol-1,4,5-triphosphate (IP3).
53-
56 These secondary messenger responses ultimately inhibit different excitatory 
neurotransmitters that include glutamate, serotonin, dopamine and acetylcholine.57 
 
1.2.2.2 Roles and challenges of Adenosine A1 receptor as drug target 
A1AR influences a wide range of physiological processes throughout different parts of the 
body, for example, the control of heart rate58, renal blood flow59, lipolysis60, insulin and 
glucagon release61 and sleep62. Additionally, A1AR mediates its effect during more extreme 
conditions (heavy exercise, high altitude or other unusually high activity in the pathways of 
the nervous system) such as the inhibition of neurotransmitter release, reduced respiration 
and analgesia.63, 64  
 Since adenosine receptors are involved in many roles and are expressed throughout 
the body, selective drug targeting of Ars for a particular conditions can prove challenging.65 
Aberrant signalling in A1AR is largely associated with fluctuations in adenosine levels in the 
body, therefore, measurement of adenosine levels is another crucial strategy to understand 
the biology and pharmacology of the entire AR system. It has been shown that this is not an 
easy task as the short half-life of adenosine has prevented efficient adenosine quantification. 
Furthermore, adenosine sampling can rapidly change the adenosine level in matter of 
seconds.66 
 A1AR has been implicated in many disease pathologies related to inflammation and 
the central nervous, respiratory and cardiovascular systems.67 High affinity A1AR ligands 
have been developed to target A1AR, however, selectivity over other AR subtypes and the 
complex adenosine signalling proved that it was challenging. As an example, clinical trials 
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of A1AR agonists for heart disease failed because of the dose-limiting factor.
68 Additionally, 
the A1AR antagonist, Rolofylline, developed as a diuretic caused side effects including 
stroke and seizures.69, 70 
Various potential alternative therapeutic approaches to target ARs include allosteric 
enhancers and signalling pathway-biased drugs.71 The recent generation of active and 
inactive A1AR crystal structures has also provided a clearer view that can assist in rationale 
design and drug discovery to improve subtype selectivity51, 72, 73. It is also worth noting that 
A1AR probing with fluorescent ligands in in vitro and in vivo has been a constant interest 
that has had a major contribution to the understanding of A1AR receptor localisation, ligand-
receptor interaction and signalling that may be useful in disease pathologies.74 The use of 
fluorescent ligands as chemical tools are further discussed in section 1.5.2.  
 
1.2.3 Crystal structures of Adenosine A1 receptor 
High resolution crystal structures of the A1AR are necessary to provide information into its 
complex structural and functional diversity. Recently, the first crystal structure of A1AR, in 
its inactive form, was solved.72 The 3.2 Å resolution receptor complex (PDB ID: 5UEN) 
bound to a covalent antagonist (DU172, 1.1) (Figure 1.3) was generated in a lipid cubic 
phase and the A1AR was crystallised in a two-receptor (chain A and chain B) mode per 
asymmetric unit in parallel orientations.  
The authors overlay the A1AR crystal structure (PDB ID: 5UEN, Figure 1.4a) with 
the crystal structure of A2AAR bound with ZM241385 (PDB ID: 4EIY, Figure 1.4b). The 
extracellular portion of both A1AR and A2AAR was found to differ considerably on TMs 1, 
2, 3 and 7. The extracellular loop 2 (ECL2) conformation of A1AR and A2AAR was found 
to differ strikingly. The A1AR residues (N148 to S161) of ELC2 forms a longer helix than 
the A2AAR (K150 to G158), extending the ECL2 of A1AR away from the TM regions.
72 
Despite the different orientation of the xanthine ring of 1.1 (on A1AR) to the triazolo-triazine 
of ZM241385 (1.2) (on A2AAR), the main interactions to anchor these ligands such as the π-
stacking interaction with F171 on A1AR (F168 on A2AAR) and a bidentate hydrogen bonding 






Figure 1.3. Ligands used in the generation of A1AR crystal structures: a) DU172 (1.1) (PDB 
ID: 5UEN); b) PSB36 (1.3) (PDB ID: 5N2S); and A2AAR crystal structure: ZM241385 (1.2) 




Figure 1.4. A) Crystal structure of A1AR bound with DU172 (1.1) (PDB ID: 5UEN); B) 
crystal structure of A2AAR bound with ZM241385 (1.2) (PDB ID: 4EIY). A1AR shown as 
purple ribbon. DU172 (1.1) shown as yellow sticks. A2AAR shown as pink ribbon. 
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ZM241385 (1.2) shown as pink sticks. Nitrogen atoms shown as blue. Oxygen atoms shown 
as red. 
 
This has shown major structural differences in the orthosteric ligand binding pocket 
between the A1AR and A2AAR which could contribute to subtype selectivity for AR ligands. 
The hydrophobic pocket formed by residues M177, L253 and T257 in the A1AR around the 
cyclohexane group of 1.1 is inaccessible in the A2AAR because the M270 (T270 in A1AR) 
points into the binding pocket and limits the access to the cavity. The wide cavity and an 
open-arrangement of extracellular domains of A1AR suggested the presence of a secondary 
pocket, however, its purpose has not been unravelled.72  
 Another A1AR crystal structure complexed in an inactive state was solved in 2017. 
Cheng et al. successfully described the structure of A1AR complexed with the reversible 
ligand PSB36 (3) (Figure 1.3) at 3.3 Å (PDB ID: 5N2S).73 The crystal structures of both 
inactive A1ARs are highly similar with the most prominent differences at the extracellular 
ends of TM1 and TM2 (Figure 1.5). A1AR-DU172 complex moved out more from the central 
axis at TM1 and TM2 compared to A1AR-PSB36. It was suggested that the benzene 
sulfonate covalent moiety of DU172 was responsible for this dissimilarity and therefore 
generated a larger pocket size in the A1AR-DU172 complex.
72 It was reported that the alkyl 
group at N1 and bulky substituent at C8 of the xanthine core of both ligands 1.1 and 1.3 were 
located at hydrophobic pockets created by residues T270, L253, T257, M177, W247, L88, 
M180 of A1AR and these hydrophobic pockets are less accessible in the A2AAR, therefore, 












Figure 1.5. Overlapping inactive crystal structures of A1AR-DU172 and A1AR-PSB36. 
A1AR shown as purple ribbon. DU172 (1.1) shown as pink sticks. PSB36 (1.3) shown as 
yellow sticks. Amino acid residues from A1AR are shown as purple sticks. Nitrogen atoms 
shown as blue. Oxygen atoms shown as red. 
 
 A PSB-A2AAR (PDB ID: 5N2R) (Figure 1.6B) crystal structure was also reported 
along with the PSB-A1AR (PDB ID: 5N2S) (Figure 1.6A) crystal structure.
73 The authors 
compared 1.3 binding on both the A1AR and A2AAR, and found that the orthosteric binding 
pocket between the A1AR and A2AAR are highly conserved. However, four residues showed 
marked differences including V62 (A59 on A2AAR), N70 (S67 on A2AAR), E170 (L167 on 
A2AAR) and T270 (M270 on A2AAR).
73 The authors further confirmed the contribution of 
these four residues on the selectivity preference of PSB on A1AR and A2AAR by 
mutagenesis. However, only T270 (M270 on A2AAR) has significant effect on the binding 
affinity of 1.3 which agreed to the finding mentioning the importance of residue T270 (M270 





Figure 1.6. A) Crystal structure of A1AR bound with PSB36 (1.3) (PDB ID: 5N2S); B) 
crystal structure of A2AAR bound with PSB36 (1.3) (PDB ID: 5N2R). A1AR shown as purple 
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ribbon. PSB36 (1.3) shown as yellow sticks. A2AAR shown as pink ribbon. Nitrogen atoms 
shown as blue. Oxygen atoms shown as red. 
 
 An A1AR structure complexed with adenosine and heterotrimeric Gi2 protein was 
determined very recently using Volta phase-plate cryo-EM (PDB ID: 6D9H).51 This success 
demonstrated the use of Volta phase-plate cryo-EM technique in solving active state protein 
structures which is otherwise commonly carried out with X-ray crystallography techniques. 
One of the key features in this structure was the absence of the large binding cavity (at the 
orthosteric site) in the activated A1AR compared to the inactive structure of 1.1 bound A1AR 
(PDB ID: 5UEN). This is due to the inward movement of TM1 and TM2 of A1AR upon 
activation which shrunk the orthosteric site of A1AR.
51   
 
1.3 Metabotropic Glutamate Receptor (mGluR) 
1.3.1 Metabotropic glutamate classifications and functions 
mGluRs are class C GPCRs which consists of 8 receptor subtypes that can be subdivided 
into 3 groups: i) Group I which consists of mGluR1 and mGluR5, ii) Group II which consists 




Table 3. Classification of mGluR and its function 
Family Receptors Function (upon activation) 
Group I mGlur1 Increases [Ca
2+], DAG and IP3 
 mGlur5  
Group II mGlur2 Decreases [Ca
2+] and cAMP 
 mGlur3  
Group III mGlur4 Decreases [Ca
2+] and cAMP  
 mGlur6  
 mGlur7  




The endogenous ligand glutamate acts as a neurotransmitter and is the main 
excitatory neurotransmitter in the vertebrate nervous system.76 mGluRs are one of the three 
major receptors (along with α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
receptor (AMPA) and N-methyl-D-aspartate receptor (NMDA)) known to biochemically 
interact with glutamate. mGluRs are distributed broadly throughout the CNS and localised 
in both synaptic and post-synaptic cells. They can be found in neurons and glia in most parts 
of the brain.77 The amino acid L-glutamate acts as the main neurotransmitter to activate 
mGluRs. Upon activation, Group I mGluRs positively couple to phospholipase C (PLC) and 
stimulate the production of diacylglycerol (DAG) and IP3 (Figure 1.7). Group I mGluRs 
couple to intracellular Ca2+ signalling because the production of IP3 subsequently promotes 
the release of Ca2+ from intracellular stores to increase Ca2+ concentration in the cytosol. 
DAG is lipophilic, and remains in the membrane to further activate protein kinase C (PKC). 
Group II and III are negatively associated with adenylate cyclase and upon receptor 
activation decrease cAMP production. The detailed physiological roles of mGluRs are 






Figure 1.7 A schematic diagram of general downstream signalling pathways upon activation 
of Group I, II and III mGluRs (Image taken from Pereira et al. 2017 – under Creative 
Commons Attribution License which permits unrestricted use and redistribution).83 
 
1.3.2  Structural features 
mGluRs consist of a large hydrophilic extracellular domain named the Venus Flytrap 
Domain (VFD), a cysteine-rich domain (CRD), a 7-transmembrane (7-TMD) domain and a 
C-terminal cytoplasmic domain of variable length.84 Unlike other GPCRs where the 
endogenous agonist binds at the 7-TMD, agonists of mGluRs (for example glutamate) bind 
at the VFD. The VFD is made up of approximately 500-600 amino acid residues and forms 
the orthosteric binding site for the endogenous ligand glutamate and other orthosteric ligands 
such as FP429 (mGluR4 agonist) and BnAPDC (mGluR8 partial agonist). There are a total 
of twenty one cysteine residues found which are conserved in all mGluRs.85 Nineteen of the 
cysteine residues are located in the extracellular space while nine of them can be found on 
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the N-terminal portion of the extracellular CRD.86 O’Hara et al. showed in a molecular 
modelling study that the extracellular domain of mGluRs is put together by two globular 
domains with the presence of a hinge region.87 Upon binding of glutamate or other 
orthosteric ligands to one or both of the orthosteric binding sites in the VFD(s), the two 
VFDs in the extracellular region dimerise and induce large conformational changes.88 The 
dimerisation of VFDs can happen in either one of the three states: open-open, closed-open 
and closed-closed (Figure 1.8). The inactive open-open conformation is stabilised by 
antagonists while both the closed-open and closed-closed conformations are caused by the 
binding of ligand to one or both the protomers.  
 The CRD connects the VFD to the 7-TMD. The conformational changes caused by 
ligand binding at the VFD will signal changes to the 7-TMD via the CRD. Despite having a 
7-TMD, mGluRs have a low sequence homology as class A GPCRs. In addition, the 7-TM 
helices of mGluRs have extracellular and intracellular loops of different sizes, and different 
sequence homologies to GPCRs of other classes. Therefore, the intracellular loops and 
carboxyl terminal of mGluRs are suggested to play different roles in G protein coupling than 
class A GPCRs.89, 90 The 7-TMD of mGluRs binds with allosteric modulators as discussed 
in Chapter 4.91, 92  
 
 
Figure 1.8 Three main states of VFDs dimerisation: open-open, closed-open and closed-
closed (image taken from Niswender & Conn (2010) – under Free PMC Article license 
where it is freely available for public use).93 
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1.3.3  Metabotropic glutamate receptor subtype 5 (mGluR5) 
1.3.3.1 mGluR5 expression and signalling 
mGluR5 is highly expressed in the hippocampus and amygdala of the forebrain. In addition 
mGluR5 can also be found abundant in neurons
94, astrocytes95, hepatocytes96, melanocytes97, 
osteoblasts98, fibroblasts99 and stem cells100, 101. mGluR5 functions mainly as excitatory
76 and 
is located predominantly near the (perisynaptic) postsynaptic membrane.102 
 In general, the activation of mGluR5 by glutamate will trigger the coupling to 
Gαq/Gα11 and activates PLCβ. This process causes the hydrolysis of phosphoinositide and 
produces IP3 and DAG. This transition leads to the activation of PKC.
79, 103 The signalling 
pathways of mGluR5 are discussed in further detail in several reviews.
104-108 
 
1.3.3.2 Roles and challenges of mGluR5 as drug target 
As mentioned earlier in section 1.3.1, glutamate is the major excitatory neurotransmitter in 
the brain and known to bind to mGluRs. The dysfunction of glutamate signalling at NMDA, 
mGluRs or AMPA affect the flow of physiological processes which is implicated in a wide 
range of CNS disorders such as Alzheimer’s disease, psychiatric disorders109, 110, traumatic 
brain injuries, addiction and pain disorders.111, 112 Thus, the glutamatergic system was a 
potential drug target to these underlying pathophysiological disorders. The NMDA receptor 
was initially an attractive drug target to be investigated due to studies showing its major role 
in these disorders in large group of patients.113-115 The agonist D-serine was used to target 
the NMDA receptor for the treatment of schizophrenia while antagonist ketamine was used 
for its antidepressant effects. However, the required high dosage of these drugs for the 
treatment ultimately caused excitotoxicity116, psychotomimetic effects117, addiction118 and 
cognitive decline119, 120.  
 mGluR5 was later identified as a potential drug target to regulate glutamatergic 
transmission because it possesses structural and functional similarity to the NMDA receptor 
while located in more selective regions of the brain.110 The orthosteric site of mGluR5 has 
been the focus for drug development to target CNS disorders.121 Despite the availability of 
VFD crystal structure in the early 2010s, selective ligands among group I mGluRs were 
unachievable. It was reported that the amino acid residues within 5 Å of mGluR1 and mGluR5 
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orthosteric site are 100% conserved and ultimately hampering the orthosteric ligand drug 
discovery process.122  
 Moving forward, the discovery of allosteric compounds of mGluR5 that demonstrate 
improved subtype selectivity are seen as a promising strategy.112, 123, 124 Both positive (PAM) 
and negative (NAM) allosteric modulators of mGluR5 is an active are of research for the 
treatment of CNS disorders including schizophrenia and other cognitive deficit-related 
diseases (reviewed in several articles).112, 125  
 
1.3.3.3 Crystal structures of mGluR5 
The discovery of ligands for mGluR5 has been of great interest because the receptor is 
implicated in the treatment of various disorders. However, the development of mGluR5 
ligands suffer a great deal with subtype selectivity issues as mentioned in section 1.3.3.2. 
The lack of reliable structural studies on the ligand-binding interaction hamper the 
understanding of the membrane-spanning signal transduction domain.  
A crystal structure of the human mGluR5 transmembrane domain complexed with 
the NAM mavoglurant (1.4) (Figure 1.7) was initially reported.92 The authors described the 
first comparison between each crystal structure from Class A (rhodopsin, PDB ID: 1F88)126, 
B (corticotropin-releasing factor receptor 1 (CRF1R, PDB ID: 4K5Y)
127 and C GPCRs 
(mGluR5, PDB ID: 4OO9)
92 and showed that the alignment of the intracellular halves of 
these receptors are better than the extracellular halves. Binding of 1.4 was found to be 
approximately 8 Å from the mGluR5 plasma surface.  
A crystal structure of mGluR1 in complex with the NAM 4-fluoro-N-methyl-N-[4-
[6-(propan-2-ylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]benzamide (FITM, 1.5 (Figure 1.9), 
PDB ID: 4OR2) was published earlier in the same year (2017).91 This provided the first view 
of superimposed mGluR1 (PDB ID: 4OR2) and mGluR5 (PDB ID: 4OO9) crystal structures 
to reveal subtype-selective information between the two receptors (Figure 1.8)128. FITM 
(1.5) was found to bind at an upper chamber of the allosteric site in mGluR1 while 1.4 was 
spanning both upper and lower chambers extending across a narrow linker region of the 
allosteric pocket in mGluR5 (Figure 1.10) which showed the possibility of different allosteric 
ligand binding modes across Class C GPCRs. In addition, significant mGluR1 and mGluR5 
structural conservation was found along the seven transmembrane helices. Several residues 
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were rationalised to be able to provide selectivity between the mGluR1 (S668
3.40 and 
C6713.43) and mGluR5 (P655
3.40 and S6583.43) receptors. A water molecule present at the 
bottom of the allosteric pocket was described to play a significant role in forming hydrogen 
bonding with three other residues (Y6593.44, T7816.46 and S8097.39) and rationalised that the 
disruption of this water molecule could present significant change of pharmacological effect 





Figure 1.9. Ligands Mavoglurant (1.4) and FITM (1.5) used in the generation of mGluR1 









Figure 1.10 A superimposed crystal structures of mGluR1 and mGluR5 in complex with 
FITM (1.5) (PDB ID: 4OR2)128 and mavoglurant (1.4) (PDB ID: 4OO9)129, respectively, 
showing that mavoglurant (1.4) binds deeper into the lower chamber than FITM (1.5). FITM 
(1.5) as light green colour stick. Mavoglurant (1.4) as maroon stick. Nitrogen, oxygen, sulfur 
and fluorine atom shown in blue, red, yellow and pale blue stick.  
 
 Christopher and co-workers worked on fragment and structure-based drug discovery 
and reported two inactive mGluR5 crystal structures in complex with two pyrimidine ligands 
(“ligand 14” (1.6) as reported in the article (PDB ID: 5CGC) and HTL14242 (1.7) (PDB ID: 
5CGD) (Figure 1.11)).130 The ligands were found to bind similarly to 1.4 with differences 
seen at the upper chamber of the mGluR5 allosteric site. The pyrimidine of 1.6 and 1.7 were 
able to fit the narrow linker region of the mGluR5 receptor. Meanwhile, a conserved water 
molecule reported in the earlier crystal structure (PDB ID: 4OO9) was still observed at the 






Figure 1.11 “Ligand 14” (1.6) and HTL14242 (1.7), that were used in the generation of 
mGluR5 crystal structures. 
 
 Christopher and co-workers later published two new mGluR5 crystal structures, one 
in complex with the NAM M-MPEP (1.8) (PDB ID: 6FFI) and the other with fenobam (1.9) 
(PDB ID: 6FFH) (Figure 1.12).131  The authors rationalised131 the unexpected mGluR5 
affinity gain was due to disruption of the water network and that this might be a beneficial 




Figure 1.12. Ligand M-MPEP (1.8) and Fenobam (1.9), that were used in the generation of 
mGluR5 crystal structures.  
 
The ECL2 of mGluR5 was found to interact extensively at the top part of the TMD 
receptor surface with TM1, TM2 and TM3 and resulted in the closure of the surface entry of 
mGluR5 to the allosteric binding site.
131 The same water molecule situated at the bottom of 
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the allosteric site was described in this article and found to be conserved across all different 
mGluR5 crystal structures reported thus far (Figure 1.13).
92, 130 Christopher et al. also 
describes the similar binding region of 1.8 in mGluR5 as 1.4.
131 However, there was a flip of 
residue W7856.50 into the binding site which makes the cavity much smaller. This finding 
informed the importance of having more than one crystal structure of a certain receptor to 




Figure 1.13 mGluR5 crystal structures complexed with fenobam (1.9) bound to the allosteric 
site. Carbon atom as green stick, nitrogen atom as blue stick and oxygen atom as red stick. 
Image was taken from Christopher et al. 2019.131 
 
Despite having an acetylene linker in 1.4 and 1.8, the acetylene linker was found not 
to overlay exactly in the mGluR5 crystal structure (Figure 1.14).
131 It emphasised the non-
transferable binding site conformation each ligand induces cross-docking process. The 
authors also generated a mGluR5 crystal structure complexed with 1.9 (PDB ID: 6FFH)
131 
and showed that most of the polar interactions were water mediated. It highlighted the key 





Figure 1.14 Overlay of mGluR5 crystal structures of M-MPEP (1.8) (pink sticks) (PDB ID: 
6FFI) and mavoglurant (1.4) (green sticks) (PDB ID: 4OO9) which shows the head of the 
both ligands were directed to a different position. Oxygen atoms as red sticks, nitrogen atoms 
as blue sticks and hydrogen as white stick.131 
 
 Recently, Koehl and co-worker successfully studied the structure of full-length active 
mGluR5. The authors reported both the generation of active and inactive states of mGluR5 
receptor dimer by use of cryo-EM.132 A comprehensive structural framework of the mGluR5 
activation mechanism was described. Generally, activation by agonist binding at the 
orthosteric binding site of mGluR5 leads to a compaction of the dimer interface which brings 
the CRD closer. Following that, the ECL2 of mGluR5 enables the repositioning of the rigid 
structure of the 7-TMD which then interacts with the CRD to initiate signalling. 
 All mGluR5 structures reported have put together important information regarding 
ligand-receptor interactions in the allosteric binding site. For instance, the conserved water 
molecule in all reported mGluR5 structures is important for hydrogen bonding interactions 
with the allosteric ligand, thus demonstrating the presence of hydrogen bond acceptor or 
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donator around the region is an important consideration during ligand design. With the 
multiple crystal structures of mGluR5 available, designed ligands can be docked and 
modified accordingly, for example, the introduction of a linker in a mGluR5 allosteric ligand 
extending towards the extracellular surface. The narrow middle binding region of ligands in 
mGluR5 (shown in the binding of 1.4 (PDB ID: 4OO9), 1.6 (PDB ID: 5CGC) and 1.7 (PDB 
ID: 5CGD) in mGluR5) showed limited tolerance to structure extension. This information 
collectively guides the design of covalent clickable mGluR5 ligands in this thesis (one of the 
objectives shown in section 1.7). 
  
1.4 Alzheimer’s disease (AD) and GPCRs 
1.4.1 Alzheimer’s disease 
Alzheimer’s disease is considered to be an irreversible progressive brain disorder that 
involves a decline in cognitive ability including memory, language, behaviour and 
personality which can greatly affect the ability to carry out daily activities. AD makes up to 
approximately 80% of all dementia diagnoses133 and is reported to be the fifth-leading cause 
of death of people aged 65 and above. In addition, in the United States of America it is 
projected that approximately 13.8 million people age 65 and older will develop AD by 2050 
.134  The main pathological hallmarks of AD consist of selective synaptic and neuronal loss 
in several brain regions (cerebral cortex and hippocampus), amyloid plaques (Aβ) and 
neurofibrillary tangles.135 Cholinesterase inhibitors and memantine are currently used for 
early symptomatic treatment in AD patients.136 However, to date, there are no effective 
treatment options available to halt or reverse the underlying pathology of AD137 and it could 
result in an immense social impact which potentially leads to increased economic burden to 
healthcare systems worldwide.138 There are various hypotheses reported to explain AD, 
however, in-depth literature review in this area is beyond the scope of this thesis but is further 
discussed in several review articles.139-142 
 
1.4.2 A1AR and mGluR5 proposed role in AD 
The involvement of GPCRs in AD pathology has long been suggested. However, the precise 
roles of GPCRs in AD remains unclear. The popular hypothesis for the development of AD 
involving GPCRs is the imbalance production and clearance of amyloid beta protein.143  
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 The endogenous neurotransmitter adenosine exhibits its activation effect on A1AR in 
the neuronal circuits by depression of the excitatory transmission.144 This A1AR-mediated 
inhibition mechanism of the synaptic transmission is suggested to couple with the actions of 
the excitatory glutamatergic receptors via the inhibition of presynaptic calcium influx.145-147 
Since many brain disorders are suggested to involve glutamate-associated excitotoxicity, 
A1AR was considered as a putative therapeutic target to manage brain disorders because of 
its excitatory transmission regulation ability. The activation of A1AR by adenosine showed 
long-term potentiation (LTP)148 while the continuous A1AR activation developed a reverse 
effect of long-term depression and depotentiation.149, 150  
 The A1AR and mGluR1 have been shown to act synergistically in the body.
151-154 
Alejandro and co-workers recently showed the novel interaction between A1AR and mGluR5 
along with A2AR in blood serum and derived exosomes in SAMP8 mice (an aging and AD 
model).155 In this work, A1AR and mGluR5 were found to significantly reduced with age.
155 
Other key findings reported in this article included the decrease of adenosine levels, 
significant reduction in glutamate levels and mGluR5 density with age in senescence 
accelerated mouse (SAMP8, a model for Alzheimer’s disease) serum compared to healthy 
subjects. However, the changes of A1AR with age in SAMP8 serum showed an unpredictable 
pattern and suggested this apparent finding could be a promising discovery for the 
development of AD biomarkers. Later in the year (2020), Cavaccini and co-workers 
published an article which focused on the role of astrocytes in the striatum.156 It was reported 
that the activation of mGluR5 signalling with high-frequency stimulation increases levels of 
Ca2+ in striatal astrocytes. This signalling process has been shown to be necessary for A1AR-
mediated LTD and this striatal-associated signal has just been recently implicated as a 
biomarker in AD research.157, 158 Both A1AR and mGluR5 have been heavily implicated in 
AD pathologies, however, the synergistic effect of these receptors in context of AD remained 
largely unexplored.  
 Unpublished data (generated by our collaborators in Monash University, not shown 
here) showed the presence of A1AR and mGluR5 in mouse cortical neurons and provided 
evidence of A1AR and mGluR5 crosstalk and potential heterodimerisation. It is therefore 
hypothesised that the co-modulation of A1AR and mGluR5 could potentially produce 
cognitive enhancement in context of AD. Thus, the overarching objective for this thesis is to 
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synthesise suitable probes that can be used by collaborators to study A1AR and mGluR5 in 
AD relevant models.  
 
1.5 Tools for studying GPCRs 
There are a variety of tools that are useful in studying GPCRs including chemical tools and 
biological tools (e.g. protein modification).159, 160 Chemical tools such as, but not limited to, 
radioligands, small-molecule fluorescent ligands, covalent ligands, antibodies, photoaffinity 
ligands, positron emission tomography (PET) tracers, bivalent ligands and bitopic ligands 
are invaluable in the interrogation of GPCR functions and physiological roles that potentially 
lead to novel drug development and enhanced understanding of receptor role in disease.160-
163 PET, for instance, is an imaging technique utilises chemical tool PET tracers to visualise 
metabolic and physiological processes in a patient’s body. However, there are limitations to 
this technique including high costs in handling and PET experiments, and safety concerns 
regarding radioactive chemical exposures. There are several other types of chemical tools - 
covalent ligands and fluorescent ligands are discussed in depth in the following sections of 
this thesis. 
 
1.5.1 Covalent ligands 
Covalent ligands, also known as affinity ligands or labels, are ligands that have the ability to 
form a reversible or irreversible covalent bond with the receptor (only irreversible covalent 
are described from this point). The covalent nature of the bond formed between a ligand and 
receptor has been exploited to obtain a wide range of information on structure and function 
of GPCRs.164-166 A successful and efficient covalent ligand is highly dependent on three 
aspects that include 1) the affinity and selectivity of the ligand to the target receptor, 2) the 
reactivity of the reactive group (chemo- or photo-reactive group) that is responsible for the 
covalent bond formation and 3) the proximity of the ligand’s reactive group to the 
nucleophilic amino acid residue of interest (this only applies to ligand containing the 
chemoreactive group) or the activation of photoreactive group that will bind to nearby amino 
acid residue (this only applies to ligand containing the photoreactive group).167 The high 
affinity of the ligand towards a target receptor is of importance to allow strong interaction 
or chances for ligands to occupy a specific receptor. One advantage of covalent ligands is 
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the prolonged residence time in the receptor binding site, which improves the likelihood of 
a chemical reaction between the chemoreactive ligand and an amino acid residue close by. 
At the same time, the irreversible reaction of covalent ligands can also take place with off-
target proteins and causes undesired side effects.168 If applied on the design of covalent 
drugs, this prolonged off-target covalent interactions could result in extended side effects 
which raises major safety concerns of the use of covalent drugs over non-covalent drugs. 
Therefore, the drug discovery process has constantly avoiding the drug design involving 
covalent interactions. For instance, the first targeted covalent inhibitor has only been FDA-
approved in 2013.169 This concern, however, is not a factor in the development of chemical 
tools because these compounds are designed to be used in vitro or ex vivo.   
 
 Generally, a covalent ligand consists of two components: the core structure that bind 
to the receptor binding pocket (the parent ligand) and the reactive group. The reactive group 
can then be further classified into two types: photoreactive (or photoactivatable) or 
chemoreactive. Covalent ligands are often designed to include a linker between the parent 
ligand and reactive group. This strategy is termed as the congener approach where an overall 
ligand is made up of ligand, linker and a utility group (in this case, a chemoreactive or 
photoreactive group).170-172 This approach stemmed from the design of molecular probes for 
the Class A GPCRs in the 1980s.173-175  
A photoreactive covalent ligand is a tool with an inert chemical group where, upon 
activation by ultraviolet source, a highly reactive species is generated (often a carbene or 
nitrene) that reacts instantaneously with whatever amino acid residue is closest in vicinity.176 
This is itself an advantage over the introduction of a chemoreactive group because the highly 
reactive intermediate has the ability to also form bonds with amino acid residues that are 
non-nucleophilic in nature. Thus, the ligand’s reactive group does not necessarily need to be 
positioned towards any particular amino acid residue.177 Photoreactive covalent ligands 
remain non-covalent until the irradiation with ultraviolet light takes place. However, 
photoreactive ligand use is often limited by the fact that the use of ultraviolet radiation is 
necessary for activation which may damage cell and tissue used in an assay.178   
Photolabeling with photoreactive covalent ligand was introduced in 1960s by 
Westheimer and colleagues in the mapping of an enzyme’s active site.179 A few of the most 
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commonly used photoreactive functional groups in design of GPCRs covalent ligands are 
benzophenone180-182, diazirine183, 184 and aryl azide185 (Figure 1.15). The selection among 
these functional groups are usually based on the careful consideration of their reactivity, 
stability, and size, which may largely affect the overall ligand hydrophobicity.  
 
 
Figure 1.15. Commonly used photoreactive functional groups in GPCR ligands.  
 
 A chemoreactive covalent ligand generally uses a reactive electrophilic functional 
group on the ligand that forms a covalent bond with a nucleophilic amino acid residue of the 
receptor. The biggest advantage of these reactive groups is the practicality in in vitro and in 
vivo studies where ultraviolet radiation is not involved that may harm cells and tissues of the 
test system. An efficient covalent ligand bearing an electrophilic group is made stable in the 
presence of water to avoid unwanted nucleophilic reactions in the test solution.186  
 Commonly used chemoreactive moieties in small molecule ligands targeting GPCRs 
includes Michael acceptors, alkylating or fluorosulfonylphenyls, mustards and 
isothiocyanates.167, 187 Ligands incorporating Michael acceptors such as the maleimides, 
fumarates and bicyclo[2.2.2]octa-2,5-diene-2-carbonyl usually form covalent bonds with 
receptor via Michael addition reaction with cysteine, lysine or histidine amino acid 
residues.188 Phenylsulfonyl fluorides have been used in the synthesis of irreversible A1AR 
ligands.189 The ligand DU172 1.1 bearing the fluorosulfonylphenyl was utilised to target 
tyrosine 271 of the A1AR.
50 The chemoreactive mustard class consisting of nitrogen 
mustards and 2-haloalkylamines usually contains reactive amine groups that cyclise to form 
electrophilic aziridinium ions that allows attack from a nucleophile. Although famous as 
DNA alkylating agents, there are examples of nitrogen mustards used to target an amino acid 
residue of a GPCR to form a covalent bond.190 Its reactivity is highly dependent on the 
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halogen group attached to the mustard moiety which can be fine-tuned with different 
halogens.191 Isothiocyanates have been incorporated in ligands targeting cysteine or lysine 
amino acid residues in GPCRs.192 The highly electrophilic carbon centre of the 
isothiocyanate functional group shows good stability in alcohol and water while able to react 
efficiently with amines and thiols. 
 
Table 1.4. Commonly used chemoreactive functional groups in small molecule ligands 
targeting amino acid residues in GPCRs. 
Chemoreactive 
class 
























































Isothiocyanates isothiocyanates199  cysteine 
lysine 
 
1.5.1.1 Covalent ligands for A1AR 
There have been various A1AR covalent ligands reported in the last few decades. Most of 
the covalent A1AR agonists reported were derived from adenosine. The m-DITC-ADAC 
(1.10) (rA1AR Ki = 0.867 nM ± 0.114) employs a flexible 2-(4-aminophenyl)acetic acid 
based linker attached to the N6 position of the adenosine scaffold and demonstrated covalent 
formation with rA1AR along with excellent 203-fold selectivity against A2R.  R-AHPIA 
(1.13) showed use of the photoactivatable aryl azide photoreactive functional group in 
studying animal A1AR while compounds 1.11 and 1.12 (Figure 1.16) bearing the 
chemoreactive isothiocyanate and fluorosulfonylphenyl moieties, respectively, were 







Figure 1.16. Early adenosine-based covalent A1AR agonists. 
 
 Meanwhile, the previously reported covalent AR antagonists can be divided into 
xanthine-based (1.14) and non-xanthine based. Most covalent A1AR antagonists which are 
xanthine-based involved in derivatisation of well-established 1,3-dipropyl-8-cyclopentyl 
xanthine (DPCPX, 1.15) with the chemoreactive fluorosulfonylphenyl moiety.200-202 FSPCX 
(1.16) (Figure 1.17) was synthesised and proven useful as an antagonist in probing the 
rA1AR
200 and contributed to the understanding of the pathophysiological role of A1AR.
203, 
204 A similar derivative DU172 1.1 (Figure 1.3) was later reported to be a covalent A1AR 
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antagonist189 and successfully used as the ligand present in the first A1AR crystal structure 
(PDB ID: 5UEN)50 (as discussed in section 2.4). Both ligands 1.1 and 1.16 containing the 
electrophilic fluorosulfonylphenyl moiety were shown to react covalently with tyrosine-271 
of A1AR.
72, 205 The xanthine scaffold will be discussed in further detail in chapter 2 section 
2.1. 
 Xanthine-based m- and p-DITC-XAC (1.17) was reported as covalent A1AR 
antagonist containing the chemoreactive isothiocyanate moiety.206 However, information 
was not provided regarding which amino acid residue it covalently interacted with. In 
addition, Jacobson and co-workers also described several series of covalent A1AR ligands 
based on the 8-aryl-substituted xanthine (compound numbering on xanthine 1.14 shown in 
Figure 1.17).207, 208 A1AR photoreactive antagonists have not been reported. The lack of 
photoreactive-containing A1AR ligands could be due to the successful utilisation of 








1.5.1.2 Covalent ligands for mGluR5 
Extensive efforts have focused on producing orthosteric drugs but failed due to issues with 
mGluR5 subtype selectivity. The shift to allosteric ligands was later seen as a promising route 
to target mGluR5. Covalent ligands can act allosterically. Gregory and co-workers very 
recently reported a series of first-in-class mGluR5 covalent ligands containing a “clickable” 
(which term will be discussed later section 1.6) feature to “click” with a fluorophore in-
situ.209 These ligands incorporated the photoreactive benzophenone (1.18) or azido (1.19 and 
1.20) (Figure 1.18) moiety that formed a covalent bond with the receptor upon UV-
irradiation. Benzophenone 1.18 was irradiated with UV light at 365 nm while aryl azides 
1.19 and 1.20 were irradiated with UV light at 254 nm for 3 minutes in HEK293 cells 
expressing high levels of mGluR5. It is worth noting that the shorter irradiation time for aryl 
azide carried out was to avoid severe damage to the biological system (the lower the UV-
irradiation wavelength, the more damage it can cause to the biological system).210 The 
benzophenone moiety was activated at 365 nm which comparatively limits degradation 
damage to the biological system. The authors observed high degree of non-specific labelling 
for these photoreactive ligands. Upon UV-irradiation, the benzophenone group of 1.18 is 
expected to generate a reactive triplet carbonyl state which can react with any nearby C-H 
bonds, while the aryl-azide ligands 1.19 and 1.20 are expected to generate the singlet nitrene 
which leads to covalent bonding with the receptor and/or side reactions forming undesired 
polymers.210 This explains the high-level non-specific labelling when using photoreactive 






Figure 1.18 Covalent mGluR5 allosteric ligands  
 
1.5.2 Fluorescent ligands 
Fluorescent-based imaging technologies are developing at a rapid rate and assisted the 
understanding of GPCRs. These technologies include Fluorescent Recovery After 
Photobleaching (FRAP), Fluorescence Resonance Energy Transfer (FRET), Fluorescence 
Correlation Spectroscopy (FCS), Fluorescence Polarisation (FP), Confocal Laser Scanning 
Microscopy (CLSM) and super-resolution microscopy. Fluorescent ligands are useful tools 
in facilitating drug development and studying GPCR roles and expression as they are highly 
sensitive. Real-time imaging of receptor and cellular signalling processes are often carried 
out using fluorescent ligands. These include studies examining the localisation of 
receptors211, 212, receptor trafficking and internalisation212, 213, receptor-ligand interactions 
and changes of receptor conformations.214 Fluorescent ligands, in particular containing near 
infrared fluorophores,  often find applications in the early diagnosis of disease via studying 
receptor expression215 and monitoring the changes in receptor regulation216.  
 There are three main approaches to how GPCRs can be studied using fluorescent 
microscopy technologies which include: a) receptors tagged/that can be tagged with a 
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fluorescent protein; b) use of receptor-specific antibodies which are/can be conjugated with 
a fluorophore; c) use of ligands conjugated/that can be conjugated with a fluorophore, to 
bind to a receptor (fluorescent ligand). While every approach mentioned has its advantage, 
only approach c) is further discussed in this thesis. 
 One of the various strategies to designing a fluorescent ligand is a three-component 
approach: a) parent ligand, b) linker and c) fluorophore (Figure 1.19). The design of a 
fluorescent ligand usually starts with the selection of a high affinity parent ligand for the 
targeted receptor. This is a major consideration, and even then, the binding affinity of the 
overall fluorescent ligand could be dramatically different to the starting ligand.212, 217, 218 A 
linker is often employed to provide a physical distance for the fluorophore away from the 
parent biologically active moiety. This is to prevent the fluorophore from sterically 
disrupting the binding of the overall ligand.219 For the same reason, the linker has to be 
appropriately attached at a site of the parent ligand, has a suitable length and type because it 
engages to the membrane surface of the receptor via specific and/or non-specific 
interactions.220 Finally, the selection of fluorophore is highly dependent on the targeted 
biological application. Factors including the excitation/ emission wavelength, Stokes shift, 
quantum yield, susceptibility to photobleaching and the availability of desired reactive group 
suitable for conjugation have to be considered before a fluorophore is chosen.221 Despite 
careful consideration in the design, a direct route to producing a useful fluorescent ligand is 























Figure 1.19 Three components of a congener approach to a fluorescent ligand: a) Parent 
ligand, b) linker and c) fluorophore. 
 
1.5.2.1 Fluorescent ligands for A1AR 
As discussed in section 1.5.2, fluorescent ligands are valuable tools in studying functions of 
receptor. Jacobson et al. reported the first few fluorescent ligands for the A1AR from the 
conjugation of parent ligands adenosine amine congener (ADAC, 1.21) (rA1AR Ki = 1.3 nM, 
agonist) and xanthine amine congener (XAC, 1.22) (rA1AR Ki = 1.4 nM, antagonist) to 
fluorophores including fluorescein isothiocyanate (FITC), 4-nitro-2,1,3-benzoxadizol-7-yl 
(NBD) and tetramethylrhodamine (TRITC) to produce FITC-ADAC (1.23, rA1AR Ki = 7.1 
± 0.3 nM), FITC-XAC (1.24, rA1AR Ki = 125 ± 27 nM), FITC-Gly3-XAC (1.25, rA1AR Ki 
= 96.5 ± 33.5 nM), NBD-ADAC (1.26, rA1AR Ki = 4.3 ± 0.10 nM) and TRITC-ADAC 
(1.27, rA1AR Ki = 41.6 ± 6.5 nM) (Figure 1.20).
222 The binding affinity of the fluorophore-
conjugated ADAC and XAC differed by a large margin on conjugation with different 
fluorophores, even if the starting parent ligand shows high binding affinity, thus showing 
that the design and synthesis of high affinity fluorescent ligands is a challenging task and 
can be very fluorophore dependent. However, this study demonstrated the feasibility of a 
tethering approach for the synthesis of fluorescent ligands for the ARs. 
   











 The high affinity non-selective adenosine receptor agonist 5’-N-
ethylcarboxamidoadenosine (NECA, 1.28) (Figure 1.21) was later utilised by Macchia et al. 
(1998) in the conjugation with fluorophore dansylaminoalkyl (Dansyl) (Eex = 340 nm; Eem 
= 520 nm) with a linear alkyl linker of 3 to 12 carbons long.223 The dansyl-hexyl-NECA 
(1.29, rA1AR Ki = 27 ± 3 nM; rA2AAR Ki = 4300 ± 400 nM; rA3AR Ki = 3600 ± 260 nM) 
exhibited excellent selectivity for rA1AR against other AR subtypes and showed capability 
in visualising and localising A1AR in rat cerebellar cortex.
223 However, the short excitation 
wavelength of Dansyl limits the use in biological experiments. Macchia et al. (2001) 
attempted to improve the practicality of these Dansyl-derivatives to a higher excitation 
wavelength fluorophore NBD, however, the synthesised series of fluorescent derivatives of 
NECA conjugated with NBD moiety (1.30, hA1AR Ki = 3476 ± 521 nM; hA2AAR Ki = 5096 








Figure 1.21. NECA (1.28), the selective rA1AR Dansyl-hexyl-NECA (1.29) and NBD-octyl-
NECA (1.30) fluorescent derivatives. 
 
 Following that, Macchia et al. (2002) also reported the synthesis of fluorescent 
derivatives of the moderately selective N,N,7-trimethyl-2-phenyl-1,8-naphthyridin-4-amine 
(1.31, bA1AR Ki = 17 ± 4 nM; bA2AAR Ki = 420 ± 29 nM; bA3AR Ki = 6220 nM, Figure 
1.22) to form a dansyl-conjugated derivative 1.32 (bA1AR Ki = 13 ± 2 nM; bA2AAR Ki = 
1430 ± 40 nM; bA3AR Ki = 1560 ± 36 nM) while retaining high affinity but improving 
selectivity for bA1AR against bA2AAR of the parent ligand.
224 Similarly to ligand 1.29, 
limited use was found in biological experiments due to the short excitation wavelength of 
fluorescent ligand Dansyl-analogues 1.32. 
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Middleton et al. (2007) later incorporated several red-shifted fluorophore BODIPY 
[630/650] (Eex = 625 nm; Eem = 642 nm) to produce several fluorescent NECA derivatives, 
1.33 (NECA-X-BODIPY630/650) as the representative for the series of ligands (Figure 
1.22) (pKD = 6.61 ± 0.10), while retaining the overall binding affinity of NECA (hA1AR pKD 
= 6.65 ± 0.09) on hA1AR.
225 However, these BODIPY-NECA derivatives were equipotent 
at both hA1AR and hA3AR. More efforts were undertaken to couple NECA with different 
fluorophores such as Alexa Fluor 488 (Eex = 490 nm; Eem = 525 nm), Alexa Fluor 532 (Eex 
= 532 nm; Eem = 554 nm), (Texas Red (Eex = 580 nm; Eem = 604 nm), EVOBlue (Eex = 635 
nm; Eem = 663 nm) and Cy5 (Eex = 651 nm; Eem = 670 nm) in the effort to produce selective 
and high affinity hA1AR fluorescent ligands, however, unsuccessful as the fluorescent 
ligands were either non-selective or selective for other hAR subtypes (hA2AAR, hA2BAR or 
hA3AR).
220, 226, 227  
 
Figure 1.22. A moderately selective parent ligand N,N,7-trimethyl-2-phenyl-1,8-
naphthyridin-4-amine (1.31) used to generate the Dansyl-analogue 1.32; A representative 
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fluorescent ligand NECA-X-BODIPY630/650 (1.33) of a series of compound synthesised 
by Middleton et al. (2007). 
 
 The most widely reported fluorescent antagonists are those based on XAC (1.22). 
Baker et al. conjugated XAC to different fluorophores with different linker composition to 
give XAC-X-BY630 (1.34, hA1AR pKi = 7.42 ± 0.07), XAC-X-Texas-Red (1.35, hA1AR 
pKi = 5.72 ± 0.07), XAC-AEAO-BYFL (1.36, hA1AR no inhibition), XAC-EVOBlue 30 
(1.37, hA1AR pKi = 5.27 ± 0.11) (Figure 1.23), XAC-Cy5 (1.38, hA1AR pKi = 5.59 ± 0.02), 
XAC-dansyl (1.39, hA1AR pKi = 6.71 ± 0.05), XAC-AO-dansyl (1.40, hA1AR pKi = 6.91 ± 
0.09), XAC-AHH-dansyl (1.41, hA1AR pKi = 6.87 ± 0.05) (Figure 1.23). However, the 
binding affinity at other AR subtypes was not reported so comments regarding the selectivity 




Figure 1.23. Fluorescent derivatives derived based on ligand XAC. 
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CA200645 (1.42, hA1AR Kb = 3.98 nM; hA3AR Kb = 2.95 nM)
228, 229 and XAC-Ser-
Tyr-X-BY630 (1.43, hA1AR pKi = 9.12 ± 0.05; hA3AR pKi = 7.62 ± 0.13)
228 (Figure 1.23), 
which are also derived from XAC, were reported as non-selective fluorescent ligand for 
hA1AR and hA3AR. There were attempts to produce high affinity selective A1AR ligands, 
however, there has yet been a successful report (including reports that did not report binding 
affinity at A2AAR, A2BAR and A3AR).
230-232 
 
1.5.2.2 Fluorescent ligands for mGluR5 
The synthesis of GPCR fluorescent ligands has been a hot topic in the last decades especially 
for class A GPCRs. However, efforts to make fluorescent ligands for class C GPCR, in 
particular the mGluR5, has lagged behind. In fact, there was no fluorescent ligand for 
mGluR5 reported until year 2020 (discussed in later part of this section). Molecular imaging 
of mGluR5 has been focusing on the use of positron emission tomography enabling ligands 
(PET).233-238 While this imaging technique is useful, the handling of PET ligands could be 
hazardous. Therefore, there is a notable need for the synthesis of fluorescent ligands to probe 
the mGluR5. 
 In 2016, Gregory et al. synthesised several first-in-class mGluR5 negative allosteric 
modulators (NAMs) 1.18 (hmGluR5 pKi = 7.60 ± 0.02 (25 nM)), 1.19 (hmGluR5 pKi = 7.15 
± 0.07 (71 nM)) and 1.20 (hmGluR5 pKi = 9.29 ± 0.06 (0.5 nM)) (Figure 1.18), consisting of 
either a benzophenone or aryl azide photoreactive moiety, and clickable arm (propargyl ether 
or azido group) that showed clickability (which term will be discuss later section 1.6) to 
suitably derivatised Cy5.5 and Cy7.5 fluorophores. The click chemistry of these compounds 
will be discussed in section 1.6.2. These ligands (1.18-1.20) are able to form covalent bonds 
with mGluR5 upon UV-irradiation, followed by an in-situ ‘click’ with a fluorophore to 
visualise the mGluR5.  
 In 2020, Fernández-Dueñas et al. reported a new series of fluorescent ligands based 
on NAM 3-((2-methyl-1,3-thiazol-4-yl)ethynyl)pyridine (MTEP, 1.44), varying the 
composition of the linkers, for mGluR5. These fluorescent derivatives contained a 
fluorophore that exhibited a narrow difference in the excitation-emission wavelength. A 
representative ligand 1.45 (hmGluR5 KD = 0.84 ± 0.74 µM) (Figure 1.26) was synthesised 
chemically via click chemistry (which term will be discuss later section 1.6) with BODIPY-
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alkyne (Eex = 573, Eem = 607) and was then used to assess the mGluR5 allosteric ligand 




Figure 1.26. A representative alkyne-BODIPY573/607 (1.45) fluorescent derivative of 
MTEP synthesised by Fernández-Dueñas et al.239  
 
1.6 Click chemistry 
1.6.1 Click chemistry concept 
Click chemistry is a term coined by Barry Sharpless in 1998 to describe the efficient 
connection of small units together via heteroatom linkages.240 There is a set of strict 
requirements for click chemistry such that a reaction has to be modular, high yielding, wide 
in scope, only produces safe by-products that can be removed by non-chromatographic 
procedures, and stereospecific. In addition, the reaction conditions involving click chemistry 
should ideally be insensitive to oxygen and water, use readily available starting materials 
and reagents, use of no solvent or environmentally benign solvent that can be easily removed 
and require simple isolation method. The products of a click reaction are required to be stable 
under physiological conditions.  
The first publication on the click chemistry concept by Barry Sharpless labelled 
several near ideal click reactions including Diels-Alder ring formation, oxidative addition of 
olefins to generate epoxides and aziridines, osmium-catalysed aminohydroxylation and 
dihydroxylation of olefins, hydroxymethylation and aminomethylation of carbonyl 
compounds and, perhaps the most reliable Huisgen’s [2+3] cycloaddition between azide and 
acetylene functional group to form a triazole ring.240 Huisgen’s [2+3] cycloaddition was 
regarded as the closest to ideal click chemistry as the azido functional group may be the only 
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one from the pool of functional groups to be stable towards dimerization and hydrolysis. The 
azido group commonly undergoes reduction to form a primary amino group, however, 
aliphatic azides have stability over a wide range of other reaction conditions.   
The classical copper (I)-catalysed azide-alkyne cycloaddition (CuAAC), a variant of 
Huisgen’s [2+3] cycloaddition, has been utilised as a strategy in the creation of clickable 
ligands209, 241 and labelling biomolecules inside living cells.242, 243 The application of click 
chemistry in live cell labelling was termed bioorthogonal chemistry, where the chemical 
reaction occurs in a living system without interfering with the native biological processes.244 
One example of bioorthogonal processes includes use of ‘clickable ligands’. The labelling 
process involving clickable ligands begins with the incorporation of a reactive chemical 
group (e.g. azido or acetylene) into a ligand. These reactive chemical groups are also termed 
as the clickable handles, where click reactions are carried out between the azido and 
acetylene groups using the CuAAC reaction to form the 1,2,3-triazole ring linkage (Figure 
1.27). The approach using a clickable ligand to click with a fluorophore upon binding to the 
receptor (further discussed in section 1.6.2) of interest is advantageous over the classical 
single fluorescent ligand entity because the parent clickable ligand undergoes little changes 
to form the clickable ligand, thus, expecting minimal interference on receptor binding 
compared to a single preassembled fluorescent ligand. The minimal changes can also 








Figure 1.27 Schematic diagram of a click reaction of a clickable ligand with a fluorophore 
forming a 1,2,3-triazole ring linking two of the modular units. 
 
One drawback of the ‘classical’ CuAAC click reaction is that copper (I) salts, used 
as a catalyst, can be cytotoxic to biological systems.245 Brewer showed that copper (I) 
promotes the production of reactive oxygen species (ROS) that can affect the function and 
structural integrity of biological molecules including DNA, proteins, and lipids.246 To 
overcome the shortcomings of the CuAAC in biological settings, several other “click” 
reactions have been developed and have found application in the field of bio-orthogonal 
labelling. These click reactions include the Ruthenium-catalysed azide-alkyne cycloaddition 
(RuAAC)247, strain-promoted azide-alkyne cycloaddition (SPAAC)248, amine-catalysed 1,3-
dipolar cycloaddition,249 sulfur (VI) fluoride exchange click chemistry250 and fluoride 
ethenesulfonyl fluoride thiol-based click reactions.251 Due to the many advantages of the 
CuAAC reaction, constant efforts have been reported to improve CuAAC methodologies 
utilising chelating ligands such as tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine 
(TBTA, 1.46), 3-(4-((bis((1-(tert-butyl)-1H-1,2,3-triazol-4-yl)methyl)amino)methyl)-1H-
1,2,3-triazol-1-yl)propane-1-sulfonic acid (BTTES, 1.47) and 3-(4-((bis((1-(tert-butyl)-1H-
1,2,3-triazol-4-yl)methyl)amino)methyl)-1H1,2,3-triazol-1-yl)propan-1-ol (BTTP, 1.48) 
(Figure 1.28) that can chelate copper (I) and limit toxicity.252 These ligation strategies were 






Figure 1.28 Copper (I)-chelating ligands used in CuAAC. 
 
1.6.2 Covalent, Clickable fluorescent GPCR ligands 
Various modifications can be coupled to a clickable ligand, for instance, the incorporation 
of a chemoreactive group to the clickable ligand to make a covalent clickable bifunctional 
ligand. Once the ligand is bound to the receptor, the chemoreactive group of the ligand can 
form a covalent bond with the receptor. The unbound ligand can be efficiently removed by 
washing procedures. Following that, fluorophore can be introduced to undergo click reaction 
with the receptor-bound ligand. This strategy prevents the click reaction between the 
unbound ligands with the fluorophore which could results in inaccurate fluorescence signal 
detection. Additionally, the clicking accessibility between a bound ligand and a fluorophore 
can be optimised (linker lengths and types) upon optimal covalent binding of ligand with the 
receptor.  
The use of covalent ligand binding followed by a ‘click’ to a fluorophore as a means 
of GPCR labelling was first demonstrated by Gregory et al. using covalent clickable mGluR5 
NAMs 1.18-1.20 (Figure 1.18).209 As described in section 1.5.2.2, NAMs 1.18-1.20 are 
bifunctional. NAM ligands are photoactivatable under UV irradiation and bind to mGluR5. 
However, a high degree of non-specific binding of the photoreactive moiety was observed.209 
Following this covalent bond formation between ligand and receptor, these ligands were 
subjected to a CuAAC “click” at a 1:1 ratio with a suitably functionalised (azide or alkyne 
containing) fluorophore Cy5.5 or Cy7.5 and showed successful labelling of mGluR5. In 
addition, chelating ligand 1.46 was used in this study to limit the toxic effects copper.  
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 In 2018, Soethoudt et al. reported a bifunctional covalent and clickable approach for 
the cannabinoid type 2 receptor (CB2R).
255 The authors described the synthesis of 
photoaffinity ligand LEI121 (1.49, hCB2R pKi = 7.2 ± 0.4) (Figure 1.29) which consisted of 
the photoreactive aziridine group and a propargyl click handle. Cross linking of LEI121 
(1.49) to the hCB2R-overexpressing CHO cells was initiated with UV irradiation at 350 nm. 
Subsequent CuAAC click reaction with a Cy5 fluorophore resulted in the visualisation of 
the endogenous hCB2R expression in human promyelocytic leukemia cell line (HL-60) and 





Figure 1.29. The photoaffinity ligand LEI121 (1.49) for CB2R which consists of an aziridine 
photoreactive group and a propargyl click handle. 
 
 In 2018, Yang et al. demonstrated a bifunctional covalent and clickable approach on 
the A2AAR using a covalent clickable ligand LUF7487 (1.50, hA2AAR pKi = 8.82 ± 0.02) 
(Figure 1.30).256 The synthesis of the bifunctional ligand 1.50 from lead compound 1.51 
(hA2AAR pKi = 8.99 ± 0.01) managed to retain binding affinity to hA2AAR. The covalent 
clickable ligand 1.50 consisted of the electrophilic fluorosulfonylphenyl warhead 
responsible for the covalent binding to an amino acid residue on hA2AAR (exact residue not 
reported). Upon covalent binding to hA2AAR, the authors described the click reaction of the 
covalent clickable ligand between a propargyl arm and Cy3-azide using the CuAAC. 
However, significant non-specific labelling was observed, which the author suggested could 
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be due to the low efficiency of the click reaction (no chelating ligand was used) or the non-




Figure 1.30. The covalent clickable ligand LUF7487 (1.50) for the A2AAR consisting of a 
fluorosulfonylphenyl chemoreactive group and a terminal alkyne click handle, based on the 
lead compound ZM2411385 (1.51). 
 
 In 2020, Hellyer et al. reported clickable photoaffinity ligands for mGluR2.
257 The 
highlight ligand of this study was the photoaffinity ligand 1.52 (hmGluR2 pEC50 = 5.94 ± 
0.10 (1.1 µM); Emax = 110.0 ± 6.9; pKB = 7.26 ± 0.02 (55 nM)) based on BINA (1.53, 
hmGluR2 pEC50 = 5.37 ± 0.07 (4.3 µM); Emax = 98.0 ± 5.3; pKB = 6.46 (347 nM)) (Figure 
1.32), an mGluR2 PAM photoreactive ligand.
257  
The clickable photoaffinity ligand 1.52 contained a photoreactive acetophenone 
moiety and a clickable propargyl ether arm that was able to improve mGluR2 agonist-PAM 
potency, maximal responses and binding affinity of the parent ligand 1.53.257 Clickable 
photoaffinity ligand 1.52 was subjected to UV irradiation at 365 nm followed by click 
reaction (click reaction conditions were not reported) with fluorophore Cy5.5 successfully 
labelled the hmGluR2. However, it was observed that the clickable photoaffinity ligand 1.52 
also labelled cells in both the absence and presence of UV irradiation and it was suggested 






Figure 1.32. The clickable photoaffinity ligand 1.52 for mGluR2 based on the lead compound 























1.7 Summary of Aims and Objectives of this Thesis  
This PhD thesis aimed to develop high affinity, selective A1AR and mGluR5 covalent 
clickable ligands that can be utilised as pharmacological tools to study the hA1AR and 
hmGluR5, respectively. The objectives necessary to achieve the overall aim included: 
 
• A thorough SAR study to identify suitable A1AR- or mGluR5-selective ligands 
modifiable to covalent clickable ligands. 
• Design of new bifunctional A1AR and mGluR5 ligands bearing a functional moiety 
capable of forming a covalent bond to the A1AR and mGluR5 receptor, respectively, and 
possessing a clickable linker in a tolerable ligand position (with varying linker length and 
types).  
• Analysis of the pharmacological evaluation of the synthesised A1AR and mGluR5 
ligands (biological studies carried out by collaborators), including rationalisation of ligand 
binding affinity and selectivity based on docking studies. 
• Design and synthesis of a follow-up series of covalent clickable ligands to refine 
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The synthesis of A1AR ligands has been an active research topic due to the fact that A1AR 
is an attractive drug target to treat a wide range of diseases.1 As discussed in Chapter 1, 
several A1AR ligands have been customised into various fluorescent ligands to study the 
dynamic processes, expression, localisation, function and distribution.2 However, the 
synthesis of preassembled A1AR fluorescent ligands have been shown to be challenging  
to produce good selectivity and affinity for hA1AR. In this project, the aim was to 
introduce a click chemistry handle into A1AR ligands where a larger fluorescent ligand 
can be generated by the joining of the ligand and a fluorophore once the ligand is bound 
to the receptor.  The two-step process begins with the binding of a high affinity A1AR 
clickable ligand to the receptor. A fluorophore containing a complementary clickable 
group then clicks with the ligand bound to A1AR. The linker connecting the ‘core ligand’ 
to the clickable moiety can play a big role in maintaining overall selectivity and affinity 
of the ligand.  
 
2.1.1 Scaffold selection 
2.1.1.1 Xanthine scaffold 
Ligand design starts with scaffold selection as a well-studied scaffold could stand a better 
chance in producing a selective and high affinity ligand. The scaffold, in this case a 
GPCR ligand, can generally be divided into 3 classes: agonist, antagonist and allosteric 
modulator. As the goal of the project is to develop a chemical tool that can ultimately be 
used to aid the study of ‘static’ A1AR localisation, a scaffold based on an inverse 
agonist/antagonist is preferred in this study. The xanthine-based scaffold was selected in 
this project for its rich and comprehensively investigated structure-activity-relationships 
(SARs).3-6 The amine congener 8-[4-[[[[(2-
aminoethyl)amino]carbonyl]methyl]oxy]phenyl]-1,3-dipropylxanthine (XAC, 1.22, 
Figure 2.1) was the first ligand to be reported to have high affinity (pKi = 1.2 nM for 
rA1AR) and moderate selectivity of 50-fold for rA1AR over rA2AR.
7, 8 Recently, the first 
A1AR crystal structure complexed with a xanthine-based antagonist DU172 (1.1) (PDB 
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ID: 5UEN)6 was published. The design of ligands in this project was inspired by features 





yl)propylcarbamoyl]benzenesulfonyl fluoride (DU172) (1.1) and 8-[4-[[[[(2-
aminoethyl)amino]carbonyl]methyl]oxy]phenyl]-1,3-dipropylxanthine (XAC) (1.22). 
Xanthine numbering is shown on XAC. 
 
2.1.1.2 SAR of alkyl substituent at N1, N3 and N7 
Caffeine (1,3,7-trimethylxanthine, 2.1, Figure 2.2) and theophylline (1,3-
dimethylxanthine, 2.2, Figure 2.2) (both xanthine-based compounds) were identified as 
the first two naturally occurring AR antagonists. However, these alkylxanthines only 
showed micromolar affinity and vary in affinity between subtypes of ARs. Early studies 
of substituents on the N1 and N3 positions of the xanthine scaffold demonstrated 
substantial AR selectivity preferences. The elongation from a methyl (2.2a, rA1AR Ki = 
14 ± 3 µM) to propyl (2.2b, rA1AR Ki = 0.7 ± 0.3 µM) on both N1 and N3 increases 
affinity at rA1AR by 20 fold.
9, 10 The N1 of xanthine with a  mono-substituted  methyl 
(2.3), propyl (2.4) or butyl (2.5) group gives selectivity for A2BAR over other AR 
subtypes while a benzyl group (2.6) at N1 showed selectivity for A1AR against other AR 
subtypes.11 The N7 position of the xanthine scaffold was studied with the replacement of 
7-unmethylated derivative 3-methyl-1-propargylxanthine with a 7-methyl (2.7, Figure 
2.2) or other substituents displayed a drastic reduction in rA1AR affinity.
10-12 An A1AR 
crystal structure (PDB ID: 5N2S)6  complexed with PSB36 (1.3, Figure 1.3 and 2.2) 
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shows an apparent deeper pocket that can accommodate a butyl chain, which was less 
accessible in the A2AAR binding pocket due to small shifts between AR subtype 




Figure 2.2. Naturally occuring alkyl xanthines (2.1, 2.2a and 2.2b) and some early 
modification on naturally occurring alkylxanthines (2.3-2.7). 
 
A series of covalent ligands including FSPCX (1.16, Figure 2.3) which comprised a 
fluorosulfonyl warhead attached to the N3 position of xanthine were developed as a 
potent and selective A1AR antagonists in hamster DDT1 MF-2 cells.
14 An analogue 2.8 
(hamster A1AR KD = 0.34 ± 0.03 nM) was then synthesised, where the ester linkage of 
the covalent arm was replaced with an amide group.15 Several more analogues with 
ketone functional group (2.9a hamster A1AR KD = 0.53 ± 0.02 nM, 2.9b hamster A1AR 
KD = 0.40 ± 0.04 nM, 2.9c hamster A1AR KD = 0.53 ± 0.02 nM) adjacent to the 
fluorosulfonyl moiety of the covalent arm have been reported, and retained affinity and 
irreversibility to A1AR in hamster DDT1 MF2 cells (Figure 2.3).
16 In this study, a 
xanthine N1 butyl chain was adopted with the hope of enhancing hA1AR selectivity over 






Figure 2.3. Covalent ligands bearing the benzenefluorosulfonyl moiety. 
 
2.1.1.3 SAR of C8 position of xanthine 
In addition to modification of N1 and N3 substituents of the xanthine core, SAR of the 
xanthine C8 position has been previously studied in depth. 1,3-Diethyl-8-phenylxanthine 
(DPX, 2.10, Figure 2.4) is the first 1,3-dialkyl analogue and it was shown to have good 
affinity (rA1AR Ki of 44 nM) and some selectivity over rA2AR
a.17 DPX was then 
developed into the first AR radioligand.18 However, the hydrophobicity of DPX limited 
its use as a radioligand. Other derivatives of 2.10, which include the homologation to the 
1,3-dipropyl derivative (2.11) or the addition of a hydroxy group (NPC-205, 2.12) were 
made but were not adequate to give good A1AR affinity or solve solubility issues.
19  An 
addition of a sulfonate group at the para position of the phenyl group generates a greater 
solubility effect on the ligand where 8-SPT (2.13) and DPSPX (2.14) were 
pharmacologically useful in experiments requiring absolute blockage of AR subtypes. 
The effort to improve both A1AR affinity and solubility produced XCC (2.15) and 1.22 
where the charged groups were placed at a distance from the 8-phenyl group where 1.22 
(rA1AR Ki = 1.2 nM
20 and hA1AR Ki = 6.8 nM
8) was found to exhibit about 50-fold 
selectivity against rA2AR
a and successfully used as an antagonist in rA1AR.
7 
 






Figure 2.4. Various bulky substituent variations at the C8 position of the xanthine 
scaffold.  
 
In addition to C8-aryl substituents, C8-cycloalkyl xanthines have been 
investigated and demonstrated to have sufficient aqueous solubility for pharmacological 
experiments. 1,3-Dipropylcyclopropylxanthine (DPCPX, 2.16, Figure 2.4) has 
approximately 500-fold selectivity for rA1AR
17 and 50-fold selectivity for hA1AR
21 over 
respective A2AAR species and emerged as a widely used radioligand for A1AR studies.  
Subsequently, other bulky cycloalkyl substituents such as 3-noradamantyl (KW3902, 
2.17), norbornyl (BG-9719, 2.18), dicyclopropylmethyl (MPDX, 2.19; KF15372, 2.20) 
and bicyclo[2.2.2]octyl (BG-9928, 2.21) were placed on the C8 position of the xanthine 
core and this generated very potent and selective A1AR antagonists. 
Kiesman et al. reported the linear extension of the 8-cycloalkylxanthine 2.21 
(Figure 2.4). The excellent hA1AR binding affinity and selectivity against hA2AAR 
shown in the series utilising a bulky bicyclo[2.2.2]octyl group  was an attractive point 
for further modification.5 Regarding the rationale for this PhD research, a 
bicyclo[2.2.2]octyl group on the C8 position of the xanthine core was thought to be 
advantageous over other cycloalkyl moieties (such as cyclopentyl and cyclohexyl due to 
the cis, trans isomer complications) for adding a linker.  The ligand design in this project 
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was particularly inspired by compound 2.22 (Figure 2.4) (compound 17 in the reported 
literature) as the authors reported several variations in this part of the molecule that all 
retained A1AR affinity. In this PhD project, molecular modelling and ligand docking 
experiments were carried out on derivatives of 2.22 with linkers appended from the a 
bicyclo[2.2.2]octyl group, which showed the end of the linker could likely be exposed to 
the receptor surface and accessible for a ‘click’ reaction (as discussed in section 2.1.2, 
see below Figure 2.5).   
 
2.1.2 Selection of linker type and clickable chemistry 
The recently reported crystal structure of hA1AR complexed with DU172 (1.1) (PDB ID: 
5UEN, Figure 2.5)6 provided a great platform to guide ligand design. A flexible linker 
terminating with a clickable handle able to link with a complementary click handle 
attached to a fluorophore was designed. By examining the A1AR crystal structure, the 
bulky group at the C8 position of the xanthine core faces upward towards the extracellular 
surface of the receptor (Figure 2.5). It was hypothesised that a flexible linker terminating 
with a clickable handle extending out at the bicyclo[2.2.2]octyl group could be an 








Figure 2.5. hA1AR crystal structure complexed with DU172 (1.1) (PDB ID: 5UEN)
6. 
A1AR shown as purple ribbon. DU172 with the xanthine scaffold shown as yellow sticks. 
Amino acid residues are shown as green sticks. Nitrogen atom shown as blue. Oxygen 
atom shown as red. 
 
 As discussed in section 1.5.2, there are a few click chemistry functional group 
pairs that could be used in ligand design. Small, clickable pairs are preferred to prevent 
significant interruption to the overall A1AR affinity. The azide-terminal alkyne pair was 
picked as it will react via the copper-catalysed azide and alkyne cycloaddition (CuAAC) 
to selectively give the 1,4-disubtituted triazole that is relatively small in size. Both azide 
and alkyne clickable handles were designed in the ligand to investigate the differences in 
A1AR affinity and AR subtype selectivity between these ligands. A 3-carbon chain linker 
(Figure 2.7) was chosen as an appropriate linker length based on docking studies that 
showed that this length linker could be accessible for click chemistry with a fluorophore. 
 
2.1.3 Covalent arm  
The design of a covalent ligand was inspired by the recently published A1AR crystal 
structure complexed with DU172 (Figure 2.5, PDB ID: 5UEN). The sulfonyl fluoride 
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covalent arm of DU172 at the N3 position was shown to react covalently with amino acid 
residue Y2717.36 of A1AR.
6 It was hypothesised that the ligands in this project would first 
reversibly bind to A1AR and then the sulfonyl fluoride would react with Y271
7.36 of 
A1AR. The residue Y271 of A1AR is conserved across other adenosine receptors (A2AAR 
and A3AR) except A2BAR.
22 The series of ligands containing two ‘functionalities’ – i.e. 
a linker terminated with a clickable group in addition to a sulfonyl fluoride covalent arm 
at the xanthine N3 position (Figure 2.7) were docked in the A1AR crystal structure (PDB 
ID: 5UEN). The series of ligands consisted of five groups of designed ligands: a) 
clickable, with the covalent arm (2.24 and 2.27), b) clickable, without the covalent arm 
(2.23 and 2.26), c) clickable, with the non-covalent arm (2.25), d) non-clickable, with the 
covalent arm (2.28 and 2.30) and e) non-clickable, with the non-covalent arm (2.29). All 
eight of the ligands were docked into the hA1AR receptor and demonstrated a conserved 
binding orientation. Figure 2.7 shows the top poses of 2.24 and 2.27 as representatives 
of the series where the xanthine core binding mode of these bifunctional ligands are 





Figure 2.6 Designed compounds to be synthesised in this project: a) clickable, covalent 
(2.24 and 2.27), b) clickable, non-covalent (2.23, 2.25 and 2.26), c) non-clickable,  





Figure 2.7. 2.24 and 2.27 docked in hA1AR (PDB ID: 5UEN) and aligned with DU172 
(A) and surface view (B) to show linker accessibility to the extracellular region. A1AR 
shown as purple ribbons. 2.24 shown as yellow sticks. 2.27 shown as magenta sticks. 
DU172 shown as orange sticks. Amino acid residues are shown as green sticks. Nitrogen 
atom shown as blue. Oxygen atom shown as red. 
 
2.1.4. Summary of ligand design 
The A1AR covalent clickable ligand design incorporated both a clickable linker and a 
covalent arm. Figure 2.6 shows the first analogues to be synthesised in this project. 2.24 
and 2.27 contain the bifunctional design while 2.23 and 2.26 are analogues that do not 
contain the covalent group to allow the influence of the covalent arm to be investigated. 
Ligand 2.28 is one without the clickable linker to explore the tolerance of the linker 
addition. 2.25 and 2.29 contain a sulfonic acid instead of fluorosulfonyl group. These 
reversible ligands can be used to provide a comparison between the covalently-bound 
versus the non-covalently-bound analogues that still contain that ‘arm’.  2.30, a similar 
compound to DU172 (an N1 butyl instead of an N1 propyl), was used to assess the 




2.2 Synthesis of A1AR ligands 
2.2.1 Synthesis of xanthine core 
Synthesis began with assembly of the xanthine core (Scheme 2.1). All compounds 
described in scheme 2.1 are novel chemical entities but are synthesised following 
literature routes23 up to compound 2.34 and isolated without the use of column 
chromatography purification. Compounds 2.35, 2.36 and 2.37 were synthesised 
according to literature route, however, with a butyl chain at the N1 position instead of 
propyl chain. The starting material 2.31 was synthesised via a carbamoylation reaction 
(mechanism shown in figure 2.8). The aq. sulfuric acid protonates the cyanate ion to form 
isocyanic acid. The nucleophilic primary amine of the 2,4-dimethoxybenzylamine 






Scheme 2.1. Synthesis of 2.39 and 2.40. Reagents and conditions: i. KOCN, H2SO4, 
85°C, 1.5 h, 96%; ii. NCCH2COOH, Ac2O, 70°C, 1.5 h, 84%; iii. NaOEt, EtOH, 70°C, 
1 h, 67%; iv. DMF-DMA, DMF, 40°C, 4 h, 74%, v. 1-bromobutane, Cs2CO3, TBAB, 
ACN, DMF, 60°C, 3 h, 76%; vi. 2 M KOH, MeOH, 50°C, 1 h, 88%; vii. NaNO2, 50% 
AcOH, 70°C, 1 h; viii. Na2S2O4, 25% aq. NH4OH, MeOH, 80°C, 4 h, 76% (over 2 steps); 
ix. Bicyclo[2.2.2.]octane-1,4-dicarboxylic acid monomethyl ester, HATU, NEt3, ACN, 
1 h, rt; x. 1 M KOH, i-PrOH, reflux, 1 h, 73% (over 2 steps); xi. Cyclohexanoic acid, 






Figure 2.8. The mechanism for formation of 2.31.24  
 
The DMB-protected urea 2.31 then underwent a condensation reaction with 
cyanoacetic acid in acetic anhydride to form 2.32 in 84% yield. Acetic anhydride was 
used as the solvent and dehydrating agent to mop up water generated as side product to 
form acetic acid and allowing the reaction to proceed without the use of a catalyst. The 
recrystalised 2.32 was washed with excess water during the filtration step to remove 
traces of acetic acid. The DMB-protected cyanoacetylurea 2.32 was treated with sodium 
ethoxide in ethanol to give 2.33 in 67% yield. The reaction proceeds in a ring closure 
mechanism, followed by tautomerisation to form uracil 2.33 (mechanism shown in figure 
2.9).25 
 
Figure 2.9. The mechanism for formation of 2.33.25   
 
The vinylamine 2.33 was then protected with an N,N-dimethylmethanimidamide 
group using N,N-dimethylformamide dimethyl acetal (DMF-DMA) (mechanism shown 
in Scheme 2.10) to allow selective alkylation on the imide group to give 2.34 in 74% 
yield. The vinylamine attacks the electrophilic carbon of DMF-DMA. The mechanism 






Figure 2.10. The mechanism for formation of 2.34.26 
 
An alkylation on the imide 2.34 with 1-bromobutane instead of 1-bromopropane, 
which was reported in the literature,23 was initiated by the use of caesium carbonate as a 
base. Caesium carbonate was used to avoid harsher bases that could hydrolyse the N,N-
dimethylmethanimidamide group. The reaction was carried out with tert-
butylammonium bromide as phase transfer catalyst to give 2.36 in 76% yield. Subsequent 
hydrolysis with KOH27 was carried out to the N,N-dimethylmethanimidamide group 




Figure 2.11. The mechanism for formation of 2.36.28 
 
Nitrosation of the olefin 2.36 was carried out using sodium nitrite and aq. acetic 
acid, and generates nitrosonium in situ. The electron rich double bond attacks the 
nitrogen of nitrosonium ion, followed by proton transfer to form an oxime group 
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(mechanism shown in scheme 2.12). The oxime form exists in equilibrium with the 
nitroso form. The reaction underwent complete reduction by sodium dithionite in 4 hours 
(monitored by TLC) to give 2.37 in a 76% yield. The nitrosation of the vinylamine was 
not observed, because the vinyl amine is less nucleophilic due to the lone electron pair 
delocalisation. The absence of an olefinic proton in 1H NMR proved that 2.37 is formed 




Figure 2.12. The mechanism for formation of the oximino-nitroso intermediate prior to 
reduction to form 2.37 (reduction mechanism not shown).29 
 
Diamine 2.37 was coupled with bicyclo[2.2.2]-1,4-dicaboxylic acid monomethyl 
ester 2.38 using (1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 
3-oxide hexafluorophosphate (HATU) and NEt3 (mechanism shown in figure 2.13). 
Exactly 1 eq. of HATU was used to prevent di-amidated uracil of 2.37. The use of HATU 
formed an unstable O-acyl(tetramethyl)isouronium salt which was then attacked by the 
generated hydroxyazabenzotriazole anion (OAT-) to form the activated ester intermediate 
of the bicyclo[2.2.2]-1,4-dicaboxylic acid monomethyl ester. Upon work-up of the 
reaction, a subsequent ring-closure and ester hydrolysis were initiated by aq. KOH. This 
one pot ring-closure and ester hydrolysis reaction was difficult to monitor as the TLC 
spotting of the crude product does not show under UV or potassium permanganate dip 
on a TLC plate. An aliquot of the crude reaction was also subjected to a mini work up 
with 10% acetic acid before attempting further TLC study but was ineffective. A 
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literature report with a closely related structure similar to 2.39, reports a good yield with 
1 h reaction time.5 Upon allowing the reaction to run for an hour, the desired product 
2.39 was obtained in 73% yield. The analogue 2.40 was synthesised in 88% yield using 
similar reaction conditions.  
 
Figure 2.13. The mechanism for the formation of 2.39.30 
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2.2.2 Synthesis of 3-azidopropan-1-amine 2.42 
3-Azidopropan-1-amine 2.42 (scheme 2.2) was synthesised according to literature.31 The 
azido anion, from the sodium azide salt, replaced the bromo in a nucleophilic substitution 
reaction. The reaction could not easily be monitored by TLC as the Rf of both starting 
material and product resided at the baseline of the TLC plate under 100% ethyl acetate. 
Upon running the reaction for 12 h, 2/3 of the water in the reaction mixture was removed 
carefully in-vacuo. This step was crucial as an excess of water could prevent extraction 
of the polar product into diethyl ether. The use of diethyl ether as an extraction medium 
was also important to allow easy ambient evaporation without rotary evaporation due to 
the low boiling point of 2.42. The MgSO4-dried organic solution was concentrated by 




Scheme 2.2. Synthesis of 3-azidopropan-1-amine 2.42. Reagents and conditions: i. NaN3, 
H2O, 80°C, 12 h, 68%.  
 
2.2.3 Synthesis of the 4-((3-bromopropyl)carbamoyl)benzenesulfonyl fluoride 2.44 
The synthesis of the covalent arm 4-((3-bromopropyl)carbamoyl)benzenesulfonyl 
fluoride 2.44 (Scheme 2.3) was carried out as reported in literature. However, compound 
2.44 resulted in 30% yield.15 In this thesis the literature procedure was adapted - pre-
neutralisation of the 3-bromopropylamine hydrobromide salt 2.41 with 1.1 equivalents 









Scheme 2.3. Synthesis of 2.44. Reagents and conditions: 4-(fluorosulfonyl)benzoic acid 
2.43, EEDQ, 3-bromopropylamine hydrobromide 2.41, DIPEA, DMF, 8 h (0°C) then 8 
h (rt), 72%. 
 
The reaction was initiated with the protonation of the ether oxygen followed by 
the expulsion of an ethanol molecule (mechanism shown in figure 2.14). The quinolinium 
group of the carbamate intermediate was displaced by the carboxylate group to generate 
an N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) anhydride derivative. The 
electrophilic centre of the anhydride adjacent to the aryl sulfonyl fluoride is more 
susceptible to nucleophilic attack by 3-azidopropan-1-amine because there are less 






Figure 2.14. The mechanism for the formation of 2.44.32 
 
 
2.2.4 Assembly of ligands 
The attachment of the covalent arm 2.44 to 2.40 was initially carried out according to 
Scheme 2.4. The imidazole nitrogen on 2.40 was protected with a pivaloyloxymethyl 
(POM) group to give DC305793, to prevent the subsequent undesired alkylation of the 
covalent arm 2.44 to it. The DMB group on 2.45 was removed with TFA at 50°C. 
Subsequently, the N3 position was then alkylated with the covalent arm 2.44 in the 
presence of K2CO3 in DMF to give 2.46. However, the required basic conditions of POM 
group removal from 2.46 with 2 M NaOH was incompatible with the fluorosulfonyl 
group, hydrolysing it to give a sulfonic acid instead (not shown). In other reaction 
attempts with differing conditions to optimise POM removal without sulfonyl fluoride 
hydrolysis (detailed in Table 2.1), a lower concentration of methanolic NaOH, aqueous 
NaOH, 7 N methanolic ammonia or a reaction temperature below 0 °C with several bases 
was trialled but the hydrolysis of sulfonyl fluoride appeared to be faster than the 
deprotection of POM. The O2S-F bond is relatively strong (bond dissociation energy of 
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379 kJ mol-1)33 and stable. However, the fluoride ion of SO2F is a good leaving group 




Scheme 2.4. Attempted synthesis of 2.30. Reagents and conditions: i. POM-Cl, K2CO3, 
DMF, 50°C, 18 h, 95%; ii. TFA, 50°C; iii. 2.46, K2CO3, DMF, 16 h, rt, 82% (over two 





Table 2.1. Various reaction conditions for the deprotection of POM group from 2.46 
trialled. 
 Reaction conditions Outcome 
1. 1 M or 2 M NaOH in 
methanol, rt 
The removal of POM group from 2.46 was 
completed in 15 mins. However, in this time the 
fluorosulfonyl group was also hydrolysed to the 
sulfonic acid derivative of 2.30. 
2. Aq. 2 M NaOH, rt36 The removal of POM group from 2.46 was 
completed in 15 mins. However, in this time the 
fluorosulfonyl group was also hydrolysed to 
sulfonic acid derivative of 2.30. 
3. 7 N NH3 in methanol at i) -
10˚C, ii) 0˚C, iii) rt23 
 
The removal of POM from 2.46 was completed 
in i) 2 h, ii) 45 mins and iii) 30 mins, 
respectively. Two new polar product TLC spots 
were observed before the complete removal of 
POM group from 2.46. However, only the 
sulfonic acid derivative of 2.47 was observed by 
the complete removal of POM from 2.30. 
4. Sodium ethoxide 21 wt% in 
ethanol, rt 
The removal of POM group from 2.46 was 
completed in 5 mins. However, the 
fluorosulfonyl group was also hydrolysed to 
sulfonic acid derivative of 2.30. 
 
 An alternative strategy was devised where the imidazole NH was not protected 
prior to the subsequent DMB-deprotection and N3 alkylation (Scheme 2.5). This method 
would therefore not require the basic conditions for POM removal which hydrolysed the 
sulfonyl fluoride. However, the imidazole NH would be potentially deprotonated by 
inorganic base K2CO3 during the alkylation with covalent arm 2.44. To minimise the 
chances of disubstitution of 2.40, the covalent arm 2.44 was made to be the limiting 
reagent (0.9 equivalent) and the alkylation reaction at N3 was carried out overnight at 
room temperature. A new spot was observed by TLC and the spot was isolated. High-
resolution mass spectrometry (HRMS) analysis was carried out on the isolated product 
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and a [M-H]- of 532.2068 was observed which matched with that of a singly alkylated 




Scheme 2.5. Synthesis of ligand 2.30. Reagents and conditions: i. TFA, 50°C; ii. 4‐[(3‐
bromopropyl)carbamoyl]benzene‐1‐sulfonyl fluoride 2.44, K2CO3, DMF, rt, 18 h, 63% 
(over 2 steps). 
 
Since the imidazole NH was not protected, there were two sites that could have 
potentially been alkylated. Therefore, the relative position following with the covalent 
arm 2.44 was then investigated. 2D-NMR spectroscopy experiments were carried out to 
characterise 2.30 in terms of regioisomers. The 1H NMR spectrum of 2.30 was first fully 
assigned (Appendix 3a, 3b, 3c, 3d). Next, HSQC NMR spectroscopy was carried out to 
correlate the protons to the carbons (Appendix 4a, 4b, 4c). The characteristic carbon 
splitting by fluorine was observed for C31 (compound 2.30 numbering shown in Scheme 
2.5). Following that, HMBC NMR spectroscopy was used to locate the position of 
covalent arm addition. 5-H (4.07 ppm) was set as a correlating point. 5-H would 
presumably correlate with 4 different carbons - C23 (2J, 27.4 ppm), C24 (3J, 36.8 ppm), 
C2 (3J) and C9 (3J) if it were alkylated at the N3 position. The HMBC spectrum (Figure 
2.15) indeed showed these correlations and was assigned accordingly. Carbonyl C2 (3J, 
150.6 ppm) can be differentiated from the olefinic C9 (3J, 147.5 ppm) by its higher 
electronegative nature, which showed in a more down-field chemical shift. H-15 would 
presumably have a correlation with C14 and not carbonyl C2 if the attachment happened 
at the imidazole NH (which was not observed). Subsequently, H38 (3.85 ppm) was 
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correlated with 4 carbons - C39 (2J, 29.7 ppm), C40 (3J, 19.6 ppm), C2 (3J, 150.6 ppm) 
and C6 (3J, 153.9 ppm). C6 can be used to justify these assignments as it only correlates 
with 38-H.  Additionally, H-24 (3.31 ppm) and H-11 (13.0 ppm) were used to assign C26 
(164.2 ppm). The aryl protons at H-29, H-30, H-32 and H-33 were used to assign C27 
(141.6 ppm). H-14 (2.62 ppm) was used to assign C12 (158.1 ppm) as there is only one 
down-field carbon nearby. The final down-field chemical shift belongs to C7 at 106.0 
ppm. Theoretically, C15 (30.9 ppm) and C19 (30.9 ppm) should be more down-field than 
C16 (25.3 ppm) and C18 (25.3 ppm), and they are assigned accordingly. The last carbon 
chemical shift at 25.2 ppm was assigned to C17. The complete 1H (Appendix 3) and 13C 
NMR (Appendix 5) spectra assignment proved that the N-alkylation took place at the N3 





















Figure 2.15. HMBC spectrum of 2.30 
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2D NOESY spectroscopy was conducted to obtain additional support for the 
proposed regioisomer of compound 2.30. There was only one spatial interaction found - 
between H-11 (13.04 ppm) and H-24 (3.32ppm). This provides information on both the 




Figure 2.16. NOESY spectrum of 2.30. 
  
 The structural characterisation of 2.30 provided confidence in synthesising the 
rest of the designed ligands without the protection of the imidazole NH. Compound 2.39 
was treated with a catalytic amount of sulphuric acid in excess methanol in an 
esterification reaction to give 2.48 in 71% yield (Scheme 2.6). Compound 2.39 was 
reacted with propargylamine and 2.42 in an amide-bond forming reaction similar to the 
preparation of 2.39 via a HATU-assisted reaction to give 2.49 and 2.50 in 76% and 85% 
yield, respectively.  All three compounds 2.48, 2.49 and 2.50 were treated with neat TFA 
to remove the DMB protecting group. Subsequently, alkylation of the three unprotected 
compounds 2.48, 2.49 and 2.50 with 2.44 using K2CO3 in DMF gave 2.28, 2.27, 2.24 in 
a yield ranging from 11% to 15% after semi-preparative HPLC purification.  The low 
yield could have resulted from the unoptimised reaction conditions preventing 
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dialkylation of N3 and N7 positions of the core ligand, or could be a result of poor 
recovery following HPLC purification. Subsequently, sulfonyl fluorides 2.28 and 2.24 
underwent hydrolysis under 2 M methanolic NaOH efficiently to give the analogous 
sulfonic acids 2.29 and 2.25 in 88% and 95% yield, respectively. The synthesis of the 
designed non-covalent derivatives 2.26 and 2.23 was carried out with the imidazole NH 
protected with a POM group. These non-covalent ligands 2.26 and 2.23 do not contain 
the base-labile sulfonyl fluoride moiety which enables both ligands to undergo optimised 
literature reaction condition23 via the protection of imidazole NH with a POM group prior 
to the alkylation with a propyl bromide (Scheme 2.12). Both 2.56 and 2.57 were treated 
with TFA to remove the DMB protecting group and then alkylated with propyl bromide 
(1.3 eq. of reagent) using K2CO3 in DMF to give 2.56 and 2.57 in 98% and 89% yield, 






Scheme 2.6. Synthesis of ligands. Reagents and conditions: i. H2SO4, MeOH, reflux, 3 
h, 71%, or propargylamine or 2.42, HATU, DIPEA, DMF, 18 h, rt, 42-98%; ii. TFA, 
50°C; iii. 2.44, K2CO3, DMF, rt, 11-15% (over 2 steps); iv. 1 M NaOH, MeOH, rt, 1 h, 
88-95%; v. POM-Cl, K2CO3, DMF, 50°C, 18 h, 52-57%; vi. Bromopropane, K2CO3, 





2.3 Discussion of pharmacological evaluation 
Eight ligands synthesised in Section 2.2 consisting of a library of designed clickable 
covalent (2.24, 2.27), clickable (2.23, 2.26), non-covalent clickable (2.25), covalent 
(2.28, 2.30) and non-covalent (2.29) were subjected to pharmacological evaluation. 
These ligands were made to inform two queries: i) binding interactions or tolerance of 
the receptor with the addition of a propargyl or propylazido linker around the surface of 
the receptor, ii) tolerance of the xanthine scaffold with bifunctionality of a covalent arm 
and clickable linker in A1AR. All pharmacological assays and data analysis were carried 
out by PhD candidate Phuc Nguyen (a PhD student in the laboratory of collaborators Dr 
Lauren May and Dr Karen Gregory at Drug Discovery Biology, Monash Institute of 
Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia).  All 
experimental details of the biological assays are described in appendix 19.37 Radioligand 
binding and cAMP assays were carried out to determine affinity at hA1AR and evaluate 
function of ligands. Selective high affinity non-covalent antagonist ligands SLV320 
(hA1AR pKi = 1.0 nM)
38, SCH442416 (hA2AAR pKi = 4.1 nM)
39, PSB603 (hA2BAR pKi 
= 9.3 nM) and MRS1220 (hA3AR pKi = 1.0 nM)
40 were used as positive controls on 









Figure 2.17. The selective high affinity non-covalent antagonist ligands SLV320 (2.62), 
SCH442416 (2.63), PSB603 (2.64) and MRS1220 (2.65) used as positive controls for the 
hA1AR, hA2AAR, hA2BAR and hA3AR, respectively. 
 
2.3.1 Radioligand binding assays 
Radioligand displacement binding assays were carried out by Ms. Nguyen to determine 
the binding affinities of ligands 2.23-2.30 at hA1AR in membranes derived from A1AR-
FlplnCHO cells in the presence of 1 nM [3H]dicyclopropylcycloxanthine ([3H]DCPCX) 
at 25°C (Figure 2.18). The affinity estimates of 2.23-2.30 are summarised in Table 2.2. 
All ligands except 2.26 and 2.30 completely inhibited specific [3H]DCPCX binding to 
hA1AR in a concentration dependent manner which indicated a competitive interaction 
for the hA1AR orthosteric site. The outlier in the binding affinity graph plotted for 2.26 
and the resurgence of total specific 3[H]DCPCX binding measured at high concentration 
of 2.30 suggested that these two ligands might not inhibit [3H]DCPCX binding to hA1AR 
in a concentration dependent manner. Since some of the compounds tested may be 
covalent, the affinity estimates after an extensive washing steps (6 x 20 min) were also 
determined (Table 2.2) (this will be further discussed in section 2.3.5). The small 
difference (less than 1 log unit) in affinity estimate data between the apparent affinity 
and affinity estimates after extensive washing steps for 2.24, 2.27 and 2.28 suggested a 
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covalent interaction in agreement with the fact that all three compounds possess the 

















Figure 2.18. Displacement of [3H]DPCPX (1 nM) binding in FlpInCHO-hA1AR cell 
membranes (15 µg) at 25°C with an incubation time of 4 hours with ligands (2.23-2.30). 
Data represent the mean ± SEM from n ≥ 3 performed in duplicate (see Table 2.2 for 
exact numbers). Error bars not shown lie within dimensions of the symbol. Experiments 























































































Table 2.2. Affinity estimates of test compounds from [3H]DPCPX competition binding 
(pKi ) in hA1AR – expressing FlpInCHO cells, before and after washing steps. 
Experiments and data analysis performed by PhD candidate Phuc Nguyen (Monash). 
Ligands 














9.25 ± 0.08 (0.6) 6 n/a  
2.23 8.27 ± 0.08 (5.4) 4 6.09 ± 0.32 (805) 3 
2.24 8.17 ± 0.14 (6.7) 6 8.19 ± 0.11 (6.5) 7 
2.25 6.22 ± 0.11 (605) 3 n/d  
2.26 7.36 ± 0.06 (43.4) 4 6.14 ± 0.12 (731) 3 
2.27 7.58 ± 0.11 (26.1) 6 7.41 ± 0.09 (38.8) 7 
2.28 7.76 ± 0.11 (17.3) 4 7.05 ± 0.11 (89.3) 9 
2.29 6.75 ± 0.40 (179) 4 n/d  
2.30 7.92 ± 0.33 (12.1) 4 n/ad  
aData are expressed as mean ± SEM from indicated number (n) of independent 
experiments performed in duplicate; n/a, denotes not applicable; n/d, denotes not 
determined. 
bNegative logarithm of the equilibrium dissociation constant for antagonists determined 
from displacement of [3H] DPCPX binding using the Cheng-Prusoff equation. 
cSLV320 (2.62) is a selective A1AR antagonist. 
dpKi not reported due to poor curve fitting. 
 
2.3.2 SAR discussion of A1AR ligand binding affinity (pKi) 
All compounds in Table 2.2 showed nanomolar binding affinity. 2.23 and 2.24 exhibited 
the highest estimated hA1AR binding affinity (pKi = 8.27 ± 0.08 (5.4 nM) and pKi = 8.17 
± 0.14 (6.7 nM) respectively) out of the eight tested compounds. Given the similar 
features of 2.23-2.30 to 2.22 (hA1AR Ki = 6.0 nM), 2.23 and 2.24, in particular, displayed 
a similar binding affinity for hA1AR. This demonstrated that the changes from an N,N-
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dimethylethylamine linker (such as in 2.22) to a propylazido linker (such as 2.24) 
retained high hA1AR binding affinity. While the non-covalent 2.23 showed excellent 
hA1AR binding affinity, the analogous 2.24 with a covalent arm appeared to bind to 
hA1AR equally well. However, changing the propylazido linker (in 2.23, pKi = 8.27 ± 
0.08 (5.4 nM) and 2.24, pKi = 8.17 ± 0.14 (6.7 nM)) to a propargyl linker (2.26 and 2.27) 
analogues moderately decreased the estimated hA1AR binding affinity to 7.58 ± 0.11 
(26.1 nM) and 7.36 ± 0.06 (43.4 nM), respectively. Compounds 2.26 and 2.27 showed 
approximately 1 log unit weaker binding at hA1AR compared to 2.23 and 2.24. This 
could be due to a polar environment around the linker region which could be interacting 
with the azido but not the alkyne group. The sulfonic acid analogue 2.25 (hA1AR pKi = 
6.22 ± 0.11 (605 nM)) and 2.29 (hA1AR pKi = 6.75 ± 0.40 (179 nM)) each bound 
approximately 100-fold weaker estimated affinity than its sulfonyl fluoride group 
counterpart 2.24 (hA1AR pKi = 8.17 ± 0.14 (6.7 nM)) and 2.28 (hA1AR pKi = 7.76 ± 0.11 
(17.3 nM)), respectively, demonstrating evidence of a strong contribution of a covalent 
interaction that could arise from the sulfonyl fluoride group which was anticipated to be 
the same covalent binding as for DU172 in A1AR described by Glukhova et al.
6 The 
hA1AR binding affinity difference between 2.24 and 2.28 further elaborated the greater 
influence of the sulfonyl fluoride covalent arm than the presence of the clickable linker 
for receptor binding. Replacing the propylazido linker (2.24, hA1AR 8.17 ± 0.14 (6.7 
nM)) to a methyl ester group (2.28, hA1AR pKi = 7.76 ± 0.11 (17.3 nM)) retained high 
hA1AR binding affinity. Meanwhile, substituting the propyl chain at the N1 position of 
DU172 (hA1AR pKi = 7.4 ± 0.1 (39.8 nM)) with a butyl chain (2.30) showed slightly 
improved hA1AR binding affinity of pKi = 7.92 ± 0.33 (12.1 nM). Although only one 
compound pair comparison was made, this potentially demonstrated the advantage of N1 
butyl as opposed to propyl chain for the covalent clickable compounds in this series and 
agrees with the finding that it can fit deep into the hA1AR binding pocket.
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2.3.3 Forskolin-stimulated cAMP assays 
The biological activity of ligands made in this chapter were also assessed by an A1AR-
mediated inhibition of forskolin-stimulated cAMP accumulation assay in hA1AR-
FlpInCHO cells. While ligands 2.23-2.30 may have functions at other signalling 
pathways, only the forskolin-stimulated cAMP accumulation assay was investigated. All 
these experiments and data analysis were conducted by PhD candidate Phuc Nguyen 
(Monash). Forskolin is used in this assay to increase levels of cyclic adenosine 
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monophosphate (cAMP) for the study of adenylate cyclase inhibition. It activates the 
enzyme adenylyl cyclase and increases intracellular levels of cAMP. Upon activation of 
A1AR with an agonist, the receptor preferentially couples to Gi/o proteins which results 
in the inhibition of adenylate cyclase and reduces cAMP production. The non-selective 
AR agonist N-ethyl-5'-carboxamidoadenosine (NECA, 1.28) was used and NECA 
concentration-forskolin inhibition curves were generated (Figure 2.9) in the absence and 
presence of ligand at a single concentration (1 µM).  
 In the absence of 2.23-2.30, the increasing concentration of agonist NECA 
binding at hA1AR (vehicle curve on Figure 2.19) increased the cAMP inhibition. A fixed 
ligand concentration of 2.23-2.30 were respectively incubated with agonist NECA and it 
was found that all test ligands decreased the cAMP inhibition (causing a right-hand shift 
curve from the vehicle curve). This showed that 2.23-2.30 acted as competitive 
antagonists at hA1AR in the cAMP inhibition assays (affinity estimates (pKb) are shown 
in Table 2.3).  
 Out of the 8 ligands tested, 2.23 showed the highest competition (pKb = 9.31 ± 
0.16 (0.5 nM)) against NECA for the hA1AR binding site. The better the antagonist 
competes with NECA, the less NECA will inhibit cAMP production and the lower the 
forskolin inhibition observed (higher pKb value).  The potency of an antagonist is 
expressed in either the estimated affinity (pKb) where equilibrium dissociation constant 
of an antagonist-receptor complex is determined through a cAMP assay (in which the 
activity of NECA is antagonised), or the concentration of antagonist that occupies half 

















Figure 2.19. NECA concentration-response curves for cAMP inhibition in the absence 
or presence of test compounds (1 µM) and SLV320 (1 µM) in hA1AR-FlpInCHO cells. 
Data represent the mean ± SEM from n ≥ 3 performed in duplicate (see Table 2 for exact 
numbers). Error bars not shown lie within dimensions of the symbol. Experiments and 
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Table 2.3. Affinity estimates of test compounds from cAMP inhibition assays (pKB) in 
hA1AR – expressing FlpInCHO cells. Experiments and data analysis performed by PhD 








9.27 ± 0.14 (0.5) 6 
2.23 8.47 ± 0.26 (3.4) 4 
2.24 9.31 ± 0.16 (0.5) 4 
2.25 7.06 ± 0.13 (87.5) 4 
2.26 7.04 ± 0.30 (91.0) 5 
2.27 6.23 ± 0.39 (585) 5 
2.28 7.77 ± 0.26 (17.1) 5 
2.29 7.04 ± 0.10 (92.0) 5 
2.30 7.59 ± 0.30 (26.0) 6 
aNegative logarithm of the equilibrium dissociation constant for antagonists as 
determined from NECA concentration response curves for cAMP inhibition.  
bSLV320 as selective A1AR antagonist  
 
2.3.4 SAR discussion of A1AR ligand estimated affinity (pKb) 
Compounds 2.23-2.30 showed hA1AR pKb values between 6.23 to 9.31 (Table 2.3). 
Generally, the propylazido linker-containing ligands 2.23 (hA1AR pKb = 8.47 ± 0.26 (3.4 
nM)) and 2.24 (hA1AR pKb = 9.31 ± 0.16 (0.5 nM)) were the best two ligands of the 
series at antagonising NECA activity, having approximately one to three log units higher 
pKb than 2.25-2.30. Replacing the propylazido linker of 2.23 and 2.24 with a propargyl 
linker as in 2.26 (hA1AR pKb = 7.04 ± 0.30 (91.0 nM)) and 2.27 (hA1AR pKb = 6.23 ± 
0.39 (585.0 nM)) greatly weakened the antagonist potency. Substituting the 
fluorosulfonyl-bearing ligand propylazido 2.24 or propargyl linker 2.27 to a methyl ester 
(2.28, hA1AR pKb = 7.77 ± 0.26 (17.1 nM)) group gave a pKb in between the former 
ligands. Meanwhile, the conversion of the fluorosulfonyl group to sulfonic acid 
analogues (2.25 and 2.29) in the series generally reduced the hA1AR pKb. The DU172 
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analogues 2.30 (hA1AR pKb = 7.59 ± 0.30 (0.5 nM)), where the propyl chain at the N1 
position of DU172 was replaced with a butyl chain, showed comparable hA1AR pKb to 
ligands 2.23 and 2.28 synthesised in the series. 
 
2.3.5 Assays of ligand activity at other AR subtypes  
Assays were also carried out to investigate ligand affinities at the other AR subtypes 
(A2AAR, A2BAR and A3AR). All these experiments and data analysis were conducted by 
PhD candidate Phuc Nguyen (Monash). A common downstream pathway linked to 
activation of all adenosine receptor subtypes was employed, namely cAMP 
accumulation, which is inhibited by the A1AR and A3AR but stimulated by the A2AAR 
and A2BAR. Concentration-response curves were generated in the absence or presence of 
a submaximal EC80 concentration of NECA (Figures 2.20a and 2.20b). Antagonists 
SLV320 (2.62), SCH442416 (2.63), PSB603 (2.64) and MRS1220 (2.65) were used as 
literature references against hA1AR-, hA2AAR-, hA2BAR- and hA3AR-FlpInCHO cells 
respectively. The estimated affinity (pKb) for hA1AR, hA2AAR, hA2BAR and hA3AR are 





Figure 2.20a. Adenosine receptor subtype selectivity of A1AR antagonists 2.23-2.30. Functional cAMP concentration-response curves to NECA 
(blue line) or A1AR antagonists in the presence of a submaximal (EC80) NECA concentration at the indicated hAR subtype stably expressed in 
FlpInCHO cells. Selective antagonists, SLV320, SCH442416, PSB603 and MRS1220 for hA1AR, hA2AAR, hA2BAR and hA3AR were performed 
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in parallel as positive controls. Data represent the mean ± SEM from n ≥ 3 performed in duplicate. Experiments and data analysis performed by 




Figure 2.20b.  Adenosine receptor subtype selectivity of A1AR antagonists 2.23-2.30. Functional cAMP concentration-response curves to NECA 
(dashed line) or A1AR antagonists in the presence of a submaximal (EC80) NECA concentration at the indicated AR subtype stably expressed in 
















































































































































































ECA 10 nM 
2.33+NECA 10 nM 
2.34+NECA 10 nM 
2.35+NECA 10 nM 
2.36+NECA 10 nM 
NECA 
PS 603+ E  10 nM 
2.37+NECA 10 nM 
2.38+NECA 10 nM 
2.39+NECA 10 nM 
2.40+NECA 10 nM 
NECA 
RS1220+NECA 10 nM 
2.33+NECA 10 nM 
2.34+NECA 10 nM 
2.35+NECA 10 nM 
2.36+NECA 10 nM 
EC  
20+NECA 10 nM 
2.37+NECA 10 nM 
2.38+NECA 10 nM 
2.39+NECA 10 nM 
2.40+NECA 10 nM 
111 
 
FlpInCHO cells. Selective antagonists, SLV320, SCH442416, PSB603 and MRS1220 for hA1AR, hA2AAR, hA2BAR and hA3AR were performed 
in parallel as positive controls. Data represent the mean ± SEM from n ≥ 3 performed in duplicate. Experiments and data analysis performed by 
PhD candidate Phuc Nguyen (Monash).
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Table 2.4. Adenosine receptor subtype affinity estimates (pKb) of 2.23-2.30 compounds 
on cAMP inhibition and accumulation in human AR-expressing FlpInCHO cells. 
Experiments and data analysis performed by PhD candidate Phuc Nguyen (Monash). 
Compound 
AR subtype 


















8.40 ± 0.32 
(4.0) 
7 
7.27 ± 0.35 
(53.7) 
6 
7.73 ± 0.14 
(18.6) 
7 




8.09 ± 0.31 
(8.1) 
8 7.42 ± 0.25 
(38.0) 
7 7.10 ± 0.15 
(79.4) 




6.99 ± 0.29b 
(102.3) 
2 n.d. 5 n.d. 5 




7.01 ± 0.66 
(97.7) 
3 n.d. 6 n.d. 6 




7.51 ± 0.16 
(30.9) 
7 n.d. 9 n.d. 8 




7.19 ± 0.45 
(64.6) 
3 n.d. 5 n.d. 5 




7.17 ± 0.33c 
(67.6) 
2 n.d. 5 n.d. 5 
7.08 ± 0.22 
(83.2) 
6 
2.30 n.d. 5 n.d. 5 n.d. 5 





9.44 ± 0.43 
(0.4) 
8 
9.47 ± 0.20 
(0.3) 
9 
8.87 ± 0.23 
(1.3) 
8 
8.30 ± 0.34 
(5.0) 
11 
aData are expressed as mean ± SEM from indicated number (n) of independent 
experiments performed in duplicate; n.d., denotes not defined due to incomplete 
inhibition and poor curve fit. 
bData are expressed as mean ± SD from indicated number (n) of independent experiments 
cSLV320, SCH442416, PSB603 and MRS1220 are used as reference antagonist in 




Compounds 2.23, 2.24 and 2.26 showed inhibition of NECA at all 4 hAR 
subtypes (refer Figure 2.11a and 2.11b). It was observed that 2.23 and 2.24 inhibited the 
activity of NECA with estimated affinity (pKb) at a log unit better at hA1AR and hA3AR 
than hA2AAR and hA2BAR. An overall inhibition of NECA was observed at hA2AAR and 
hA2BAR, however, the pKb for 2.25-2.29 at hA2AAR and hA2BAR could not be generated 
due to a poor curve fitting from the data set (labelled n.d. in the table).  
In general, 2.23-2.29 showed similar Kb values (within 4-fold) between hA1AR 
and hA3AR. 2.23 and 2.24 which possess the propylazido linker showed up to 13-fold 
hA1AR or hA3AR selectivity against hA2AAR and hA2BAR. The designed clickable 2.23 
competed strongest at hA1AR (pKb = 8.40 ± 0.32 (4.0 nM)) while addition of the covalent 
arm (2.24) gave the best pKb at hA3AR (pKB = 8.38 ± 0.29 (4.2 nM)) among all other 
synthesised A1AR analogues. The ligands 2.23-2.30 were designed and aimed to be 
A1AR selective, inspired by the selective A1AR ligands “compound 17” (2.22) and 
DU172 (1.11). However, the synthesised 2.23-2.30 demonstrated only narrow selectivity 
profile. Although disappointing in terms of a selective A1AR tool, the closely related 
activity observed for both hA1AR and hA3AR is not unusual due to the high similarity 
between structures of hA1AR and hA3AR (61% of sequence identity homology),
41 in 
particular, the conserved Y271 found on the hA1AR and hA3AR which could contribute 
to the covalent bonding to synthesised analogues containing the fluorosulfonyl group. 
Molecular modelling and docking studies were carried out in section 2.4 to further 
discuss the selectivity of synthesised ligands on ARs. 
 
2.3.6 Irreversibility assays 
The potential irreversibility of the designed covalent clickable ligands 2.24, 2.27 and 2.28 
were investigated with a washout assay. All these experiments and data analysis were 
performed by PhD candidate Phuc Nguyen (Monash). The washout assay was performed 
with 3 h pre-incubation with increasing concentration of ligands 2.24, 2.27 or 2.28 
followed by six extensive washes (6 x 20 min). After the subsequent incubation with 
[3H]DPCPX, radioligand binding was assessed and compared to the control condition 
without any competitor.  
 A ligand with a suitably positioned covalent functional group would be expected 
to bind covalently to the receptor within the 3 h incubation time with A1AR. The 
following washing steps would remove any non-covalent bound ligand while leaving the 
covalently bound ligand attached to A1AR. Then a specific high binding A1AR 
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radioligand, the same used in earlier experiments (refer section 2.3.1) was introduced to 
the system to bind to all “available” A1AR. The higher percentage of specific radioligand 
binding detected signifies more A1AR orthosteric sites were ‘free’ of ligand (either 
washed out or competed out). The literature covalent ligand FSCPX was used as a 
positive control. The designed covalent ligands 2.24, 2.27 and 2.28 containing a sulfonyl 
fluoride warhead were tested and all three resulted in lower specific [3H]DCPCX binding 
even than FSPCX (1.16) at the highest ligand concentration (Figure 2.21), suggesting 
good covalent and irreversible binding to hA1AR on the timescale of the experiment. 
Compounds 2.24 and 2.27 achieved complete inhibition of the ability of [3H]DPCPX to 
bind to hA1AR. It is postulated that the irreversible binding is associated with the ligand’s 
sulfonyl fluoride reacting with Y271 of A1AR (discussed later, Figure 2.25), which is 
analogous to the covalent interaction of DU172 towards Y271 of A1AR (discussed 
further in section 2.4). In contrast and as expected, radioligand binding was observed 
after treatment and washing with the analogous sulfonic acid-containing 2.25 and 2.29 
which indicated that the washing procedure was extensive enough to remove these 
ligands and implies, as expected, a non-covalent ligand-receptor interaction for the 
sulfonic acid derivatives. 
 
Figure 2.21. Displacement of specific [3H]DPCPX (1 nM) binding in hA1AR-FlpInCHO 
cells at 4°C with an incubation time of 4 hours after 3 h pre-incubation at 37°C followed 
by six extensive washing cycles. Experiments and data analysis performed by PhD 










2.3.7 In-situ click chemistry and imaging 
Covalent ligands 2.24 and 2.27 consisting of the azido or terminal alkyne functional 
group, respectively, were subjected to in-situ click reactions to examine clickability with 
a fluorophore (experiments and data analysis were performed by PhD candidate Phuc 
Nguyen (Monash)). hA1AR-FlpInCHO cells were pre-incubated with increasing 
concentrations of 2.24 or 2.27 to allow covalent binding, washed, followed by a CuAAC 
click reaction to attach a Cy5.5-azide or Cy5.5-alkyne fluorophore (Figure 2.22). The 
red-shifted Cy5.5 fluorophore was chosen because of the its high molar absorption 









Figure 2.22. A representative structure of a covalent ligand ‘clicked’ to a Cy5.5 
fluorophore (2.24-Cy5.5 shown here, assuming successful click reaction between 2.24 
and Cy5.5 alkyne fluorophore) bound to hA1AR. Reagents and conditions used in click 
reaction: 1 µM cyanine 5.5 azide or cyanine 5.5 alkyne, 1 mM ascorbic acid, TBTA in 
(t-butanol), 1 mM CuSO4, 1 h, rt (click reaction performed by PhD candidate Phuc 
Nguyen (Monash)). 
 
 Figure 2.13 showed in-gel Cy5.5 fluorescence image, immunoblot and a merged 
image of both 2.24 and 2.27. The presence of hA1AR was identified on the 








click reaction increased the intensity of Cy5.5 fluorescence (Panel A of Figure 2.23). The 
merged Cy5.5 fluorescence and hA1AR immunoblot was shown as red signal.  In 
contrast, there was minimal Cy5.5 fluorescence detected with probe 2.27 even at a 






















Figure 2.23. Concentration-dependent incorporation of Cy5.5 was evident in hA1AR-
FlpIn CHO cells by 2.24 but not 2.27. Panel (A) and (B) shows in-gel Cy5.5 fluorescence 
images coupled with immunoblots (indicative for hA1AR) shown in gray scale and 
merged Cy5.5 fluorescence in red and green. Experiments and data analysis performed 
by PhD candidate Phuc Nguyen (Monash). 
 
The quantification of Cy5.5 fluorescent signal was plotted against the 
concentration of 2.24 and 2.27 (Figure 2.24). Concentration-dependent click chemistry 
tethering of Cy5.5 fluorophore was observed with 2.24 but not 2.27. This suggests that 
±[2.24] µM - 0.1 1 10 
Cy5.5 
alkyne 
+ + + + 
±[2.27] µM - 0.1 1 10 30 





the propargyl linker on 2.27 could be less accessible for the click reaction with the 
fluorophore than for 2.24, perhaps due a shorter linker length.  
 
 
Figure 2.24. Quantification of fluorescence intensity labelled with increasing 
concentration of 2.24 or 2.27. Cy5.5 fluorescence was corrected for relative hA1AR level, 
expressed as fold over basal. Data represent the mean ± SEM from n = 3. Error bars not 
shown lie within dimensions of the symbol. Experiments and data analysis performed by 
PhD candidate Phuc Nguyen (Monash). 
 
2.4 Rationalisation of results using molecular modelling and docking 
The binding affinity and affinity estimates measured for 2.23-2.30 (section 2.3) generally 
showed an equipotent trend at both hA1AR and hA3AR. Since the series of ligand 2.23-
2.30 were inspired by the reported A1AR ligand DU172, computational studies were 
carried out to compare binding interactions and also attempt to rationalise the similar 
binding affinity of 2.24 at hA1AR and hA3AR. The only reported AR subtype selectivity 
studies for DU172 were carried out to compare binding of DU172 at hA1AR and 
hA2AAR
6 and data is not reported in literature for the binding of DU172 to hA3AR. 
Compound 2.24 was docked into the hA1AR crystal structure (PDB: 5UEN)
6 
using a covalent linkage to Y2717.36. The hA1AR crystal structure mentioned beyond this 
point refers to PDB ID 5UEN unless otherwise stated. As expected, 2.24 bound to A1AR 
in a similar fashion to DU172 with the same key interactions described by Gluhova et 










































al.6 such as a bidendate hydrogen bonds between N254 and the xanthine scaffold as well 
as the stabilisation of the covalent arm by the hydrogen bonding with Y12 via the amide 
carbonyl oxygen (Figure 2.25 A). The π-stacking of the xanthine core with F171 was 
well-preserved to anchor the ligand in the binding site. The flexible propylazido linker 
of 2.24 was easily accommodated and oriented towards the plasma membrane, with a 
hydrogen bond seen between E172 and the amide of 2.24 and another between the azide 
and the NH of K265 along EL3. 
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Figure 2.25. Docking studies of 2.24: (A) Highest ranked pose of 2.24 in the crystal 
structure of hA1AR (PDB: 5UEN), (B) Highest ranked pose of 2.24 docked in hA3AR 







hA1AR and hA3AR homology model; A1AR shown as purple ribbon; A3AR shown as a 
pink ribbon, 2.24 shown as yellow sticks in A and C, white sticks in B and C; Dashed 
yellow lines indicate hydrogen bond interactions. 2.24 was docked covalently to Y271 
(hA1AR) and Y265 (hA3AR). Amino acid residues are shown as green sticks in A and B, 
purple and pink in C. Nitrogen atom shown as blue. Oxygen atoms shown as red. 
 
2.24 was also docked into an A3AR homology model (Figure 2.15 B) using a 
covalent linkage to Y265, where the Y265 has been recently shown to be targetable by a 
fluorosulfonyl containing ligand.42 The hA3AR homology model was generated using 
Modeller v9.2243 using the structure of the hA1AR in complex with the covalent 
antagonist DU172 (PDB ID: 5UEN)6 by co-supervisor Assoc. Prof. Joel Tyndall. The 
model was based on the sequence alignment (Appendix 6) generated from the T-Coffee 
server.44 
The key bidentate interaction of N250 and the π-interaction of F168 with the 
xanthine scaffold of 2.24 are retained in the A3AR homology model. However, the 
hydrogen bonding between Y12 and the amide carbonyl oxygen of the covalent arm was 
not seen. The propylazido linker of 2.24 is stabilised differently in A3AR as compared to 
A1AR by electrostatic interactions of Q167, S165 and the hydrogen bonding between 
E258 and the carbonyl oxygen of the amide linker with A3AR. After this project was well 
through, the A3AR residue Y265 was identified by Yang et al.
45 to be involved in 
covalent bond formation with the fluorosulfonyl warhead of their compound ‘17b’, a 
similar ligand to 2.24. Residue Y265 of A3AR is in an analogous position as Y271 in 
A1AR thus rationalising the measured covalent binding and high apparent affinity (Table 
2.2) of 2.24 for both hA1AR and hA3AR. The docked poses of 2.24 in A1AR (PDB ID: 
5UEN) and A3AR homology model (UniProt code: P0DMS8) were aligned to better 
understand the A1AR/A3AR binding affinity (Figure 2.15 C). The xanthine core of 2.24 
docked in a similar fashion to A1AR and A3AR with subtle differences. The hA1AR (PDB 
ID: 5UEN)/hA3AR (UniProt code: P0DMS8) α-helix of TM7 was found to differ 
considerably towards the extracellular region. This causes a slight difference in position 
of residue Y271/Y265 which in turn resulted in a shift of the covalent arm by a small 
angle in the A3AR homology model. The residues H264 and K265 along EL3 of A1AR 
tend to flip outward creating a bigger cavity at the “gateway”. There is hydrogen bonding 
interaction between the carbonyl oxygen of H264 and the azido group of 2.24 and 
hydrogen bonding between E172 (hA1AR) and the amide NH of the linker. Residues 
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P260 and E258 along EL3 of A3AR homology model in turn show an inward closure 
leaving the opening of the extracellular surface more crowded. The propylazido linker of 
2.24 docked in a position away from what was seen in A1AR because of the hydrogen 
bonding interactions with Q167 and E258. This docking study indicated that the 
differences of amino acid residue around the extracellular surface could be used as an 
advantage to produce A1AR/A3AR selectivity. 
Compounds 2.24 and 2.27 (Figure 2.6) are two covalent clickable ligands with 
binding affinities of pKi 8.17 ± 0.14 (6.7 nM) and 7.58 ± 0.11 (26.1 nM) at hA1AR, 
respectively. A docking study was carried out to investigate the binding interactions that 
contributed to the one log unit difference in hA1AR binding affinity. The lowest energy 
poses of 2.24 and 2.27 (Figure 2.26) in the A1AR crystal structure (PDB ID: 5 UEN) 
were aligned. The core structures of both ligands sit in the binding site with only subtle 
differences. The key interactions around the core structure and the covalent arm of 2.24 
and 2.27 are similar to what was described in Figure 2.15 A. However, the more polar 
propylazido linker stretched towards the extracellular surface is further stabilised by 
hydrogen bonding to the NH of K265. This could partially explain the better affinity of 




Figure 2.26. Highest ranked pose of 2.24 and 2.27 in the hA1AR crystal structure (PDB: 
5UEN). A1AR shown as purple ribbon. 2.24 shown as yellow sticks. 2.27 shown as 
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magenta sticks. Dashed yellow lines indicate hydrogen bond interactions. Amino acid 
residues from A1AR are shown as green sticks. Nitrogen atoms shown as blue. Oxygen 
atoms shown as red. 
 
2.5 Summary, conclusions future directions 
The chapter aimed to develop selective high affinity clickable covalent A1AR ligands. A 
library of ligands consisting of: a) clickable and covalent (2.24 and 2.27), b) clickable 
and non-covalent (2.23, 2.25 and 2.26), c) non-clickable and covalent (2.28 and 2.30) 
and e) non-clickable and non-covalent (2.29) ligands were developed by the inspiration 
of the recently published A1AR crystal structure (PDB ID: 5UEN) complexed with 
DU172 and the A1AR selective bicyclo[2.2.2]octyl ligands recently reported (e.g. 
‘compound 17’ (2.22)).5  
The series of ligands (2.23-2.30) showed estimated hA1AR binding affinity 
between pKi 8.27 (5.4 nM) and 6.22 (605 nM). All ligands synthesised in this chapter 
acted as competitive antagonists at hA1AR in the cAMP inhibition assays. Compounds 
2.24 and 2.27, two ligands that showed particularly promising properties, had moderate 
to high binding affinities at hA1AR and hA3AR.  
The covalent clickable ligand with a propylazido linker (2.24) demonstrated 
better estimated affinity (pKb) at all AR subtypes than the covalent with a propargyl linker 
(2.27). Docking studies have been carried out to investigate ligand interactions between 
hA1AR and 2.24 and 2.27, however, the information generated was insufficient to 
determine specifics of the crucial selectivity issue between ligands binding at A1AR and 
A3AR. The irreversibility assay carried out showed covalent interactions between ligands 
2.24 and 2.27 with hA1AR.  
Moving forward, two avenues were proposed, one being development of ligands 
with longer linker (refer to Chapter 3 for design rationale and details), and the other being 
analogues with clickable linkers at different positions (2.66, 2.67, Appendix 7). 
Compounds 2.66 and 2.67 were designed as docking experiments with the A1AR crystal 
structure (PDB ID: 5UEN) (Figure 2.27) showed this linker position could be exposed to 
the extracellular surface of A1AR and potentially accessible by a fluorophore. However, 
the chemical synthesis was not pursued since the other avenue (Chapter 3) was 
undertaken instead and because the current series of compounds (and as reported in 
Chapter 3) has demonstrated excellent A1AR affinity and ability to “click” with a 
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fluorophore, albeit that the subtype selectivity could be improved on. A follow-up series 
of A1AR ligands consisting of similar ligands to 2.24 and 2.27 conjugated with different 
linker types and lengths is presented in Chapter 3. 
 
 
Figure 2.27. Docking poses of 2.66 (A) and 2.67 (B) in the hA1AR crystal structure. 
A1AR shown as purple ribbon. 2.66 shown as yellow sticks in Figure 2.27 A. 2.67 shown 
as yellow sticks in Figure 2.27 B. Dashed yellow lines indicate hydrogen bond 
interactions. Amino acid residues are shown as green sticks. Nitrogen atoms shown as 


















2.6 Experimental  
2.6.1 Methods and material (Chemistry).  
Chemicals were purchased from Sigma Aldrich, AK Scientific, Alfa Aesar or Merck and 
were used without further purification. Unless stated, anhydrous solvents and dry 
atmospheric conditions were used in all reactions.  Otherwise stated, all reactions were 
carried out at room temperature (rt) under atmospheric pressure. Thin layer 
chromatography (TLC) was carried out on silica gel plates 60 F254 and visualized under 
UV light at 254 nm. Potassium permanganate dip was used to visualise non-UV active 
compounds. Flash column chromatography separations using 40-63 µm silica were 
performed by gradient elution method and the elution solvent system are given in each 
instance. Reverse-phase high performance liquid chromatography (RP-HPLC) was 
carried out on an Agilent 1260 Infinity system, using a YMC-C8 5µm (150 × 10mm) 
column at 3mL/min for semi-preparative RP-HPLC and a YMC-C8 5µm (150 × 4.6mm) 
column at 1mL/min for analytical RP-HPLC. The mobile phases used were A: H2O 
(0.05% TFA) and B: 9:1 ACN/H2O (0.05% TFA). The standard analytical method for 
analytical RP-HPLC (for which retention times of compounds are given) was - 5% B for 
1 min, linear gradient from 5-95% B from 1-27 min (followed by 1 min hold at 95% B, 
then 2 min linear gradient from 95-5% B and 4 min re-equilibration at 5% B). All final 
compounds were > 95% RP-HPLC analytical purity as assessed by peak integration at 
245 nm. A typical semi-preparative HPLC method was carried out as described – 5% B 
for 1 min, linear gradient from 5-95% B from 1-12 min (followed by 2 min hold at 95% 
B, then 3 min linear gradient from 95%-5%.  High resolution electrospray ionisation mass 
spectra (HRMS-ESI) were obtained on a microTOFQ mass spectrometer. Proton (
1H), 
fluorine (19F) and carbon (13C) nuclear magnetic resonance (NMR) spectroscopy was 
carried out using 400 MHz or 500 MHz Varian NMR spectrometer. Two-dimensional 
NMR experiments, including COSY, HSQC, HMBC and NOESY, were used to assign 
chemical shifts and for some compounds to assign regioisomers. Chemical shifts are 
listed on the 𝛿 scale in part(s) per million (ppm), referenced to CDCl3 (1H NMR: 𝛿 7.26, 
13C NMR: 𝛿 77.16) or DMSO-d6 (1H NMR: 𝛿 2.50, 13C NMR: 𝛿 39.52) with residual 
solvent as the internal standard and coupling constants (J) recorded in Hertz (Hz). Note 
– not all magnetically non-equivalent carbons were observed in 13C NMR spectrum for 
all compounds. Signal multiplicities are assigned as: s, singlet; d, doublet; t, triplet; q, 










To a solution of 0.5M aq. H2SO4 (90 mL) was added 2,4-dimethoxybenzylamine (13.5 
mL, 89.7 mmol). The reaction mixture was heated to 85 °C and then potassium cyanate 
(7.3 g, 89.7 mmol) was added. The mixture was stirred for 1.5 h at 85 °C and then cooled 
to rt. Upon cooling a precipitate formed, which was collected by filtration, washed with 
water, cold ethanol (10 mL) and oven-dried at 80 °C. The crude product was 
recrystallized from ethanol/water (1:1) to give 2.31 (18.2 g, 86.6 mmol, 96 %) as 
colourless crystals. 1H NMR (400 MHz, DMSO-d6): 𝛿 3.73 (s, 3H), 3.78 (s, 3H), 4.04 
(d, J = 5.8 Hz, 2H), 5.46 (br s, 2H), 6.09 (t, J = 6.0 Hz, 1H), 6.46 (dd, J = 2.4, 8.4 Hz, 
1H), 6.53 (d, J = 2.4 Hz, 1H), 7.07 (d, J = 8.4 Hz, 1H). 13C NMR (400 MHz, DMSO-d6): 
𝛿 37.7, 55.2, 55.4, 98.2, 104.2, 120.4, 128.7, 157.7, 158.6, 159.5. HRMS (ESI) calculated 
for C10H14N2NaO3
+ [M+Na]+ 233.0897; found m/z 233.0886. The experimental data is 






Under vigorous stirring, cyanoacetic acid (8.0 g, 94.2 mmol) and 2.31 (18.0 g, 85.6 
mmol) were added to acetic anhydride (85 mL). The mixture was heated to 70 °C and 
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stirred for 1.5 h. Upon cooling to rt, the reaction mixture was diluted with diethyl ether 
(85 mL) and the precipitate formed was collected by filtration and washed two times (2 
x 200 mL) with diethyl ether. The crude product was recrystallized from methanol to 
give 2.32 (20.0 g, 72.1 mmol, 84 %) as colourless crystals. 1H NMR (400 MHz, DMSO-
d6): 𝛿 3.75 (s, 3H), 3.81 (s, 3H), 3.90 (br s, 2H), 4.24 (d, J = 6.0 Hz, 2H), 6.47 (dd, J = 
2.4, 8.4 Hz, 1H), 6.57 (d, J = 2.4 Hz, 1H), 7.09 (d, J = 8.4 Hz, 1H), 8.29 (br s, 1H), 10.57 
(br s, 1H). 13C NMR (400 MHz, DMSO-d6): 26.7, 38.2, 55.2, 55.5, 98.4, 104.4, 115.1, 
118.4, 129.2, 152.2, 158.0, 160.1, 165.1. HRMS (ESI) calculated for C13H15N3NaO4
+ 
[M+Na]+ 300.0955; found m/z 300.0952. The experimental data is in agreement with the 







2.32 (1.9 g, 7.0 mmol) was suspended in ethanol (18 mL) and heated to 70 °C. Under 
stirring a solution of sodium ethoxide in ethanol (0.9 mL of a 21 % solution in ethanol, 
2.4 mmol) was added dropwise and the resulting suspension was stirred for 1 h at 70 °C. 
The reaction mixture was diluted with water (19 mL), neutralised to pH 7 with 32 % HCl 
and cooled overnight. The precipitate formed was collected by filtration, washed with a 
small amount of methanol (5 mL), diethyl ether (10 mL) and air-dried to give 2.33 (1.4 
g, 4.9 mmol, 67 %) as a colourless solid. 1H NMR (400 MHz, DMSO-d6): 𝛿 3.73 (s, 3H), 
3.82 (s, 3H), 4.59 (d, J = 1.6 Hz, 1H), 4.84 (s, 2 H), 6.49 (dd, J = 2.4, 8.6 Hz, 1 H), 6.58 
(d, J = 2.4 Hz, 1 H), 6.65 (br s, 2 H), 6.73 (d, J = 8.6 Hz, 1H), 10.41 (s, 1H). 13C NMR 
(400 MHz, DMSO-d6): 𝛿 39.3, 55.3, 55.5, 75.4, 98.4, 104.7, 116.3, 126.0, 151.3, 156.0, 
157.1, 159.8, 162.3. HRMS (ESI) calculated for C13H15N3NaO4
+ [M+Na]+ 300.0955; 










To a stirred suspension of 2.33 (3.4 g, 12.4 mmol) in DMF (60 mL) at 40 °C, 
dimethylformamide-dimethyl acetal (3.0 g, 24.8 mmol) was added and the mixture was 
stirred for 4 h at 40 °C. Ice water (120 mL) was added and the resulting mixture was 
stirred for 1 h and cooled overnight. The precipitate formed was collected by filtration, 
washed with water and oven-dried at 80 °C to give 2.34 (3.1 g, 9.2 mmol, 74 %) as 
colourless crystals. 1H NMR (400 MHz, DMSO-d6): 𝛿 2.82 (s, 3H), 3.04 (s, 3H), 3.71 
(s, 3H), 3.78 (s, 3H), 4.99 (s, 2H), 5.03 (s, 1H), 6.42 (dd, J = 2.4, 8.4 Hz, 1H), 6.53 (d, J 
= 2.4 Hz, 1H), 6.66 (d, J = 8.4 Hz, 1H), 8.02 (s, 1H), 10.7 (br s, 1H). 13C NMR (400 
MHz, DMSO-d6): 𝛿 34.1, 39.5, 39.9, 55.1, 55.4, 82.2, 98.1, 104.4, 118.8, 126.2, 151.8, 
155.8, 157.0, 159.2, 160.5, 163.2. HRMS (ESI) calculated for C16H20N4NaO4
+ [M+Na]+ 




















To a stirred suspension of 2.34 (3.1 g, 9.3 mmol) in acetonitrile (11 mL) and DMF (6 
mL), Cs2CO3 (3.3 g, 10.0 mmol) and tetra-N-butylammonium bromide (TBAB) (20 mg, 
0.06 mmol) were added. The 1-bromobutane (1.9 g, 1.5 mL, 13.9 mmol) was added drop-
wise over 15 min and the reaction mixture was stirred for 1 h at rt and then 3 h at 60 °C. 
Ice water (75 mL) was added and mixture was stirred for 30 min. The mixture was 
extracted with CH2Cl2 (50 mL) and washed with saturated aq. NaHCO3 (50 mL) and 
brine (50 mL). The pooled organic layers were dried with MgSO4, filtered and 
concentrated in vacuo. The solid obtained was recrystallized with 50 % aq. methanol, 
filtered and washed with cold 50 % aq. methanol and air-dried to give 2.35 (2.8 g, 7.1 
mmol, 76 %) as off-white crystals. 1H NMR (400 MHz, DMSO-d6): 𝛿 0.88 (t, J = 7.4 
Hz, 3H), 1.25 (m, 2H), 1.47 (m, 2H), 2.83 (s, 3H), 3.04 (s, 3H), 3.71 (s, 3H), 3.76 (t, J = 
7.2 Hz, 2H), 3.78 (s, 3H), 5.05 (s, 2H), 5.17 (s, 1H), 6.41 (dd, J = 2.4, 8.4 Hz, 1H), 6.53 
(d, J = 2.4 Hz, 1H), 6.64 (d, J = 8.4 Hz, 1H), 8.04 (s, 1H). 13C NMR (400 MHz, DMSO-
d6): 𝛿 13.7, 19.6, 29.6, 34.1, 39.5, 39.7, 39.9, 55.1, 55.4, 81.8, 98.1, 104.4, 118.2, 126.2, 
151.8, 155.8, 157.0, 158.9, 159.2, 162.1. HRMS (ESI) calculated for C20H29N4O4
+ 
[M+H]+ 389.2183 and C20H28N4NaO4














To a stirred suspension of 2.35 (3.5 g, 9.0 mmol) in methanol (46 mL) was added 2 M 
aq. KOH (30 mL). The suspension was stirred at 50 °C for 1 h. The reaction mixture was 
cooled to rt and neutralised to pH 7 with 2 M aq. HCl. Upon cooling to 5 °C and stirring 
for 2 h a precipitate formed, which was collected by filtration, washed with water and 
air-dried to give 2.36 (2.6 g, 7.7 mmol, 86 %) as colourless fluffy crystals. 1H NMR (400 
MHz, DMSO-d6): 𝛿 0.86 (t, J = 7.2 Hz, 3H), 1.23 (m, 2H), 1.43 (m, 2H), 3.71 (t, J = 7.6 
Hz, 2H), 3.73 (s, 3H), 3.82 (s, 3H), 4.72 (s, 1H), 4.90 (br s, 2H), 6.49 (dd, J = 2.2, 8.4 
Hz, 1H), 6.59 (d, J = 2.2 Hz, 1H), 6.67 (br s, 2H), 6.71 (d, J = 8.4 Hz, 1H). 13C NMR 
(400 MHz, DMSO-d6): 𝛿 13.7, 19.6, 29.7, 39.3, 39.9, 55.3, 55.5, 75.2, 98.4, 104.7, 116.3, 
126.1, 151.3, 154.6, 157.2, 159.8, 161.2. HRMS (ESI) calculated for C17H24N3O4
+ 
[M+H]+ 334.1761 and C17H23N3NaO4


















The aminouracil 2.36 (2.3 g, 7.0 mmol) was dissolved in 50 % aq. acetic acid (50 mL) 
and heated to 70 °C. NaNO2 (1.0 g, 14.1 mmol) was added in 3 batches over 30 min, and 
the reaction was stirred for 1 h at 70 °C. The mixture was cooled to rt and the precipitate 
that formed was collected by filtration, washed with water (50 mL) and diethyl ether (30 
mL) and air-dried to give the nitro-intermediate as a pink solid (2.3 g). Some of this nitro 
intermediate (0.70 g) was dissolved in 25 % aq. ammonia (10 mL) and methanol (10 mL) 
and heated to 80 °C. Na2S2O4 (0.9 g, 5.2 mmol) was added in 3 batches over 30 min and 
the reaction was stirred for 4 h at 80 °C. The mixture was cooled to rt and stirred 
overnight. The crystals that formed were collected by filtration, washed with water (50 
mL) and diethyl ether (30 mL) and air-dried to give 2.37 (0.6 g, 1.6 mmol, 76 %) as grey-
green crystals. Compound 2.37 was used immediately without further purification due to 
instability. 1H NMR (400 MHz, DMSO-d6): 𝛿 0.87 (t, J = 7.4 Hz, 3H), 1.24 (m, 2H), 
1.47 (m, 2H), 3.73 (s, 3H), 3.78 (t, J = 7.2 Hz, 2H), 3.83 (s, 3H), 4.96 (s, 2H), 6.47 (dd, 
J = 2.4, 8.4 Hz, 1H), 6.59 (d, J = 2.4 Hz, 1H), 6.73 (d, J = 8.4 Hz, 1H). The two -NH2 
hydrogens were not detected. 13C NMR (400 MHz, DMSO-d6): 𝛿 13.7, 19.6, 29.7, 40.2, 
40.3, 55.0, 55.2, 55.3, 96.1, 109.6, 116.5, 126.6, 144.3, 149.6, 157.2, 158.8, 159.8. 
HRMS (ESI) calculated for C17H24N4NaO4
+ [M+H]+ 371.1690 and C34H48N8NaO8
+ 












To a suspension of bicyclo[2.2.2]octane-1,4-dicarboxylic acid monomethyl ester (49 mg, 
0.23 mmol) in acetonitrile (2 mL) was added Et3N (90 mg, 124 µL, 0.99 mmol) and the 
reaction stirred for 5 min. HATU (88 mg, 0.23 mmol) was added and the reaction stirred 
for 15 min. The diaminouracil 2.37, dissolved in acetonitrile (2 mL), was added dropwise 
and the reaction stirred for 1 h. The mixture was concentrated in vacuo and 10% citric 
acid (10 mL) was added. The aq. solution was extracted 3 times with ethyl acetate (3 x 
10 mL) then the pooled organic layers were washed with saturated NaHCO3 (10 mL), 
brine (10 mL) and concentrated in vacuo. Isopropanol (1.1 mL) and 1 M aq. KOH (1.1 
mL) were added and the reaction was heated at reflux for 1 h. The mixture was cooled, 
concentrated in vacuo, water (5 mL) was added, and the mixture was washed twice with 
CH2Cl2, (10 mL) discarding the organic washings. The aq. solution was acidified to pH 
5 with 12 M aq. HCl. The mixture was refrigerated overnight and the resultant precipitate 
was collected by filtration, rinsed with water and oven-dried at 80 °C to give 2.39 (87 
mg, 0.17 mmol, 73 %) as a white solid. 1H NMR (400 MHz, DMSO-d6): 𝛿 0.88 (t, J = 
7.2 Hz, 3H), 1.27 (m, 2H), 1.50 (m, 2H), 1.70-1.88 (m, 12H), 3.71 (s, 3H), 3.81 (s, 3H), 
3.86 (t, J = 7.2 Hz, 2H), 5.04 (s, 2H), 6.39 (dd, J = 2.4, 8.4 Hz, 1H), 6.57 (d, J = 2.4 Hz, 
1H), 6.69 (d, J = 8.4 Hz, 1H), 12.07 (br s, 1H), 12.96 (s, 1H). 13C NMR (400 MHz, 
DMSO-d6): 𝛿 13.7, 19.6, 27.4, 27.6, 29.4, 29.7, 33.2, 37.6, 37.7, 40.0, 40.3, 40.8, 55.2, 
55.5, 98.3, 104.5, 106.5, 116.7, 126.9, 147.6, 150.6, 154.0, 157.4, 159.6, 160.2, 178.4, 
178.5. HRMS (ESI) calculated for C27H35N4O6
+ [M+H]+ 511.2551 and C27H34N4NaO6
+ 








According to the procedure described for 2.39, cyclohexanoic acid (129 mg, 1.0 mmol), 
Et3N (392 mg, 3.9 mmol), HATU (383 mg, 1.0 mmol), 2.37 (351 mg, 1.0 mmol) followed 
with column elution with n-hexane/ethyl acetate (4:6) gave 2.40 (391 mg, 0.88 mmol, 
88 %) as a white solid. 1H NMR (400 MHz, DMSO-d6): 𝛿 0.88 (t, J = 7.2 Hz, 3H), 1.10-
1.90 (m, 14H), 1.72 (m, 2H), , 3.71 (s, 3H), 3.82 (s, 3H), 3.86 (t, J = 7.4 Hz, 2H), 5.04 
(s, 2H), 6.39 (dd, J = 2.4, 8.4 Hz, 1H), 6.57 (d, J = 2.4 Hz, 1H), 6.66 (d, J = 8.4 Hz, 1H), 
13.10 (br s, 1H). 13C NMR (400 MHz, DMSO-d6): 𝛿 13.7, 19.6, 25.3, 25.3 (2 equivalent 
cyclohexyl carbons), 29.7, 31.0 (2 equivalent cyclohexyl carbons), 37.6, 40.3, 41.1, 55.2, 
55.5, 98.3, 104.4, 106.1, 109.6, 116.7, 126.7, 147.8, 150.7, 154.0, 157.4, 158.3, 159.6. 
HRMS (ESI) calculated for C24H33N4O4
+ [M+H]+ 441.2496 and C24H32N4NaO4
+ 






3-Bromopropylamine hydrobromide 2.41 (3.0 g, 13.7 mmol) was dissolved in water (12 
mL), then NaN3 (2.7 g, 41.0 mmol) was added and stirred for 10 min and then heated to 
80 °C for 12 h. The reaction mixture was cooled to rt and approximately 2/3 of the water 
was removed under vacuum. The residue was diluted with diethyl ether (10 mL) and the 
biphasic mixture was cooled in ice. KOH (4.0 g) was added and the aq. layer was 
extracted 3 times with diethyl ether (3 x 50 mL). The pooled organic layer was dried with 
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anhydrous MgSO4, filtered and the solvent air-dried overnight to give 3-azidopropan-1-
amine 2.42 (939 mg, 9.4 mmol, 68 %) as a pale yellow oil. 1H NMR (400 MHz, DMSO-
d6): 𝛿 1.59 (m, 2H), 2.59 (t, J = 6.6 Hz, 2H), 3.37 (t, J = 6.8 Hz, 2H). The -NH2 hydrogens 
were not detected. 13C NMR (400 MHz, DMSO-d6): 𝛿 32.1, 38.7, 48.5. The experimental 
data is in agreement with the literature reported compound.47 
 




4-(Fluorosulfonyl)benzoic acid 2.43 (1.0 g, 4.9 mmol) was dissolved in DMF (25 mL). 
2-Ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (EEDQ) (1.4 g, 5.6 mmol) was added 
and the mixture was cooled to 0 °C and then stirred for 2 min. 3-Bromopropylamine 
hydrobromide 2.41 (1.4 g, 6.4 mmol) was pre-neutralised with DIPEA (1.1 mL, 6.4 
mmol) in DMF (5 mL), and was then added drop-wise to the benzoic acid solution. 
DIPEA (1.9 g, 14.7 mmol) was added dropwise and the reaction mixture was stirred for 
8 h at 0 °C and then 8 h at rt. Water was added and the mixture was extracted three times 
with ethyl acetate (3 x 30 mL). The pooled organic layer was washed three times with 
2% aq. HCl (3 x 20 mL), dried with MgSO4, filtered and concentrated in vacuo. The 
residue was purified using flash column chromatography on silica gel with hexane/ ethyl 
acetate (4:6) to give 2.44 (1.1 g, 3.5 mmol, 72 %) as white crystals. 1H NMR (400 MHz, 
DMSO-d6): 𝛿 2.09 (m, 2H), 3.42 (q, J = 6.4 Hz, 2H), 3.60 (t, J = 6.6 Hz, 2H), 8.17 (d, J 
= 8.2 Hz, 2H), 8.26 (d, J = 8.2 Hz, 2H), 8.93 (t, J = 5.6 Hz, 1H). 13C NMR (400 MHz, 
DMSO-d6): 𝛿 32.0, 32.4, 38.1, 128.6 (2 equivalent aryl carbons), 129.1 (2 equivalent 
aryl carbons), 133.4 (d), 141.4, 164.5. 19F NMR (400 MHz, DMSO-d6): 𝛿 66.13. HRMS 
(ESI) calculated for C10H12BrFNO3S
- [M+H]+ 323.9700 and 325.9679; found m/z 











The xanthine 2.40 (250 mg, 0.57 mmol) was dissolved in DMF (5 mL) then K2CO3 (118 
mg, 0.85 mmol) was added and the reaction mixture was stirred for 45 min at 50 °C. 
Pivaloxymethyl chloride (112 mg, 0.74 mmol) was added drop-wise and the reaction 
mixture was stirred for 5 h at 50 °C. The reaction mixture was cooled to rt and 
concentrated in vacuo. Water (30 mL) was added and the aq. solution was extracted 2 
times with ethyl acetate (2 x 25 mL). The pooled organic layers were dried over MgSO4, 
filtered and concentrated in vacuo. The residue was purified using flash column 
chromatography on silica gel with hexane/ ethyl acetate (6:4) to give 2.45 (292 mg, 0.50 
mmol, 95 %) as white crystals. 1H NMR (400 MHz, DMSO-d6): 𝛿 0.87 (t, J = 7.4 Hz, 
3H), 1.12 (s, 9H), 1.18-1.82 (m, 14H), 2.97 (m, 1H), 3.72 (s, 3H), 3.79 (s, 3H), 3.85 (t, J 
= 7.2 Hz, 2H), 5.05 (s, 2H), 6.25 (s, 2H), 6.40 (dd, J = 8.4, 2.6 Hz, 1H), 6.57 (d, J = 2.6 
Hz, 1H), 6.77 (d, J = 8.4 Hz, 1H). 13C NMR (400 MHz, DMSO-d6): 𝛿 13.7, 19.5, 25.2 
(2 equivalent cyclohexyl CH2 carbons), 26.5 (3 equivalent CHCH3 carbons), 29.6, 31.3 
(2 equivalent cyclohexyl CH2 carbons), 34.5, 38.2, 39.8, 41.1, 55.2, 55.5, 67.1, 98.3, 
104.5, 105.1, 116.4, 127.5, 148.0, 150.3, 153.8, 157.5, 159.4, 159.8, 176.3. The 













The DMB-protected carboxamide 2.45 (245 mg, 0.44 mmol) was dissolved in neat TFA 
(2 mL) and stirred overnight at 50 °C. The reaction mixture was cooled to rt and blown 
with compressed air for 20 min to evaporate excess TFA. CH2Cl2 (30 mL) was added 
and the organic solution was concentrated in vacuo and then dried overnight on high 
vacuum. The residue was dissolved in DMF (5 mL) then K2CO3 (79 mg, 0.57 mmol) was 
added and the reaction mixture was stirred for 45 min. 4-((3-
Bromopropyl)carbamoyl)benzenesulfonyl fluoride 2.44 (in a solution of DMF (2 mL)) 
(171 mg, 0.53 mmol) was added drop-wise and the reaction mixture was stirred 
overnight. The reaction mixture was concentrated in vacuo and water (30 mL) was added. 
The aq. solution was extracted 3 times with ethyl acetate (3 x 25 mL). The pooled organic 
layers were dried with MgSO4, filtered and concentrated in vacuo. The crude product 
was purified by column chromatography eluting with n-hexane/ ethyl acetate (7:3) to 
give 2.46 (184 mg, 0.28 mmol, 64%) as a colourless liquid. 1H NMR (400 MHz, DMSO-
d6): 𝛿 0.87 (t, J = 7.2 Hz, 3H), 1.10 (s, 9H), 1.19-1.77 (m, 14H), 1.96 (m, 2H), 2.92 (m, 
1H), 3.32 (q, J = 6.4 Hz, 2H), 3.84 (t, J = 7.2 Hz, 2H), 4.08 (t, J = 6.4 Hz, 2H), 6.22 (s, 












The DMB-protected carboxamide 2.40 (332 mg, 0.75 mmol) was dissolved in neat TFA 
(2.5 mL) and stirred overnight at 50 °C. The reaction mixture was cooled to rt and blown 
with compressed air for 20 min to evaporate excess TFA. CH2Cl2 (30 mL) was added 
and the organic solution was concentrated in vacuo and then dried overnight on high 
vacuum. The residue was dissolved in DMF (5 mL) then K2CO3 was added and the 
reaction mixture was stirred for 45 min. 4-((3-Bromopropyl)carbamoyl)benzenesulfonyl 
fluoride 2.44 (in a solution of DMF (2 mL)) (370 mg, 1.1 mmol) was added drop-wise 
and the reaction mixture was stirred overnight. The reaction mixture was concentrated in 
vacuo and water (30 mL) was added. The aq. solution was extracted 3 times with ethyl 
acetate (3 x 25 mL). The combined organic layers were dried with MgSO4, filtered and 
concentrated in vacuo. The crude product was purified by column chromatography 
eluting with n-hexane/ ethyl acetate (4:6) to give 2.30 (343 mg, 0.64 mmol, 85 %) as a 
white solid. 1H NMR (500 MHz, DMSO-d6): 𝛿 0.88 (t, J = 7.3 Hz, 3H, 41-H), 1.12-2.00 
(m, 16H, 15-H, 16-H, 17-H, 18-H, 19-H, 23-H, 39-H, 40-H), 2.62 (m, 1H, 14-H), 3.31 
(q, J = 6.5 Hz, 2H, 24-H), 3.85 (t, J = 7.3 Hz, 2H, 38-H), 4.07 (t, J = 6.8 Hz, 2H, 5-H), 
8.17 (d, J = 8.5 Hz, 2H, 29-H and 33-H), 8.26 (d, J = 8.5 Hz, 2H, 30-H and 32-H), 8.87 
(t, J = 5.5 Hz, 1H, 25-NH), 13.04 (br s, 1H, 11-NH).  13C NMR (500 MHz, DMSO-d6): 
𝛿 13.7 (C-41), 19.6 (C-40), 25.2 (C-17), 25.3 (C-16), 25.3 (C-18), 27.4 (C-23), 29.7 (C-
39), 30.9 (C-15,19), 36.8 (C-24), 37.5 (C-14), 40.2 (C-38), 40.7 (C-5), 106.0 (C-7), 128.6 
(2 equivalent aryl carbons, C-29 and 33), 129.0 (2 equivalent aryl carbons, C-30 and 32), 
133.4 (d) (C-31), 141.6 (C-27), 147.5 (C-9), 150.6 (C-2), 153.9 (C-6), 158.1 (C-12), 
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164.2 (C-26). 19F NMR (400 MHz, DMSO-d6): 𝛿 66.04. HRMS (ESI) calculated for 
C25H31FN5O5S
- [M-H]- 532.2035; found m/z 532.2068. HPLC: 19.52 min. 
 
Methyl 4-{1-butyl-3-[(2,4-dimethoxyphenyl)methyl]-2,6-dioxo-2,3,6,7-tetrahydro-




2.39 (400 mg, 0.78 mmol) was dissolved in methanol (20 mL) and H2SO4 (5 drops) were 
added and the reaction mixture was stirred at reflux for 3 h. The mixture was cooled to rt 
overnight and the resultant crystals were collected by filtration, washed with water and 
oven-dried at 80 °C to give 2.48 (291 mg, 0.55 mmol, 71 %) as white fluffy crystals. 1H 
NMR (400 MHz, DMSO-d6): 𝛿 0.88 (t, J = 7.4 Hz, 3H), 1.27 (m, 2H), 1.50 (m, 2H), 
1.70-1.89 (m, 12H), 3.58 (s, 3H), 3.71 (s, 3H), 3.81 (s, 3H), 3.86 (t, J = 7.4 Hz, 2H), 5.04 
(s, 2H), 6.39 (dd, J = 2.4, 8.4 Hz, 1H), 6.57 (d, J = 2.4 Hz, 1H), 6.69 (d, J = 8.4 Hz, 1H), 
13.00 (br s, 1H). 13C NMR (400 MHz, DMSO-d6): 𝛿 13.7, 19.6, 27.6 (3 equivalent CH2 
carbons), 29.2 (3 equivalent CH2 carbons), 29.7, 33.1, 38.2, 40.3, 41.1, 51.6, 55.2, 55.5, 
98.3, 104.4, 106.5, 116.7, 126.9, 147.5, 150.6, 154.0, 157.4, 159.6, 160.0, 177.0. HRMS 
(ESI) calculated for C28H36N4NaO6
+ [M+Na]+ 547.2527; found m/z 547.2509. 
 
General procedure for the synthesis of carboxamides 2.49, 2.50. The carboxylic acid 
was dissolved in DMF, then N,N-diisopropylethylamine (DIPEA) was added and the 
reaction mixture stirred for 5 min. HATU was added and the reaction mixture was stirred 
for 15 min. The NH2-‘linker’ was added dropwise and the reaction was stirred for 2.5 h. 
The mixture was concentrated in vacuo and then ethyl acetate and saturated aq. NaHCO3 
were added. The aq. layer was washed 2 times with ethyl acetate and the pooled organic 
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phases were concentrated in vacuo. The residue was purified using flash column 
chromatography on silica gel.  
 
4-{1-Butyl-3-[(2,4-dimethoxyphenyl)methyl]-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-




2.39 (990 mg, 1.9 mmol), DMF (4 mL), DIPEA (751 mg, 5.8 mmol), HATU (737 mg, 
1.9 mmol) and propargyl amine (138 mg, 2.5 mmol) following column elution with n-
hexane/ethyl acetate (6:4) gave 2.49 (807 mg, 1.5 mmol, 76 %) as a colourless oil. 1H 
NMR (400 MHz, DMSO-d6): 𝛿 0.88 (t, J = 7.4 Hz, 3H), 1.27 (m, 2H), 1.50 (m, 2H), 
1.66-1.87 (m, 12H), 3.02 (t, J = 2.4 Hz, 1H), 3.71 (s, 3H), 3.80 (m, 2H), 3.81 (s, 3H), 
3.86 (t, J = 7.4 Hz, 2H), 5.03 (s, 2H), 6.39 (dd, J = 2.4, 8.4 Hz, 1H), 6.57 (d, J = 2.4 Hz, 
1H), 6.68 (d, J = 8.4 Hz, 1H), 7.89 (t, J = 5.6 Hz, 1H), 13.00 (br s, 1H). 13C NMR (400 
MHz, DMSO-d6): 𝛿 13.8, 19.6, 27.7 (3 equivalent carbons), 28.1, 29.7 (3 equivalent 
carbons), 33.2, 38.1, 40.3, 41.1, 55.2, 55.5, 72.3, 72.4, 81.8, 98.3, 104.4, 106.6, 116.7, 
126.9, 147.6, 150.6, 154.0, 157.4, 159.7, 160.3, 176.2. HRMS (ESI) calculated for 
C30H37N5NaO5
+ [M+Na]+ 570.2687 and C60H74N10NaO10
+ [2M+Na]+ 1117.5482; found 













2.39 (1.0 g, 2.0 mmol), DMF (4 mL), DIPEA (744 mg, 5.8 mmol), HATU (744 mg, 2.0 
mmol) and 3-azidopropan-1-amine 2.42 (255 mg, 2.5 mmol) following column elution 
with CH2Cl2/methanol (9.7:0.3) gave 2.50 (985 mg, 1.7 mmol, 85 %) as a colourless 
gummy liquid. 1H NMR (400 MHz, DMSO-d6): 𝛿 0.88 (t, J = 7.4 Hz, 3H), 1.28 (m, 2H), 
1.51 (m, 2H), 1.64 (m, 2H), 1.66-1.87 (m, 12H), 3.09 (q, J = 6.4 Hz, 2H), 3.30 (t, J = 6.8 
Hz, 2H), 3.72 (s, 3H), 3.81 (s, 3H), 3.86 (t, J = 7.4 Hz, 2H), 5.04 (s, 2H), 6.39 (dd, J = 
2.4, 8.4 Hz, 1H), 6.57 (d, J = 2.4 Hz, 1H), 6.70 (d, J = 8.4 Hz, 1H), 7.47 (t, J = 5.8 Hz, 
1H), 12.87 (br s, 1H). 13C NMR (400 MHz, DMSO-d6): 𝛿 13.7, 19.6, 27.8 (3 equivalent 
carbons), 28.4, 29.6 (3 equivalent carbons),  33.2, 36.1, 38.1, 38.2, 40.3, 41.1, 48.5, 55.2, 
55.5, 98.3, 104.4, 106.5, 116.7, 127.0, 147.5, 150.6, 154.0, 157.4, 159.6, 160.4, 176.5. 
HRMS (ESI) calculated for C30H41N8O5
+ [M+H]+ 593.3194 and C30H40N8NaO5
+ 
[M+Na]+ 615.3014; found m/z 593.3187 and 615.3014. 
 
General procedure of the synthesis of sulfonyl fluorides 2.28, 2.27, 2.24. The DMB-
protected carboxamide was dissolved in neat TFA and stirred overnight at 50 °C. The 
reaction mixture was cooled to rt and blown with compressed air for 20 min to evaporate 
excess TFA. CH2Cl2 was added and the organic solution was concentrated in vacuo and 
then dried overnight on high vacuum. The residue was dissolved in DMF then K2CO3 
was added and the reaction mixture was stirred for 45 min. 4-((3-
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Bromopropyl)carbamoyl)benzenesulfonyl fluoride 2.44 (in a solution of DMF) was 
added drop-wise and the reaction mixture was stirred overnight. The reaction mixture 
was concentrated in vacuo and water was added. The aq. solution was extracted 3 times 
with ethyl acetate. The pooled organic layers were dried with MgSO4, filtered and 
concentrated in vacuo. The crude product was purified by column chromatography and 
underwent subsequent semi-preparative RP-HPLC purification. 
 
Methyl 4-[1-butyl-3-(3-{[4-(fluorosulfonyl)phenyl]formamido}propyl)-2,6-dioxo-




2.48 (290 mg, 0.55 mmol), TFA (2 mL), DMF (4 mL), K2CO3 (77 mg, 0.55 mmol), 4-
((3-bromopropyl)carbamoyl)benzenesulfonyl fluoride 2.44 (270 mg, 0.83 mmol) (in a 
solution of DMF (2 mL) following column elution with CH2Cl2/ (CH3)2CO (9:1) gave a 
white solid (218 mg). Some of this white solid (68 mg) was further purified by semi-
preparative RP-HPLC purification to give 2.28 (15 mg, 0.024 mmol, 15%) as white 
crystals. 1H NMR (500 MHz, DMSO-d6): 𝛿 0.88 (t, J = 7.3 Hz, 3H, 13-H), 1.27 (m, 2H, 
12-H), 1.50 (m, 2H, 11-H), 1.64-1.81 (m, 12H, 18-H, 19-H, 21-H, 22-H, 26-H, 27-H), 
1.96 (m, 2H, 28-H), 3.31 (q, J = 6.3 Hz, 2H, 29-H), 3.58 (s, 3H, 43-H), 3.85 (t, J = 7.3 
Hz, 2H, 10-H), 4.06 (t, J = 7.0 Hz, 2H, 9-H), 8.17 (d, J = 8.5 Hz, 2H, 34-H and 38-H), 
8.27 (d, J = 8.5 Hz, 2H, 35-H and 37-H), 8.86 (t, J = 5.5 Hz, 1H, 30-NH), 12.96 (br s, 
1H, 14-NH). 13C NMR (500 MHz, DMSO-d6): 𝛿 13.7 (C-13), 19.6 (C-12), 27.5 (C-28), 
27.5 (3 equivalent carbons, C-18, C-22, C-27), 29.2 (3 equivalent carbons, C-19, C-21, 
C-26), 29.7 (C-11), 30.7 (C-17), 36.9 (C-29), 38.1 (C-20), 40.2 (C-10), 40.7 (C-9), 51.5 
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(C-43), 106.5 (C-8), 128.6 (2 equivalent carbons, C-34 and C-38), 129.0 (2 equivalent 
carbons, C- 35 and C-37), 133.4 (d, C-36), 141.5 (C-32), 147.2 (C-1), 150.6 (C-3), 153.9 
(C-6), 159.9 (C-15), 164.2 (C-31), 176.9 (C-23). 19F NMR (400 MHz, DMSO-d6): 𝛿 
66.13. HRMS (ESI) calculated for C29H36FN5NaO7S
+ [M+Na]+ 640.2212 and 
C58H72F2N10NaO14S2
+ [2M+Na]+ 1257.4531; found m/z 640.2177 and 1257.4438. 
HPLC: 19.28 min. 
 
4-{[3-(1-Butyl-2,6-dioxo-8-{4-[(prop-2-yn-1-yl)carbamoyl]bicyclo[2.2.2]octan-1-yl}-




2.49 (508 mg, 0.93 mmol), TFA (3 mL), DMF (4 mL), K2CO3 (128 mg, 0.93 mmol), 4-
((3-bromopropyl)carbamoyl)benzenesulfonyl fluoride 2.44 (270 mg, 0.83 mmol) (in a 
solution of DMF (2 mL)) following column elution with CH2Cl2/ (CH3)2CO (7:3) gave a 
white solid (300 mg). Some of this white solid (101 mg) was further purified by semi-
preparative RP-HPLC purification to give 2.27 (16 mg, 0.025 mmol, 12 %) as white 
crystals. 1H NMR (500 MHz, DMSO-d6): 𝛿 0.88 (t, J = 7.3 Hz, 3H, 13-H), 1.28 (m, 2H, 
12-H), 1.50 (m, 2H, 11-H), 1.77-1.88 (m, 12H, 18-H, 19-H, 21-H, 22-H, 26-H, 27-H), 
1.97 (m, 2H, 28-H), 2.24 (s, 1H, 45-H), 2.24 (s, 2H, 43-H), 3.31 (q, J = 6.5 Hz, 2H, 29-
H), 3.86 (t, J = 7.3 Hz, 2H, 10-H), 4.08 (t, J = 7.0 Hz, 2H, 9-H), 6.66 (m, 1H, 24-NH), 
8.17 (d, J = 8.5 Hz, 2H, 34-H and 38-H), 8.26 (d, J = 8.5 Hz, 2H, 35-H and 37-H), 8.87 
(t, J = 5.5 Hz, 1H, 30-NH), 12.98 (br s, 1H, 14-NH). 13C NMR (500 MHz, DMSO-d6): 
𝛿 13.7 (C-13), 19.6 (C-12), 27.5 (C-28), 29.0 (3 equivalent carbons, C-18, C-22, C-27), 
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29.3 (3 equivalent carbons, C-19, C-21, C-26), 29.7 (C-11), 32.9 (C-43), 36.9 (C-29), 
40.2 (C-10), 40.7 (C-9), 106.5 (C-8), 122.1 (C-45), 128.6 (2 equivalent carbons, C-34 
and C-38), 129.0 (2 equivalent carbons, C-35 and C-37), 133.4 (d, C-36), 141.6 (C-32), 
147.3 (C-1), 147.8 (C-44), 150.6 (C-3), 153.9 (C-6), 160.1 (C-15), 164.2 (C-31), 167.7 
(C-23). 19F NMR (400 MHz, DMSO-d6): 𝛿 66.19. HRMS (ESI) calculated for 
C31H37FN6NaO6S
+ [M+Na]+ 663.2372 and C62H74F2N12NaO12S
+ [2M+Na]+ 1303.4851; 
found m/z 663.2321 and 1303.4685. HPLC: 19.24 min. 
 
4-{[3-(8-{4-[(3-Azidopropyl)carbamoyl]bicyclo[2.2.2]octan-1-yl}-1-butyl-2,6-dioxo-




2.50 (469 mg, 0.79 mmol), TFA (2.5 mL), DMF (4 mL), K2CO3 (109 mg, 0.79 mmol), 
4-((3-bromopropyl)carbamoyl)benzenesulfonyl fluoride 2.44 (230 mg, 0.71 mmol) (in a 
solution of DMF (2 mL)) following column elution with CH2Cl2/ (CH3)2CO (7:3) gave a 
white solid (190 mg). Some of this white solid (76 mg) was further purified by semi-
preparative RP-HPLC purification to give 2.24 (22 mg, 0.032 mmol, 11 %) as white 
crystals. 1H NMR (500 MHz, DMSO-d6): 𝛿 0.80 (t, J = 7.3 Hz, 3H, 13-H), 1.27 (m, 2H, 
12-H), 1.50 (m, 2H, 11-H), 1.65 (m, 2H, 44-H), 1.65-1.81 (m, 12H, 18-H, 19-H, 21-H, 
22-H, 26-H, 27-H), 1.96 (m, 2H, 28-H), 3.09 (q, J = 6.3 Hz, 2H, 45-H) 3.31 (t, J = 6.8 
Hz, 2 H, 43-H), 3.31 (q, J = 6.5 Hz, 2H, 29-H), 3.86 (t, J = 7.5 Hz, 2H, 10-H), 4.06 (t, J 
= 7 Hz, 2H, 9-H), 7.45 (t, J = 5.8 Hz, 1H, 24-H), 8.16 (d, J = 8.8 Hz, 2H, 34-H and 38-
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H), 8.25 (d, J = 8.8 Hz, 2H, 35-H and 37-H), 8.85 (t, J = 5.5 Hz, 1H, 30-H), 12.94 (s, 1H, 
14-H). 13C NMR (500 MHz, DMSO-d6): 𝛿 13.7, 19.6, 27.5 (3 equivalent carbons), 27.8, 
28.4, 29.6 (3 equivalent carbons), 29.7, 33.2, 36.0, 37.0, 38.1, 40.2, 40.7, 48.5, 106.5, 
128.6 (2 equivalent carbons), 129.0 (2 equivalent carbons), 133.4 (d), 141.5, 147.2, 
150.6, 153.9, 160.3, 164.2, 176.4. 19F NMR (400 MHz, DMSO-d6): 𝛿 66.18. HRMS 
(ESI) calculated for C31H40FN9NaO6S
+ [M+Na]+ 708.2699 and C62H80F2N18NaO12S2
+ 
[2M+Na]+ 1393.5505; found m/z 708.2656 and 1393.5440. HPLC: 18.49 min. 
 
General procedure of the synthesis of sulfonic acids 2.29, 2.25. The sulfonyl fluoride 
was dissolved in 1M methanolic NaOH and stirred for 1 h. The reaction mixture was 
acidified to pH 4 with 12M HCl and concentrated in vacuo. Ethyl acetate was added, then 
the organic layer was washed with saturated aq. NaHCO3 and concentrated in vacuo.  
 
4-[(3-{1-Butyl-8-[4-(methoxycarbonyl)bicyclo[2.2.2]octan-1-yl]-2,6-dioxo-2,3,6,9-




2.28 (24 mg, 0.039 mmol) and 1 M methanolic NaOH (2 mL) following semi-preparative 
RP-HPLC purification gave 2.29 (21 mg, 0.034 mmol, 88 %) as a white solid. 1H NMR 
(500 MHz, DMSO-d6): 𝛿 0.89 (t, J = 7.3 Hz, 3H, 13-H), 1.28 (m, 2H, 12-H), 1.51 (m, 
2H, 11-H), 1.73-1.90 (m, 12H, 18-H, 19-H, 21-H, 22-H, 26-H, 27-H), 1.92 (m, 2H, 28-
H), 3.27 (q, J = 6.8 Hz, 2H, 29-H), 3.59 (s, 3H, 43-H), 3.86 (t, J = 7.3 Hz, 2H, 10-H), 
4.04 (t, J = 7 Hz, 2H, 9-H), 6.54 (br s, 1H, 42-OH), 7.64 (d, J = 8.3 Hz, 2H, 34-H and 
38-H), 7.75 (d, J = 8.3 Hz, 2H, 35-H and 37-H), 8.44 (t, J = 5.8 Hz, 1H, 30-NH), 12.98 
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(s, 1H, 14-NH). 13C NMR (500 MHz, DMSO-d6): 𝛿 13.7, 19.6, 27.5 (3 equivalent 
carbons), 27.9, 29.2 (3 equivalent carbons), 29.7, 33.1, 36.8, 38.2, 40.2, 40.9, 51.6, 106.5, 
128.6 (2 equivalent carbons), 129.0 (2 equivalent carbons), 134.4, 147.2, 150.6, 150.7, 
153.9, 157.9, 160.0, 165.8, . HRMS (ESI) calculated for C29H37N5O8S
- [M-H]- 614.2290; 
found m/z 614.2249. HPLC: 14.29 min. 
 
4-{[3-(8-{4-[(3-Azidopropyl)carbamoyl]bicyclo[2.2.2]octan-1-yl}-1-butyl-2,6-dioxo-




2.24 (21 mg, 0.031 mmol) and 1M methanolic NaOH (2 mL) following semi-preparative 
RP-HPLC purification gave 2.25 (19 mg, 0.028 mmol, 95%) as a white solid. 1H NMR 
(500 MHz, DMSO-d6): 𝛿 0.89 (t, J = 7.3 Hz, 3H, 13-H), 1.28 (m, 2H, 12-H), 1.51 (m, 
2H, 11-H), 1.57-1.73 (m, 12H, 18-H, 19-H, 21-H, 22-H, 26-H, 27-H), 1.68 (m, 2H, 44-
H), 1.93 (m, 2H, 28-H), 3.10 (q, J = 6.3 Hz, 2H, 45-H), 3.26 (q, J = 6.3 Hz, 2H, 29-H), 
3.32 (t, J = 7.0 Hz, 2H, 43-H), 3.86 (t, J = 7.5 Hz, 2H, 10-H), 4.06 (t, J = 7.0 Hz, 2H, 9-
H), 4.99 (br s, 1H, 42-OH), 7.51 (t, J = 5.8 Hz, 1H, 24-NH), 7.69 (d, J = 8.5 Hz, 2H, 34-
H and 38-H), 7.81 (d, J = 8.5 Hz, 2H, 35-H and 37-H), 8.46 (t, J = 5.8 Hz, 1H, 30-NH), 
12.85 (br s, 1H, 14-NH). 13C NMR (500 MHz, DMSO-d6): 𝛿 13.7, 19.6, 27.6 (3 
equivalent carbons), 27.8, 28.4, 29.5 (3 equivalent carbons), 29.7, 33.1, 36.1, 36.3, 38.0, 
48.6, 106.4, 125.4 (2 equivalent carbons), 126.8 (2 equivalent carbons), 134.7, 147.3, 
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150.4, 150.6, 153.9, 158.2, 158.5, 160.3, 165.8, 176.4. HRMS (ESI) calculated for 
C31H40N9O7S
- [M-H]- 682.2777; found m/z 682.2761. HPLC: 14.04 min. 
 
General procedure for POM protection to give 2.56, 2.57. The xanthine was dissolved 
in DMF then K2CO3 was added and the reaction mixture was stirred for 45 min at 50°C. 
Pivaloxymethyl chloride was added drop-wise and the reaction mixture was stirred for 5 
h at 50°C. The reaction mixture was cooled to rt and concentrated in vacuo. Water was 
added and the aq. solution was extracted 2 times with ethyl acetate. The pooled organic 








 2.49 (600 mg, 1.1 mmol), DMF (5 mL), K2CO3 (227 mg, 1.6 mmol) and pivaloxymethyl 
chloride (214 mg, 1.4 mmol) following column elution with n-hexane/ ethyl acetate (1:1) 
gave 2.56 (384 mg, 0.58 mmol, 52 %) as a gummy liquid. 1H NMR (400 MHz, DMSO-
d6): 𝛿 0.86 (t, J = 7.4 Hz, 3H), 1.12 (s, 9H), 1.25 (m, 2H), 1.48 (m, 2H), 1.69-2.00 (m, 
12H), 3.00 (t, J = 2.8 Hz, 1H), 3.72 (s, 3H), 3.79 (s, 3H), 3.81 (t, J = 2.4 Hz, 2H), 3.85 
(t, J = 7.4 Hz, 2H), 5.06 (s, 2H), 6.33 (br s, 2H), 6.42 (dd, J = 2.4, 8.4 Hz, 1H), 6.57 (d, 
J = 2.4Hz, 1H), 6.80 (d, J = 8.4 Hz, 1H), 7.87 (t, J = 5.6 Hz, 1H). 13C NMR (400 MHz, 
DMSO-d6): 𝛿 13.7, 19.5, 26.5 (3 equivalent carbons), 27.5 (3 equivalent carbons), 28.1, 
29.3 (3 equivalent carbons), 29.5, 34.6, 37.9, 38.2, 40.0, 40.9, 54.9, 55.2, 55.5, 77.3, 81.7, 
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98.3, 104.5, 106.7, 109.5, 116.4, 127.7, 146.8, 150.3, 153.8, 157.5, 159.8, 159.9, 176.0. 
HRMS (ESI) calculated for C36H47NaN5O7
+ [M+Na]+ 684.3368 and C72H94NaN10O14
+ 








2.50 (475 mg, 0.80 mmol), DMF (4 mL), K2CO3 (166 mg, 1.2 mmol) and pivaloxymethyl 
chloride (157 mg, 1.0 mmol) following column elution with n-hexane/ ethyl acetate (1:1) 
gave 2.57 (325 mg, 0.46 mmol, 57 %) as a gummy liquid. 1H NMR (400 MHz, DMSO-
d6): 𝛿 0.86 (t, J = 7.4 Hz, 3H), 1.12 (s, 9H), 1.25 (m, 2H), 1.48 (m, 2H), 1.64 (m, 2H), 
1.69-2.00 (m, 12H), 3.09 (q, 2H), 3.31 (t, J = 6.8 Hz, 2H), 3.72 (s, 3H), 3.79 (s, 3H), 3.85 
(t, J = 7.4 Hz, 2H), 5.06 (s, 2H), 6.33 (br s, 2H), 6.42 (dd, J = 2.4, 8.4 Hz, 1H), 6.57 (d, 
J = 2.4Hz, 1H), 6.81 (d, J = 8.4 Hz, 1H), 7.46 (t, J = 5.6 Hz, 1H). 13C NMR (400 MHz, 
DMSO-d6): 𝛿 13.7, 19.5, 26.5 (3 equivalent carbons), 27.6 (3 equivalent carbons), 28.4, 
29.3 (3 equivalent carbons), 29.5, 34.6, 36.0, 37.9, 38.2, 40.0, 40.9, 48.5, 55.2, 55.5, 69.0, 
98.3, 104.5, 106.7, 116.4, 127.7, 146.8, 150.3, 153.8, 157.5, 159.8, 160.0, 176.0, 176.3. 
HRMS (ESI) calculated for C36H50N8NaO7
+ [M+Na]+ 729.3695, C72H100N16NaO14
+ 
[2M+Na]+ 1435.7497 and C108H150N24NaO21
+ 2142.1300; found m/z 729.3659, 




General procedure for DMB-deprotection and alkylation to give 2.58, 2.59. The 
DMB-protected xanthine was dissolved in neat TFA and stirred overnight at 50°C. The 
reaction mixture was cooled to rt and blown with compressed air for 20 min to evaporate 
excess TFA. CH2Cl2 was added and the organic solution was concentrated in vacuo and 
then dried overnight on high vacuum. The residue was dissolved in DMF, then K2CO3 
was added and the reaction mixture was stirred for 45 min at 50°C. 1-Bromopropane was 
added drop-wise and the reaction mixture was stirred overnight at 50°C. The reaction 
was cooled to rt and concentrated in vacuo. Water was added and the aq. solution was 
extracted 2 times with ethyl acetate. The pooled organic layers were dried over MgSO4, 
filtered and concentrated in vacuo.  
 
 (1-Butyl-2,6-dioxo-8-{4-[(prop-2-yn-1-yl)carbamoyl]bicyclo[2.2.2]octan-1-yl}-3-




2.56 (370 mg, 0.56 mmol), TFA (2.5 mL), DMF (4 mL), K2CO3 (154 mg, 1.1 mmol) and 
1-bromopropane (136 mg, 1.1 mmol) following column elution with n-hexane/ ethyl 
acetate (7:3) gave 2.58 (239 mg, 0.43 mmol, 77 %) as a gummy liquid. 1H NMR (400 
MHz, CDCl3): 𝛿 0.92 (t, J = 7.4 Hz, 3H), 0.97 (t, J = 7.6 Hz, 3H), 1.20 (s, 9H), 1.36 (m, 
2H), 1.60 (m, 2H), 1.79 (m, 2H), 2.01-2.17 (m, 12H), 2.29 (s, 1H), 2.29 (s, 2H), 3.98 (t, 
J = 7.4 Hz, 2H), 4.05 (t, J = 7.2 Hz, 2H), 6.37 (br s, 2H), 6.65 (m, 1H). 13C NMR (400 
MHz, CDCl3): 𝛿 11.3, 11.6, 14.2, 20.6, 21.8, 27.1 (3 equivalent carbons), 29.4 (3 
equivalent carbons), 29.9 (3 equivalent carbons), 33.6, 35.4, 39.1, 41.5, 45.2, 69.3, 77.6, 
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107.9, 122.0, 147.6, 148.9, 151.5, 154.8, 159.9, 168.6, 177.4. HRMS (ESI) calculated for 
C30H43N5NaO5
+ [M+Na]+ 576.3156; found m/z 576.3132. 
 
(8‐{4‐[(3‐Azidopropyl)carbamoyl]bicyclo[2.2.2]octan‐1‐yl}‐1‐butyl‐2,6‐dioxo‐3‐




2.57 (288 mg, 0.41 mmol), TFA (2 mL), DMF (4 mL), K2CO3 (113 mg, 0.81 mmol) and 
1-bromopropane (75 mg, 0.61 mmol) following column elution with n-hexane/ ethyl 
acetate (8:2) gave 2.59 (102 mg, 0.17 mmol, 42 %) as a white solid. 1H NMR (400 MHz, 
DMSO-d6): 𝛿 0.86 (t, J = 7.4 Hz, 3H), 0.86 (t, J = 7.4 Hz, 3H), 1.11 (s, 9H), 1.25 (m, 
2H), 1.48 (m, 2H), 1.65-2.02 (m, 16H), 3.10 (q, 2H), 3.31 (t, J = 6.8 Hz, 2H), 3.84 (t, J 
= 7.2 Hz, 2H), 3.93 (t, J = 6.4 Hz, 2H), 6.32 (s, 2H), 7.48 (t, J = 5.4 Hz, 1H). 13C NMR 
(400 MHz, DMSO-d6): 𝛿 10.9, 13.6, 26.4 (3 equivalent carbons), 27.5 (3 equivalent 
carbons), 28.3, 29.3 (3 equivalent carbons), 29.5, 34.4, 36.0, 37.8, 38.2, 44.0, 48.4, 56.0, 
68.9, 106.5, 109.3, 128.3, 146.5, 150.2, 153.7, 159.9, 175.9, 176.2. HRMS (ESI) 
calculated for C30H46N8NaO5
+ [M+Na]+ 621.3483 and C60H92N16NaO10
+ [2M+Na]+ 
1219.7075; found m/z 621.3456 and 1219.6990. 
 
General procedure for POM-deprotection to give 2.26, 2.23. The POM-protected 
xanthine was dissolved in 2M methanolic NaOH and stirred for 1 h. The reaction mixture 
was neutralised with AcOH to pH 4, cooled overnight and the precipitate formed was 








2.58 (110 mg, 0.20 mmol) and 2M methanolic NaOH (2 mL) gave 2.26 (85 mg, 0.19 
mmol, 98 %) as a white fluffy solid. 1H NMR (500 MHz, DMSO-d6): 𝛿 1.11 (t, J = 7.2 
Hz, 3H, 13-H), 1.14 (t, J = 7 Hz, 3H, 31-H), 1.53 (m, 2H, 12-H), 1.76 (m, 2H, 11-H), 
1.93 (m, 2H, 30-H), 2.11-2.25 (m, 12H, 18-H, 19-H, 21-H, 22-H, 26-H, 27-H), 2.24 (s, 
2H, 28-H), 2.25 (s, 1H, 32-H), 3.86 (t, J = 7.3 Hz, 2H, 10-H), 3.93 (t, J = 7.3 Hz, 2H, 9-
H), 6.67 (s, 1H, 24-NH), 12.97 (s, 1H, 14-NH). 13C NMR (500 MHz, DMSO-d6): 𝛿 10.5, 
11.0, 13.7, 19.6, 20.9, 29.1 (3 equivalent carbons), 29.4 (3 equivalent carbons), 29.7, 
32.9, 33.2, 39.9, 40.2, 44.2, 106.5, 122.2, 147.8, 150.6, 153.9, 160.1, 167.8. HRMS (ESI) 
calculated for C24H33N5NaO3
+ [M+Na]+ 462.2476 and C48H66N10NaO6
+ [2M+Na] 
















2.59 (11 mg, 0.018 mmol) and 2M methanolic NaOH (200 µL) following column elution 
with n-hexane/ ethyl acetate (3:7) and then semi-preparative RP-HPLC purification gave 
2.23 (8 mg, 0.016 mmol, 89 %) as a white solid. 1H NMR (500 MHz, DMSO-d6): 𝛿 0.85 
(t, J = 7.5 Hz, 3H, 13-H), 0.89 (t, J = 7.3 Hz, 3H, 31-H), 1.27 (m, 2H, 12-H), 1.51 (m, 
2H, 11-H), 1.61-1.91 (m, 16H, 18-H, 19-H, 21-H, 22-H, 26-H, 27-H), 3.10 (q, J = 6.2 
Hz, 2H, 32-H), 3.31 (t, J = 6.8 Hz, 2H, 28-H), 3.86 (t, J = 7.5 Hz, 2H, 10-H), 3.92 (t, J = 
7.5 Hz, 2H, 9-H), 7.48 (t, J = 5.8 Hz, 1H, 24-NH), 12.92 (br s, 1H, 14-NH). 13C NMR 
(500 MHz, DMSO-d6): 𝛿 11.0, 13.7, 13.9, 19.6, 20.9, 27.8 (3 equivalent carbons), 28.4, 
29.6 (3 equivalent carbons), 33.2, 36.1, 38.1, 39.5, 44.2, 48.5, 106.4, 147.3, 150.6, 153.9, 
160.3, 176.5. HRMS (ESI) calculated for C24H36N8NaO3
+ [M+Na]+ 507.2803 and 
C48H72N16NaO6
+ [2M+Na]+ 991.5713; found m/z 507.2804 and 991.5728. HPLC: 17.76 
min. 
 
2.6.3 Computational studies 
The crystal structures of A1AR (PDB ID: 5UEN) was downloaded from the Protein Data 
Bank.48 The A3AR homology model (UniProt code: P0DMS8) was generated using 
Modeller 9.2243 based on the antagonist-bound DU172-A1AR crystal structure (PDB ID: 
5UEN).6 All three-dimensional structure created in this thesis were generated using 
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Avogadro 1.2.049 and minimized using the universal force field (UFF). Ligand docking 
was carried out with GOLD 5.8.1 (CCDC Software)50 using ChemPLP scoring method 
with default settings. The docking process was centred on residues F171 (A1AR – PDB 
ID: 5UEN) and F168 (A3AR homology model - UniProt code: P0DMS8) with a distance 
extension of 15 Å. Covalent binding mode was used and the covalent link was defined 
between the 4 position of Y2717.36 (A1AR - PDB ID: 5UEN) or Y265
7.36 (A3AR 
homology model - UniProt code: P0DMS8) and the oxygen atom of the sulfonyl moiety 
(-SO3). The highest ranked pose at each receptor are presented. The docking results were 
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Chapter 3 Optimisation of A1AR ligands. 
 
3.1 Introduction 
The ligands 2.23-2.30 developed in chapter 2 generally demonstrated high affinity for 
hA1AR and hA3AR. The covalent clickable 2.24 and 2.27 showed successful covalent 
attachment to hA1AR and subsequent clickability to a Cy5.5 fluorophore. The best 
performing ligand 2.24 (hA1AR pKi = 8.17 ± 0.14 (6.7 nM); hA1AR pKb = 8.09 ± 0.31 
(8.1 nM); hA3AR pKb = 8.38 ± 0.29 (7.4 nM)), was of interest for its covalent and 
clickability properties, however, the lack of selectivity of this compound was evident by 
equipotent activity at hA1AR and hA3AR. Since the N1 and N3 of the xanthine ring have 
been tested to favour hA1AR against other AR subtypes, as can be seen from 2.22
1 
(Figure 2.4), the linker was considered as a reasonable point for further optimisation. 
Therefore, the introduction of different linker lengths and types on 2.24 was carried out 
to explore linker influence on ligand affinity and selectivity for hAR subtypes. The butyl 
chain at the N1 position of 2.24 was originally designed with A1AR selectivity in mind 
however 2.24 was not A1AR selective. Therefore, for comparison and further probing of 
subtype selectivity, the corresponding N1-propyl chain version of 2.24 was synthesised. 
 
3.1.1 Modification of the clickable linker 
3.1.1.1 Linker length and composition 
As mentioned in section 1.5.2, the linker can have significant influence on the overall 
ligand binding affinity and subtype selectivity due to the interaction around its vicinity. 
Unlike a preassembled “ligand-linker-fluorophore” fluorescent ligand where the 
influence of the linker chosen could only be assessed along with the fluorophore attached, 
the influence of linker in ligand binding affinity and selectivity of the clickable ligand 
2.24 could be accessed directly without the presence of a fluorophore.   
The azido containing non-covalent 2.23 (hA1AR pKi = 8.27 ± 0.08 (5.4 nM)) and 
the equivalent but covalent 2.24 (hA1AR pKi = 8.17 ± 0.14 (6.7 nM)) analogues (Figure 
2.6) had better binding affinity at hA1AR than the respective alkyne-containing non-
covalent 2.26 (hA1AR pKi = 7.36 ± 0.06 (43.4 nM)) and covalent 2.27 (hA1AR pKi = 
7.58 ± 0.11 (26.1 nM)), therefore, an azide was chosen to be the click handle in most of 
the clickable linkers used in this chapter.   
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Since 2.27 appeared to be inaccessible to the Cy5.5 fluorophore for the click 
reaction to take place (discussed in section 2.3.7), longer linkers were rationalised to 
provide better accessibility to the extracellular space and be in closer proximity to the 
complementary click reaction components, the second being to the fluorophore. 
Additionally, linkers of different compositions were used (e.g. hydrophobic alkyl chain 
and hydrophobic PEG linkers) to investigate if these linkers were capable of interacting 
with the extracellular surface of the receptor and could directly contribute to the binding 
affinity and selectivity at hA1AR against other receptor subtypes. The PEG linkers which 
possesses better aqueous solubility was rationalised to have more accessibility to the 
fluorophore in the extracellular space as it should not interact as much with the cell 
membrane or receptor than the hydrophobic alkyl chain. 
Therefore, a set of covalent clickable ligands consisting of the more hydrophobic 
hydrocarbon linkers: azidobutyl (3.2) and azidooctyl (3.3); and the more hydrophilic 
polyethylene linkers: azidopropylene-2 (azido-PEG2) (3.4) and azidopropylene-3 (azido-
PEG3) (3.5) linkers were designed (Figure 3.1). In addition, for the same reasons of click 
reaction accessibility, an analogue of 2.27 with a hexyne linker (3.6) replacing the 
propargyl linker of 2.27 was synthesised to investigate clickability to fluorophore in 






Figure 3.1. Second-generation covalent clickable ligands. 
 
3.1.1.2 The design of 3.1 
As mentioned in section 3.1, the synthesis of A1AR ligands with a butyl substituent (as 
opposed to the more commonly employed propyl substituent) on the N1 position of the 
xanthine ring (Figure 2.6) was rationalised to be able to give rise to A1AR selectivity 
over other AR subtypes (described in section 2.1.1.b). However, there was only a small 
margin of hA1AR selectivity preference demonstrated by 2.23-2.29. Therefore 3.1, the 
corresponding N1-propyl chain version of 2.24, was designed for comparison, in 
particular regarding selectivity, to the N1 butyl-containing ligands. 
 
3.2 Synthesis of A1AR ligands 
The linkers 5-hexyne-1-amine 3.10, 4-azidobutan-1-amine 3.11, 2-(2-(2-
azidoethoxy)ethoxy)ethan-1-amine 3.12, and 2-(2-(2-(2-
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azidoethoxy)ethoxy)ethoxy)ethan-1-amine 3.13 were purchased commercially and used 
without further purification. 
 
3.2.1 Synthesis of linkers 
3.2.1.1 8-Azidooctan-1-amine hydrochloride 3.14 
The first attempted synthesis of linker 3.14 was unsuccessful (Scheme 3.1). The 
conversion of 8-hydroxyoctan-1-amine 3.7 to 8-bromooctan-1-amine 3.8 was attempted 
using 48% aq. HBr. Upon reaction work-up, the aq. layer was expected to contain the 
hydrobromic acid amine salt of 8-bromooctan-1-amine 3.8. The recovered off-white 
solid was dissolved in D2O and investigated using NMR spectroscopy. However, 20 mg 
of the off-white solid gave only trace signal of proton shifts by 1H NMR spectroscopy, 
which made structure elucidation impractical. The majority of the mass from the off-
white solid was thought to be an unknown salt recovered from the reaction mixture. It 




Scheme 3.1 Attempted synthesis of 8-azidooctan-1-amine 3.14. Reagents and conditions: 
i. 48% aq. HBr, reflux, 3h; ii. NaN3, DMF, reflux, 16 h. 
 
An alternative synthetic route to 3.14 by using a tosylate intermediate (Scheme 










Scheme 3.2. The synthesis of 3.14. Reagents and conditions: i. (Boc)2O, NEt3, MeOH, 
rt, 18 h, 78%; ii. TsCl, DMAP, NEt3, DCM, rt, 18 h, 74%; iii. NaN3, DMF, 50°C, 18 h, 
86%; iv. 4 M HCl/ dioxane, rt, 1 h, ~100%. 
 
The amine group of 8-hydroxyoctan-1-amine was first Boc-protected to form 
3.15 in 78% yield (Scheme 3.2). 3.15 was then treated with tosyl chloride to form the 
tosylated 3.16 intermediate which was isolated in 86% yield. The displacement of the 
tosylate group of 3.16 with the azide anion took place smoothly and was then purified to 
give 3.17 in 86% yield. Then, the Boc group of 3.17 was removed with 4 M HCl (in 
dioxane) to give quantitative yield of 3.14 which was used without further purification.  
 
3.2.1.2 5-Hexyn-1-amine 3.10 
The synthesis of 5-hexyne-1-amine 3.10 was attempted as shown in Scheme 3.3. 
6-Chloro-1-hexyne 3.9 was treated with sodium azide to undergo nucleophilic 
substitution of the chlorine by the azide anion to give 6-azidohex-1-yne 3.18. The 
subsequent transformation of the azido group to amine via the Staudinger reduction was 
then attempted.2 Ninhydrin was used to monitor the transformation of the azide group to 
amine. However, the reaction was unsuccessful and almost quantitative amounts of the 
starting material 3.18 was recovered. One reason for the reaction failure could have been 
the poor solubility of 3.18 in water. Following, the same reaction condition was carried 
out in a biphasic reaction medium condition consisting of THF and water (10:1 
THF:water).3, 4 The TLC did not show changes overnight and the starting material was 
recovered. The synthesis of 5-hexyne-1-amine 3.10 was also attempted by the reduction 
of the azido group to amine using lithium aluminium hydride in diethyl ether at 0˚C.5  
After leaving the reaction mixture stirring overnight, there was no change to the TLC. 
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Mass spectrometry analysis of the crude mixture showed a high intensity ion for the 
starting material while the parent ion of the desired product was not observed. After these 




Scheme 3.3. Reagents and conditions: i. NaN3, DMF, 50°C, 16 h, 80%; ii. Ph3P, H2O, rt, 
16 h; iii. Ph3P, THF/H2O, rt, 16 h; iv. LiAlH4, Et2O, 0˚C, 3 h, then rt, 16 h. 
 
3.2.2 Assembly of ligands 
The synthesis of 3.2-3.6 began via the amidation reaction between 2.39 and respective 
linkers including 3.10-3.14 (scheme 3.4) to give 3.19, 3.20, 3.21, 3.22 and 3.23, 
respectively, in yields between 50-98%. These amidation reactions proceeded similarly 
to the reaction mechanism described for 2.39 (in section 2.2.4) via the HATU-activated 
amide bond forming reaction. Subsequently, 3.19-3.23 were treated with neat TFA to 
remove the DMB protecting group and followed by the subsequent N-alkylation of the 
unprotected 3.19-3.23 with 2.44 using K2CO3 in DMF gave 3.6, 3.2, 3.4, 3.5 and 3.3, 
respectively. The desired products appeared to be faint on the TLC plate which could 
translate to a low conversion of the starting material. Further purification using 






Scheme 3.4. Reagents and conditions: i. NH2-linkers (3.10, 3.11, 3.12, 3.13 or 3.14), 
HATU, DIPEA, DMF, 18 h, rt, 50-98%; ii. TFA, 50°C; iii. 2.44, K2CO3, DMF, rt, 19-
43% (over 2 steps). 
 
The analogue 3.1 was synthesised according to scheme 3.5. The introduction of 
the propyl chain at the N1 position of the xanthine core was carried out via alkylation of 
2.34 with bromopropane to give 3.24. The deprotection of the N,N-
dimethylmethananimidamide group of 3.24 gave 3.25 (reaction mechanism is the same 
as described in scheme 2.5). Following that, the nitrosation of the olefin 3.25 to give 3.26 
was carried out using sodium nitrite and aq. acetic acid (reaction mechanism proceeded 
the same as one described in scheme 2.6). Compound 3.26 was unstable and has to be 
made fresh for the following reaction. The instability of the 3.26 could be due to the lone 
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pair of electrons of diamino groups being delocalised into the π-bond which made it 
highly nucleophilic. 
Following that, 3.26 underwent amidation with bicyclo[2.2.2]-1,4-dicaboxylic 
acid monomethyl ester 3.27 to give 3.28. While the vinylamine was still present, the 
transformation to 3.28 was carried out and isolated after two steps to avoid potential 
degradation. Upon reaction work-up, the reaction mixture was acidified and 3.28 
precipitated out as a white solid.  
The subsequent amidation of carboxylic acid 3.28 using the amino-linker 2.42 via 
an HATU-assisted reaction gave 3.29 in 70% yield (reaction mechanism the same as 
described in scheme 2.8). Compound 3.29 underwent DMB-deprotection and alkylation 
with covalent arm 2.44 to give 3.1. The TLC spot of 3.1 appeared faint. However, 
standard silica column chromatography followed with semipreparative HPLC 




Scheme 3.5 Reagents and conditions: i. Bromopropane, Cs2CO3, TBAB, ACN, DMF, 
60°C, 3 h, 80%; ii. 2M KOH, MeOH, 50°C, 1 h, 88%; iii. NaNO2, 50% AcOH, 70°C, 1 
h; iv. Na2S2O4, 25% aq. NH4OH, MeOH, 80°C, 4 h, 62% (over two steps); v. 
Bicyclo[2.2.2.]octane-1,4-dicarboxylic acid monomethyl ester 3.27, HATU, NEt3, ACN, 
1 h, rt; vi. 1M KOH, i-PrOH, reflux, 1 h, 59% (over 2 steps); vii. 2.42, HATU, DIPEA, 
DMF, 18 h, rt, 70%; viii. TFA, 50°C; ix. 2.44, K2CO3, DMF, rt, 22% (over 2 steps). 
 
3.3 Discussion of pharmacological results 
Six second generation covalent clickable ligands were synthesised in Section 3.2 (3.1-
3.6) consisting of analogues of 2.24 coupled with hydrocarbon linkers: azidopropyl 
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(propyl chain instead of a butyl chain on N1 of xanthine core, 3.1), azidobutyl (3.2) and 
azidooctyl (3.3); and the more hydrophilic polyethylene linkers: azidopropylene-2 
(azido-PEG2) (3.4), azidopropylene-3 (azido-PEG3) (3.5); and hexyne linker (3.6) were 
subjected to pharmacological evaluation. All pharmacological assays were carried out by 
PhD candidate Phuc Nguyen (a PhD student in the laboratory of collaborators Dr Lauren 
May and Dr Karen Gregory at Drug Discovery Biology, Monash Institute of 
Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia). All 
experimental details of the biological assays are described in appendix 19.6 Covalent 
clickable ligands 3.1-3.6 were developed to investigate accessibility to a fluorophore for 
click reaction. Additionally, ligands 3.1-3.6 also explore the binding interactions around 
the vicinity of the extracellular surface that may contribute to hA1AR binding affinity 
and selectivity against other AR subtypes. Radioligand binding and cAMP assays were 
carried out to determine affinity at hA1AR and evaluate the function of the ligands. 
Selective high affinity non-covalent antagonist ligands SLV320 (2.62) (hA1AR pKi = 1.0 
nM)7, SCH442416 (2.63) (hA2AAR pKi = 4.1 nM)
8, PSB603 (2.64) (hA2BAR pKi = 9.3 
nM) and MRS1220 (2.65) (hA3AR pKi = 1.0 nM)
9 were used as positive controls for 
hA1AR-, hA2AAR-, hA2BAR- and hA3AR biological assays (shown in Figure 2.8 in 
section 2.3).  
    
3.3.1 Radioligand binding assays 
A radioligand displacement binding assay was carried out to determine estimated binding 
affinities of ligands 3.1-3.6 at hA1AR in membrane derived from FlplnCHO-A1AR cells 
in the presence of 1 nM [3H]DCPCX at 25°C (Figure 3.4) (Table 3.1). Ligands 3.1-3.6 
showed complete inhibition of specific [3H]DCPCX binding to hA1AR in a concentration 
dependent manner (Figure 3.4) which suggested a competitive interaction for the hA1AR 
orthosteric site. Similar to the covalent property of 2.24, the affinity estimates of 3.1-3.6 
were also measured after an extensive washing steps (6 × 20 min) (Table 3.1) (This will 
be further discussed in section 3.3.6). The small margin of loss in affinity estimates (less 
than 1 log unit) upon extensive washing steps of 3.1-3.6 showed that these 









Figure 3.4 Displacement of [3H]DPCPX (1 nM) binding in FlpInCHO- hA1AR cell 
membranes (15 µg) at 25°C with an incubation time of 4 h with ligands (3.1-3.6). Data 
represent the mean ± SEM from n ≥ 4 performed in duplicate (see Table 3.1 for exact 
numbers). Error bars not shown lie within dimensions of the symbol. Experiments and 





























































Table 3.1 Affinity estimates of test compounds from [3H]DPCPX competition binding 
(pKi ) in hA1AR–expressing FlpInCHO cells, before and after washing steps. 
Experiments and data analysis performed by PhD candidate Phuc Nguyen (Monash). 
Compound 












9.25 ± 0.08 (0.6) 6 n/a - 
3.1 8.46 ± 0.15 (3.5) 4 8.11 ± 0.07 (7.8) 2 
3.2 7.84 ± 0.31 (14.4) 4 7.24 ± 0.15 (58.1) 2 
3.3 8.43 ± 0.18 (3.7) 4 7.79 ± 0.10 (16.1) 2 
3.4 8.22 ± 0.13 (6.1) 4 8.00 ± 0.05 (10.0) 5 
3.5 8.30 ± 0.16 (5.0) 4 7.86 ± 0.08 (13.9) 5 
3.6 8.81 ± 0.24 (1.6) 4 8.03 ± 0.28 (9.3) 5 
aData are expressed as mean ± SEM from indicated number (n) of independent 
experiments performed in duplicate; n/a, denotes not applicable 
bNegative logarithm of the equilibrium dissociation constant for antagonists determined 
from displacement of [3H] DPCPX binding using the Cheng-Prusoff equation. 
cSLV320 is a selective A1AR antagonist. 
 
3.3.2 SAR discussion of A1AR ligands binding affinity (pKi)  
The influence of different linker lengths and types, replacing the azidopropyl linker of 
2.24, on binding affinity at hA1AR over other AR subtypes was investigated. Generally, 
ligands 3.2-3.6 (between hA1AR 7.84 ± 0.31 (14.4 nM) and 8.81 ± 0.24 (1.6 nM)) 
exhibited similar binding affinity as 2.24 (hA1AR pKi = 8.17 ± 0.14 (6.7 nM)). The 
increment in length from an azidopropyl (hA1AR 2.24, pKi = 8.17 ± 0.14 (6.7 nM)) to 
azidobutyl (3.2, hA1AR pKi = 7.84 ± 0.31 (14.4 nM)) and azidooctyl (3.3, hA1AR pKi = 
8.43 ± 0.18 (3.7 nM)) linkers did not show any significant changes in binding affinity at 
hA1AR. Meanwhile, the alteration of linker type of similar length from an azidooctyl (3.3, 
hA1AR pKi = 8.43 ± 0.18 (3.7 nM)) to an azido-PEG2 (3.4, hA1AR pKi = 8.22 ± 0.13 
(6.1 nM)) linker did not show a considerable difference in binding affinity at hA1AR. In 
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addition, moving from an analogue consisting the azido-PEG2 (3.4, hA1AR pKi = 8.22 ± 
0.13 (6.1 nM)) to azido-PEG3 (3.5, hA1AR pKi = 8.30 ± 0.16 (5.0 nM)) linker showed 
similar binding affinity at hA1AR. In turn, the analogue with a hexyne alkyne linker (3.6, 
hA1AR pKi = 8.81 ± 0.24 (1.6 nM)) showed an improvement of approximately 1 log unit 
in pKi compared to the analogue with shorter propargyl linker (2.27, hA1AR pKi = 7.58 
± 0.11 (26.1 nM)). A possible reason for the small change in pKi observed across 3.2-3.6 
could be that the majority of the clickable linker is physically situated well outside of the 
orthosteric site when the ligand is bound, which resulted in minimal specific receptor 
interactions.  
 Aside from the influence of clickable linker lengths and types on the binding 
affinity, 3.1 (hA1AR pKi = 8.46 ± 0.15 (3.5 nM)) which corresponded to the N1-propyl 
chain version of 2.24 (hA1AR pKi = 8.17 ± 0.14 (6.7 nM)) was also tested for comparison 
of hA1AR binding affinity. Ligand 3.1 did not show a notable difference in pKi compared 
to 2.24. This informed that the A1AR binding site around the N1 of the synthesised A1AR 
analogues were able to tolerate a propyl or a butyl substituent as A1AR has been reported 
to have a deep binding cavity near the N1 position of xanthine-based ligands.10  
 The highest binding affinity ligand synthesised within chapters 2 and 3, 3.6, had 
an affinity approximately 20-fold stronger than DU172 (hA1AR pKi = 7.4 ± 0.1 (39.8 
nM)) at hA1AR.  
  
3.3.3 Forskolin-stimulated cAMP assays 
3.1-3.6 were subjected to a forskolin-stimulated cAMP accumulation assay in 
FlpInCHO-A1AR cells to examine the function of these ligands. While ligands 3.1-3.6 
may have functions at other signalling pathways, only a forskolin-stimulated cAMP 
accumulation assay was investigated. The non-selective AR agonist N-ethyl-5'-
carboxamidoadenosine (NECA) was used and NECA concentration-forskolin inhibition 
curves were generated (Figure 3.5) in the absence and presence of ligand at a single 
concentration (1 µM). All these experiments were conducted by PhD candidate Phuc 
Nguyen (Monash).  
 In the absence of ligands 3.1-3.6, cAMP inhibition increased with increasing 
NECA concentration. Incubation of ligands 3.1-3.6 with agonist NECA in A1AR-
FlpInCHO cells showed reduction in cAMP inhibition and caused a right-hand shift of 
the curve from the vehicle curve which indicated that ligands 3.1-3.6 behaved as 
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competitive antagonists at hA1AR in the cAMP inhibition assays. The affinity estimates 
of 3.1-3.6 were measured and summarised on Table 3.2.  
 
 
Figure 3.5. NECA concentration-response curves for cAMP inhibition in the absence or 
presence of test compounds (1µM) and SLV320 (1µM) in FlpInCHO-hA1AR cells. Data 
represent the mean ± SEM from n = 6 performed in duplicate. Error bars not shown lie 
within dimensions of the symbol. Experiments and data analysis performed by PhD 























































 (1 μM)  
3.1 (1 μM) 
3.2 (1 μM) 
3.3 (1 μM) 
3.4 (1 μM) 
3.5 (1 μM) 
3.6 (1 μM) 
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Table 3.2 Affinity estimates of test compounds from cAMP inhibition assays (pKb) in 
FlpInCHO-A1AR cells. Experiments and data analysis performed by PhD candidate Phuc 
Nguyen (Monash). 
Ligands cAMP inhibition 
pKb




9.27 ± 0.14 (0.5) 6 
3.1 9.19 ± 0.13 (0.6) 6 
3.2 8.28 ± 0.31 (5.2) 6 
3.3 8.62 ± 0.17 (2.4) 6 
3.4 8.86 ± 0.06 (1.4) 6 
3.5 8.65 ± 0.13 (2.2) 6 
3.6 9.20 ± 0.22 (0.6) 6 
aNegative logarithm of the equilibrium dissociation constant for antagonists as 
determined from NECA concentration response curves for cAMP inhibition.  
bSLV320 as selective A1AR antagonist 
 
3.3.4 SAR discussion of A1AR ligand estimated affinity (pKb) 
The potency of antagonists 3.1-3.6 were compared based on the affinity estimates shown 
in Table 3.2. 3.1 (hA1AR pKb = 9.19 ± 0.13 (0.6 nM)) and 3.6 (hA1AR pKb = 9.19 ± 0.13 
(0.6 nM)) demonstrated the highest competition against NECA for the binding site, while 
3.2-3.5 showed affinity estimates in a narrow range between pKb 8.28 – 8.86.  Ligand 3.1 
(hA1AR pKb = 9.19 ± 0.13 (0.6 nM)) which has a propyl chain instead of a butyl chain at 
the N1 position of 2.24 (hA1AR pKb = 9.31 ± 0.16 (0.5 nM)) showed near identical 
potency in NECA antagonism activity compared to 2.24.  
 A dramatic increment in pKb of approximately three log units was observed from 
replacing the propargyl linker on 2.27 (hA1AR pKb = 6.23 ± 0.39 (585 nM)) to a hexyne 
linker (3.6, hA1AR pKb = 9.20 ± 0.22 (0.6 nM)). Generally, a consistently high antagonist 
potency can be observed in all synthesised A1AR analogues consisting of an azido-
bearing linker. Overall, 3.1-3.6 expectedly showed a similar pKb trend as the pKi, and 
this informed that the clickable linkers used in this chapters were tolerated by A1AR and 
would hopefully provide accessibility to the fluorophore for a click reaction.  
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3.3.5 Assays of ligand activity at other AR subtypes 
The assay described in section 2.3.5 was carried out to measure ligand affinity of 3.1-3.6 
at other AR subtypes (A2AAR, A2BAR and A3AR) (Table 3.3). All these experiments 
were conducted by PhD candidate Phuc Nguyen (Monash). Antagonists SLV320 (2.62), 
SCH442416 (2.63), PSB603 (2.64) and MRS1220 (2.65) (Figure 2.17) were used as 
literature references against A1AR-, A2AAR-, A2BAR- and A3AR-FlpInCHO cells 
respectively. The estimates affinity (pKb) for hA1AR, hA2AAR, hA2BAR and hA3AR are 
shown in Table 3.3. 
 Generally, ligands 3.1-3.6 showed some inhibition on NECA activity at all four 
AR subtypes (hA1AR, hA2AAR, hA2BAR and hA3AR). Out of the six covalent clickable 
ligands synthesised in this chapter, 3.6, which contained a hexyne linker, demonstrated 
the best selectivity for hA1AR of approximately 18-fold, 9-fold and 11-fold against 
hA2AAR, hA2BAR and hA3AR respectively. Compound 3.4, which constituted the azido-
PEG2 linker, also showed some selectivity for hA1AR of approximately 9-fold, 6-fold 
and 11-fold against hA2AAR, hA2BAR and hA3AR respectively.  
 Ligand 3.2 showed a good selectivity (42-fold) for hA1AR against hA2AAR while 
3.5 demonstrated a 29-fold selectivity for hA1AR against hA2BAR. Compound 3.3 
showed cAMP inhibition at A1AR and A3AR while cAMP accumulation at A2AAR and 
A2BAR.  However, the pKb for 3.3 at A2AAR could not be generated because of poor 
curve fitting. 3.3 showed almost equipotency at hA1AR, hA2BAR and hA3AR. Ligands 
3.1 exhibited some selectivity at hA2AAR (9-fold) and a narrow margin of selectivity 






Table 3.3 Adenosine receptor subtype affinity (pKb) estimates values of 3.1-3.6 
compounds on cAMP inhibition and accumulation in human AR-expressing FlpInCHO 






















8.56 ± 0.21 
(2.8) 
4 
7.58 ± 0.19 
(26.3) 
5 
7.75 ± 0.26 
(17.8) 
4 




8.41 ± 0.13 
(3.9) 
4 
6.78 ± 0.31 
(166) 
5 
7.58 ± 0.70 
(26.3) 
4 




7.99 ± 0.19 
(10.2) 
4 n.d. 5 
8.17 ± 0.68 
(6.7) 
4 




8.45 ± 0.18 
(3.5) 
4 
7.50 ± 0.26 
(31.6) 
5 
7.64 ± 0.59 
(22.9) 
4 




8.48 ± 0.16 
(3.3) 
4 
7.44 ± 0.34 
(36.3) 
5 
7.02 ± 0.15 
(95.5) 
4 




8.41 ± 0.17 
(3.9) 
5 
7.15 ± 0.28 
(70.8) 
5 
7.45 ± 0.12 
(35.4) 
4 





9.44 ± 0.43 
(0.4) 
8 
9.47 ± 0.20 
(0.3) 
9 
8.87 ± 0.23 
(1.3) 
8 
8.30 ± 0.34 
(5.0) 
11 
aData are expressed as mean ± SEM from indicated number (n) of independent 
experiments performed in duplicate; n.d., denotes not defined due to incomplete 
inhibition and poor curve fit. 
bSLV320, SCH442416, PSB603 and MRS1220 are used as reference antagonist in 
A1AR-, A2AAR-, A2BAR- and A3AR-FlpInCHO cells, respectively 
 
Several interesting selectivity preferences were observed from the comparison of 
both the series of A1AR ligands made in chapter 2 (Table 2.4) and 3 (Table 3.3). The 
elongation of an azidopropyl (2.24) to an azidobutyl (3.2) linker did not show significant 
improvement on selectivity preferences. However, the further elongation to an azidooctyl 
(3.3) linker resulted in a near-equipotency on hA1AR, hA2BAR and hA3AR. Meanwhile, 
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replacing a more hydrophobic azidooctyl (3.3) with an azido-PEG2 (3.4) linker decreased 
competition against NECA at hA2AAR, hA2BAR and hA3AR, increasing the overall 
selectivity for hA1AR against other AR subtypes.  
The striking refinement of ligand selectivity was observed from the substitution 
of a propargyl (2.27) to a hexyne (3.6) linker surprisingly increased ligand competition 
against NECA at hA1AR for approximately one log unit in the presence of other AR 
subtypes, thus resulted in moderate selectivity preference for hA1AR against other AR 
subtypes (hA2AAR, hA2BAR and hA3AR). This selectivity preference shown by 3.6 for 
hA1AR against other AR subtypes was an interesting finding as the AR selectivity data 
for the similar xanthine-based DU172 which bear the same fluorosulfonylphenyl 
covalent arm was not published. In an attempt to rationalise the binding interaction of 3.6 
at all AR subtypes, molecular docking experiments are discussed later in section 3.4.  
 
3.3.6 Irreversibility assays 
The potential irreversibility of covalent clickable ligands 3.1-3.6 was investigated with a 
similar assay described in section 2.3.6 and the displacement curve of specific 
[3H]DPCPX with increasing concentration of ligands are shown in figure 3.7 (pKi after 
washing are shown in table 3.1. All these experiments were performed by PhD candidate 







Figure 3.7 Displacement of specific [3H]DPCPX (1 nM) binding in FlpInCHO-hA1AR 
cells at 4°C with an incubation time of 4 h after 3 h pre-incubation at 37°C followed by 
six extensive washing cycles. Experiments and data analysis performed by PhD 
candidate Phuc Nguyen (Monash). 
 
 Ligands 3.1-3.6 that contained a sulfonyl fluoride putative covalent warhead 
showed complete inhibition of the ability of [3H]DPCPX to bind to hA1AR following the 
extensive washing experiments informed that 3.1-3.6 were bound covalently to hA1AR. 
This covalent binding was assumed to take place at residue Y271 of A1AR (as described 
in section 2.4).  
  
3.3.7 In-situ click chemistry and imaging 
From the six ligands 3.1-3.6, ligands 3.1 and 3.6, which demonstrated the highest pKi’s 
at hA1AR, were chosen to investigate the clickability to a Cy5.5 fluorophore. The red-
shifted Cy5.5 fluorophore was chosen because of the its high molar absorption coefficient 
and fluorescence quantum yield which produces superior fluorescence brightness. All 
these experiments were conducted by PhD candidate Phuc Nguyen (Monash).  
The immunoblot showed the presence of hA1AR between 37 kDA to 50 kDA for 
both test assays which involved 3.1 (Panel A) and 3.6 (Panel B) (Figure 3.8). The 

























































fluorescence seen on both panel A and panel B (and was quantified, see Figure 3.9). The 
merged Cy5.5 fluorescence and hA1AR immunoblot was shown in red. This 
demonstrated that the hexyne linker incorporated in 3.6 had sufficient length for access 
to click to a Cy5.5 fluorophore, which was previously unachievable by use of a propargyl 
























Figure 3.8 Concentration-dependent incorporation of Cy5.5 was evident in FlpIn CHO-
A1AR cells by 3.1 and 3.6. Panel (A) and (B) shows representative in-gel Cy5.5 
fluorescence images coupled with immunoblots (indicative for hA1AR) shown in gray 
scale and merged Cy5.5 fluorescence in red. Experiments and data analysis performed 
by PhD candidate Phuc Nguyen (Monash). 
 
 The Cy5.5 fluorescence signal was quantified against the concentration of 3.1 and 
3.6 (Figure 3.9). Concentration-dependent click chemistry incorporation of the Cy5.5 
fluorophore was measured for both the azido-bearing 3.1 and terminal alkyne-bearing 
3.6 ligands. The azido-bearing ligands 3.1 demonstrated higher Cy5.5 fluorescent signal 
over the basal signal (approximately 2-fold at the highest test concentration) than the 
terminal alkyne-bearing 3.6. 
 
 
±[3.1] µM - 0.1 1 10 
Cy5.5 alkyne + + + + 
±[3.6] µM - 0.1 1 10 











Figure 3.9 Quantification of fluorescence intensity labelled with increasing concentration 
of 3.1 or 3.6. Cy5.5 fluorescence was corrected for relative hA1AR level, expressed as 
fold over basal. Data represent the mean ± SEM from n = 3. Error bars not shown lie 
within dimensions of the symbol. Experiments and data analysis performed by PhD 
candidate Phuc Nguyen (Monash). 
 
3.4  Rationalisation of results using molecular modelling and docking 
Given that 3.6 showed moderate selectivity for hA1AR over other AR subtypes, docking 
studies were carried out in an attempt to rationalise the hA1AR affinity (pKb = 8.41 ± 
0.17 (3.9 nM)) compared to the hA2AAR (pKb = 7.15 ± 0.28 (70.8 nM)), hA2BAR (pKb = 
7.45 ± 0.12 (35.4 nM)) and hA3AR (pKb = 7.36 ± 0.38 (43.7 nM)) affinity.  
3.6 was covalently docked to the A1AR crystal structure (PDB ID: 5UEN) where 
a covalent bond was formed between the sulfur atom of the chemoreactive fluorosulfonyl 
(-SO2F) group and the residue Y271. The residue Y271 of A1AR was chosen as the 
anchor point because this amino acid residue has been shown targetable by site-directed 
mutagenesis studies and bound experimentally with DU172, a ligand which has the same 
fluorosulfonyl covalent arm on the N3 position of a xanthine scaffold (described in 
section 2.1.3).10 Compound 3.6 was also covalently docked into the A3AR homology 
model (UniProt code: P0DMS8) using Y265 as the covalent linkage because this tyrosine 
has been reported to interact covalently with a similar xanthine scaffold and aligns with 











































11 These dockings were carried out in an attempt to rationalise the higher 
estimated affinity (pKb) (11-fold) of 3.6 at hA1AR over hA3AR.  
The overlay of 3.6 docked into both A1AR and A3AR (Figure 3.10) revealed a 
number of different amino acid residues at equivalent positions of A1AR and A3AR 
within 4 Å from 3.6. These nearby amino acid residues included N70, V87, E172, T270 
and T277 in A1AR (equivalent to S73, L90, V169, L264 and S271 in A3AR) were 
rationalised to potentially interact differently to 3.6 and could lead to a difference in 
ligand affinity towards A1AR or A3AR. The main difference in the ligand-receptor 
interaction was found to be the additional hydrogen bonding between T270 and the 
oxygen of the amide group. Additionally, the bulky L90 group of A3AR that projected 
into the binding site could potentially disrupt binding of the butyl substituent at the N1 
position of 3.6 which confers a reduced binding affinity at A3AR. This result agreed with 
the rationalisation that a butyl (or even longer/bulkier) substituent at N1 of synthesised 








Figure 3.10. Comparison of docked poses of 3.6 in A1AR and A3AR. Amino acid residues 
within 4 Å of the highest ranked docked pose of 3.6 in the A1AR crystal structure (PDB 
ID: 5UEN) and the A3AR (UniProt code: P0DMS8) homology model that can potentially 
lead to A1AR-A3AR selectivity. A1AR shown in purple ribbon, A3AR shown in green 
ribbon, 3.6 shown in purple (for A1AR) and green (for A3AR); Dashed yellow lines 
indicate hydrogen bond interactions. 3.6 was docked covalently to Y271 (hA1AR) and 
Y265 (hA3AR). Amino acid residues are shown as purple sticks (for A1AR) and green 
sticks (for A3AR). Nitrogen atoms shown as blue. Oxygen atoms shown as red. 
 
 3.6 was also docked with a covalent bond and non-covalently into the A2AAR 
crystal structure (PDB ID: 6PS7). The amino acid residue Y271 present in the A2AAR is 
conserved as an equivalent tyrosine in 3 of the 4 adenosine receptors (Y271 for A1AR, 
Y271 for A2AAR and Y265 for A3AR) (Figure 3.11),
12 was chosen to be the covalent 







Figure 3.11. The amino acid residues sequence alignment of A1AR, A2AAR, A2BAR, 
A3AR. The tyrosine amino acid residue of Y271
7.36 in A1AR is conserved in A2AAR and 
A3AR but not A2BAR. 
 
In the non-covalent docking mode (Figure 3.12 A), ligand 3.6 was docked into 
the orthosteric site of A2AAR, overlapping with the ligand originally complexed with 
A2AAR (PDB ID: 6PS7). The top-ranked pose (out of a cluster of 9 of 9 poses) showed 
the orientation of the xanthine ligand flipped vertically comparted to the orientation seen 
in the binding in A1AR (Figure 3.10). No hydrogen bonding interaction between 3.6 and 
A2AAR was found in this orientation. The covalent arm was found protruding out of the 
receptor surface.  
 In the covalent docking mode (Figure 3.12 B), the core xanthine structure of 
ligand 3.6 was oriented out of the orthosteric site (cluster of 9 out of 9 poses) of A2AAR 















Figure 3.12. A) The overlapping non-covalently docked 3.6 and orthosteric ligand 
ZM241385 showed the xanthine core of 3.6 was in the orthosteric site of A2AAR; B) A 
single cluster of 3.6 covalently bound to Y271 docked into the A2AAR crystal structure 
(PDB ID: 6PS7) (green sticks) and did not show binding at the A2AAR orthosteric site. 
A2AAR shown in green ribbon. Nitrogen atom shown as blue. Oxygen atoms shown as 
red. Ligand ZM241385 in yellow sticks. 3.6 in cyan sticks (Panel A) or various colours 
(Panel B). 
 
 Additionally, the comparison of structures A1AR (PDB ID: 5UEN) and A2AAR 
(PDB ID: 6PS7), both with 3.6 covalently docked, (Figure 3.13) identified a bulky M270 
(equivalent to T270 in A1AR) in A2AAR that could potentially disfavour binding of 3.6 
to A2AAR. The TM1 of A2AAR near the extracellular surface is moved inward into the 
binding pocket which reduced the size of the cavity of the A2AAR which could have 
hindered binding of a bulky covalent arm on a xanthine ring. Whilst xanthine-based 
ligands bind at A2AAR, none of them have a bulky covalent arm as is the case here. These 






Figure 3.13. Comparison of docked poses of 3.6 in A1AR and A2AAR. The highest ranked 
pose of 3.6 in A1AR and A2AAR were shown. A1AR shown in purple ribbon, A2AAR 
shown in green ribbon, 3.6 shown in purple (for A1AR) and green (for A2AAR); 
Compound 3.6 was docked covalently to Y271 (A1AR and A2AAR). Amino acid residues 
are shown as purple sticks (for A1AR) and green sticks (for A2AAR). Nitrogen atoms 
shown as blue. Oxygen atoms shown as red. 
 
 Compound 3.6 was docked non-covalently in a A2BAR homology model obtained 
from GPCRdb (Uniprot: P29274) in an attempt to rationalise the lower estimated affinity 
(9-fold) of 3.6 at A2BAR over A1AR. The ligand was docked non-covalently as the 
equivalent amino acid tyrosine 271 of A1AR is not conserved in A2BAR (Figure 3.11). 
The highest ranked pose of 3.6 in A1AR crystal structure (PDB ID: 5UEN) and in the 
A2BAR homology model were superimposed (Figure 3.14). Compound 3.6 was found to 
bind in the orthosteric site of A2BAR, however, in a different orientation than in A1AR 
where the xanthine core structure sat higher than in A2AAR than in A1AR. The covalent 
184 
 
arm bound downwards towards the intracellular surface and showed hydrogen bonding 
interaction between the carbonyl oxygen and the amide NH of N254. Both the bulky 
bicyclooctane and clickable linker groups of 3.6 were found to be much higher towards 
the extracellular surface in A2AAR than in A1AR. The key ligand-receptor interactions 
found between 3.6 and A1AR included the bidendate interaction of N254 and the π-
stacking of F171 – but these two interactions were not observed in docked results 
between 3.6 and A2BAR. 3.6 was also stabilised by multiple hydrogen bond interactions 




Figure 3.14. Overlay docked results of 3.6 in A1AR (PDB ID: 5UEN) and A2BAR 
homology model (Uniprot: P29274). Dashed yellow lines indicate hydrogen bond 
interactions. 3.6 was docked covalently to Y271 (hA1AR). Amino acid residues are 
shown as purple sticks (for A1AR) and light pink (for A2BAR). Nitrogen atom shown as 




3.5 Summary and conclusions 
The second generation of covalent clickable A1AR derivatives 3.1-3.6 were designed and 
synthesised based on pharmacological evaluation data of chapter 2 lead compound 2.24 
(hA1AR pKi = 8.17 ± 0.14 (6.7 nM); hA1AR pKb = 8.09 ± 0.31 (8.1 nM); hA3AR pKb = 
8.38 ± 0.29 (7.4 nM)), with the main aim to explore different click linker types and 
lengths in place of the azidopropyl linker of 2.24. This series of ligands was also designed 
to further evaluate how ligand changes affect the selectivity across the AR subtypes.  
 Compounds 3.1 and 3.6 were the two covalent clickable ligands that 
demonstrated the highest binding affinity while 3.2-3.5 showed slightly lower binding 
affinity at hA1AR. The covalent ligand 3.6 synthesised in chapter 2 and 3 is the highest 
affinity covalent ligand at hA1AR ever reported (e.g. higher affinity than LUF7746
14 and 
DU17210) .  While the two series of covalent ligands synthesised in chapter 2 and 3 were 
not  selective at either hA1AR or hA3AR, ligand 3.3 was the highest affinity covalent 
ligand at hA3AR reported currently (e.g. higher affinity than LUF7602
15).  
Generally, 3.1-3.6 showed that the aliphatic clickable linkers used in this chapter 
were tolerated by A1AR. All covalent clickable ligands in this chapter (3.1-3.6) acted as 
competitive antagonists at hA1AR in the cAMP inhibition assays. Irreversibility assays 
at hA1AR were carried out and 3.1-3.6 demonstrated complete inhibition of [
3H]DPCPX 
to bind hA1AR, similar to 2.24 and confirming irreversibility.  
 Covalent clickable 3.6 demonstrated moderate selectivity of 18-fold, 9-fold and 
11-fold for hA1AR against hA2AAR, hA2BAR and hA3AR, respectively. Apart from 3.4, 
which also showed moderate selectivity of 9-fold, 6-fold and 11-fold for hA1AR against 
hA2AAR, hA2BAR and hA3AR, respectively, covalent clickable ligands 3.2, and 3.5 
showed good selectivity for hA1AR against hA2AAR and hA2BAR, respectively. 
Compound 3.1 (azido linker derivative) and 3.6 (alkyne linker derivative) showed 
imaging capability and successful in-situ click reaction with a Cy5.5 fluorophore. 
Compound 3.6 was docked into all AR subtypes and rationalisations were made to 
attempt to explain the moderate A1AR selectivity shown by 3.6 over other AR subtypes.  
 Overall, the aim of improving binding selectivity of covalent clickable 
ligand 2.24 at hA1AR by exploration of different linker types and length was achieved 
by the generation of derivative 3.6. However, although the hA1AR selectivity was 
improved, 3.6 is 18-fold, 9-fold and 11-fold selective for hA1AR against hA2AAR, 
hA2BAR and hA3AR, respectively, and for many biological applications an A1AR 
selectivity of >100-fold is desirable. Despite the moderate selectivity shown by 3.4 and 
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3.6, these ligands will be useful in probing cells that have a high expression of A1AR 
while co-expressing low levels of A2AAR,
16 A2BAR
17 or A3AR.
18 Compound 3.2 which 
demonstrated good selectivity at hA1AR over hA2AAR can be utilised in hA1AR imaging 
studies for cells showing abundant level of A1AR and A2AAR (but not the other 2 AR 
subtypes) such as the striatum of the brain.19  
 
3.6  Future Directions  
In order to obtain even higher A1AR selectivity, further ligand modifications could be 
carried out on 3.1 and 3.6. There are several options for the modification of 3.1 and 3.6 
including the N1, N3, N7 and the clickable linker lengths and types. N3 is an important 
point for the attachment of the fluorosulfonylphenyl covalent arm while the hydrogen of 
N7 has been shown to be important for the hydrogen bonding interaction (discussed in 
section 2.4). The various clickable linker lengths and types have provided the synthesised 
A1AR ligands with excellent binding affinity and accessibility to a fluorophore, however 
little change in AR selectivity. If working with the same overall ligand scaffold, the 
modifications and results in this thesis have therefore narrowed down the potential 
options to improve A1AR selectivity to the N1 of 3.1 and 3.6.  
 



















3.7.1 General methods and material (Chemistry) 
The general methods and materials are as described in section 2.6.1. 
 
3.7.2 Experimental procedure and data for compounds as described in chapter 3 
 




8-Aminooctanol (100 mg, 0.85 mmol) was slowly added to a stirring 48 % HBr solution 
(5 mL) at 0 ˚C and the reaction mixture was heated and stirred at 80 ˚C overnight. The 
reaction mixture was cooled to rt and neutralised by addition of 2 M NaOH. The mixture 
was extracted 3 times with ethyl acetate (3 x 20 mL) and the pooled organic solution was 
washed with water (25 mL), dried over MgSO4, filtered and concentrated. The crude was 
dissolved in 4 M HCl (in dioxane) solution (3 mL) and washed with Et2O (15 mL) and 
filtered. The resulting solid was analysed, however, was not the desired 8-bromohexan-
1-amine 3.8. 
 




6-Aminooctanol (503 mg, 4.3 mmol) was first dissolved in MeOH (5 mL). Triethylamine 
(1.3 g, 12.9 mmol) and boc-anhydride (1.9 g, 8.6 mmol) (in 10 mL of MeOH) were then 
added sequentially and the reaction mixture was stirred overnight. MeOH was removed 
in-vacuo and the residue was dissolved in DCM, washed with water and dried with 
MgSO4 to give 3.15 (822 mg, 3.4 mmol) as colourless liquid. 
1H NMR (400 MHz, 
CDCl3): 𝛿 1.25-1.38 (m, 8H), 1.44 (s, 9H), 1.40-1.60 (m, 4H), 3.09 (t, J = 7.2 Hz, 2H), 
3.63 (t, J = 6.8 Hz, 2H). The proton chemical shift of NH and OH were not detected. 13C 
NMR (400 MHz, CDCl3): 𝛿 25.8, 26.8, 28.6 (3 equivalent carbons), 29.3, 29.4, 30.2, 
32.9, 40.7, 63.1, 156.1. The carbon chemical shift of the quaternary carbon of tert-butyl 
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group was not detected. HRMS (ESI) calculated for C13H27NaNO3
+ [M+Na]+ 268.3522, 
found m/z 268.1889. 
 




3.15 (100 mg, 0.41 mmol), DMAP (2.5 mg, 0.020 mmol) and triethylamine (74 mg, 0.73 
mmol) were dissolved in DCM (5 mL). 4-Toluenesulfonyl chloride (116 mg, 0.61 mmol) 
(in 5 mL DCM) was added dropwise (over 1 h) and the solution was stirred overnight. 
The reaction mixture was quenched with addition of water and stirred for 10 mins. The 
organic solution was washed with water, dried over MgSO4, filtered and concentrated. 
The residue was purified using flash column chromatography on silica gel eluted with n-
hexane/ethyl acetate (8:2) gave 3.16 (154 mg, 0.39 mmol) as white solid. 1H NMR (400 
MHz, CDCl3): 𝛿 1.17-1.33 (m, 8H), 1.43 (s, 11H), 1.62 (m, 2H), 2.44 (s, 3H), 3.07 (m, 
2H), 4.00 (t, J = 6.4 Hz, 2H), 7.34 (d, J = 8.4 Hz, 2H), 7.78 (d, J = 8.4 Hz, 2H). The 
proton chemical shift of NH was not detected. 13C NMR (400 MHz, C DCl3): 𝛿 21.8, 
25.4, 26.7, 28.6 (3 equivalent carbons), 29.0, 29.0, 29.1, 30.1, 40.7, 70.8, 128.0 (2 
equivalent carbons), 130.0 (2 equivalent carbons), 133.3, 144.8, 156.1. The carbon 
chemical shift of the quaternary carbon of tert-butyl group was not detected. HRMS (ESI) 
calculated for C20H33NaNO5S
+ [M+Na]+ 422.1972, found m/z 422.1976. 
 




To a solution of 3.16 (86 mg, 0.22 mmol) in DMF (3 mL), sodium azide (28 mg, 0.43 
mmol) was added and the suspension was stirred at 50 ̊ C overnight. The reaction mixture 
was cooled to rt and DMF was removed by rotary evaporation. Water was added and the 
aq. solution was extracted 2 times with ethyl acetate. The organic solution was washed 
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with water, dried over MgSO4, filtered and concentrated. The residue was purified using 
flash column chromatography on silica gel eluted with n-hexane/ethyl acetate (8:2) gave 
3.17 (51 mg, 0.19 mmol, 88 %) as colorless liquid. 1H NMR (400 MHz, CDCl3): 𝛿 1.24-
1.38 (m, 8H), 1.39 (s, 9H), 1.43 (t, J = 7.2 Hz, 2H), 1.57 (m, 2H), 3.08 (t, J = 7.2 Hz, 2H), 
3.24 (t, J = 6.8 Hz, 2H). The proton chemical shift of NH was not detected. 13C NMR 
(400 MHz, CDCl3): 𝛿 26.7, 26.8, 28.5 (3 equivalent carbons), 28.9, 29.1, 29.2, 30.1, 40.7, 
51.5, 156.1. The carbon chemical shift of the quaternary carbon of tert-butyl group was 
not detected. HRMS (ESI) calculated for C13H26NaN4O2S







In a moisture excluded condition, 4 M HCl (in dioxane) (5 mL) was added to 3.17 (100 
mg, 0.37 mmol). After 1 h, the reaction mixture was concentrated in vacuo to give 3.14 
(quantitative) as yellowish solid. 1H NMR (400 MHz, DMSO-d6): 𝛿 1.22-1.36 (m, 8H), 
1.53 (m, 4H), 2.73 (m, 2H), 3.31 (t, J = 7.0 Hz, 2H), 7.99 (br s, 2H). 13C NMR (400 MHz, 
DMSO-d6): 𝛿 25.7, 26.0, 26.9, 28.2, 28.3, 28.4, 38.7, 50.6. HRMS (ESI) calculated for 
C8H19N4






In a solution of 6-chloro-1-hexyne 3.9 (500 mg, 4.30 mmol) in DMF (4 mL), sodium 
azide (557 mg, 8.60 mmol) was added and the reaction mixture was heated to 80 ˚C 
overnight. The reaction mixture was cooled to rt and DMF was removed by rotary 
evaporation. Water (30 mL) was added the solution was extracted 2 times with ethyl 
acetate (2 x 25 mL). The combined organic layers were dried with MgSO4, filtered and 
concentrated in vacuo. The residue was purified using flash column chromatography on 
silica gel eluted with 100 % ethyl acetate gave 3.18 (425 mg, 3.50 mmol, 80 %) as a 
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colorless liquid. 1H NMR (400 MHz, CDCl3): 𝛿 1.59 (m, 2H), 1.73 (m, 2H), 1.98 (t, J = 
2.8 Hz, 1H), 2.23 (dt, J = 2.8, 6.8 Hz, 2H), 3.31 (t, J = 6.8 Hz, 2H). 13C NMR (400 MHz, 
CDCl3): 𝛿 18.0, 25.5, 27.7, 51.0, 69.0, 83.7. HRMS data not available because the MS 
was uncalibrated for low molecular weight compound. The experimental data is in 
agreement with the literature reported compound.20 
 




Several trials (i, ii, iii below) were carried out to synthesise hex-5-yn-1-amine 3.10. 
However, all 3 of them were unsuccessful. 
i. To a solution of 3.18 (134 mg, 1.10 mmol) in Et2O (2 mL) at 0˚C, PPh3 (572 mg, 
2.2 mmol) was added and the reaction mixture was stirred for 3 h. Water was 
added and the reaction was stirred overnight. The reaction mixture was poured 
into 10 % HCl and extracted 3 times with diethyl ether (3 x 20 mL). The aq. layer 
was basified to pH 10 and then extracted 5 times with Et2O (5 x 20 mL). The 
pooled organic solution was dried with MgSO4, filtered and concentrated in 
vacuo. However, almost quantitative amount of starting material was recovered 
and no desired product was isolated. 
ii. The same procedure was carried out as (i) except where the solvents used were 
THF and water (10:1 THF:water). However, almost quantitative amount of 
starting material was recovered and no desired product was isolated. 
iii. To a solution of LiAlH4 (123 mg, 3.2 mmol) in Et2O (6 mL) under stirring, was 
added dropwise of 6-azido-1-hexyne (in Et2O) (100 mg, 0.81 mmol) at 0 ˚C. The 
reaction mixture was warmed to rt and stirred for 3 h. The reaction was quenched 
with a small amount of water, filtered through Celite and extracted 3 times with 
Et2O (3 x 20 mL). The pooled organic layers were dried with MgSO4, filtered and 
concentrated in vacuo. However, mass spectrometry analysis of the crude mixture 
was showed high intensity of starting material while the parent ion of the desired 




General procedure for the synthesis of carboxamides 3.20, 3.23, 3.21, 3.22, 3.19. The 
carboxylic acid 2.39 was dissolved in DMF, then N,N-diisopropylethylamine (DIPEA) 
was added and the reaction mixture stirred for 5 min. HATU was added and the reaction 
mixture was stirred for 15 min. The NH2-‘linker’ was added dropwise and the reaction 
was stirred for overnight. The mixture was concentrated in vacuo and then ethyl acetate 
and saturated aq. NaHCO3 were added. The aq. layer was washed 2 times with ethyl 
acetate and the pooled organic phases were concentrated in vacuo. The residue was 
purified using flash column chromatography on silica gel. 
 
N-(4-azidobutyl)-4-(1-butyl-3-(2,4-dimethoxybenzyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-




2.39 (100 mg, 0.19 mmol), DMF (1 mL), DIPEA (76 mg, 0.59 mmol), HATU (75 mg, 
0.19 mmol) and 4-azidobutan-1-amine 3.11 (22 mg, 0.19 mmol) following column 
elution with 100% ethyl acetate gave 3.20 (118 mg, 0.19 mmol, 98 %) as a colourless 
gummy liquid. 1H NMR (400 MHz, DMSO-d6): 𝛿 0.88 (t, J = 7.4 Hz, 3H), 1.28 (m, 2H), 
1.39-1.55 (m, 6H), 1.66-1.87 (m, 12H), 3.04 (q, J = 6.2 Hz, 2H), 3.31 (t, J = 6.4 Hz, 2H), 
3.72 (s, 3H), 3.81 (s, 3H), 3.86 (t, J = 7.4 Hz, 2H), 5.04 (s, 2H), 6.39 (dd, J = 2.4, 8.4 Hz, 
1H), 6.57 (d, J = 2.4 Hz, 1H), 6.70 (d, J = 8.4 Hz, 1H), 7.43 (t, J = 5.8 Hz, 1H), 12.97 (s, 
1H). 13C NMR (400 MHz, DMSO-d6): 𝛿 13.7, 19.6, 25.6, 26.3, 27.8 (3 equivalent 
carbons), 29.6 (3 equivalent carbons), 30.8, 33.2, 38.1, 38.2, 40.3, 41.1, 50.3, 55.2, 55.5, 
98.3, 104.5, 106.5, 116.7, 126.9, 147.6, 150.6, 154.0, 157.4, 159.6, 160.4, 176.3. HRMS 
(ESI) calculated for C31H42NaN8O5








2.39 (100 mg, 0.19 mmol), DMF (1 mL), DIPEA (76 mg, 0.59 mmol), HATU (75 mg, 
0.19 mmol) and 2.36 (33 mg, 0.19 mmol) following column elution with 100% ethyl 
acetate gave 3.23 (100 mg, 0.15 mmol, 77 %) as a colourless gummy liquid. 1H NMR 
(400 MHz, DMSO-d6): 𝛿 0.88 (t, J = 7.4 Hz, 3H), 1.14-1.41 (m, 12H), 1.45-1.56 (m, 
4H), 1.64-1.88 (m, 12H), 3.01 (q, J = 6.6 Hz, 2H), 3.30 (t, J = 6.8 Hz, 2H), 3.72 (s, 3H), 
3.81 (s, 3H), 3.86 (t, J = 7.4 Hz, 2H), 5.04 (s, 2H), 6.39 (dd, J = 2.4, 8.4 Hz, 1H), 6.57 
(d, J = 2.4 Hz, 1H), 6.70 (d, J = 8.4 Hz, 1H), 7.35 (t, J = 5.8 Hz, 1H), 12.97 (s, 1H). 13C 
NMR (400 MHz, DMSO-d6): 𝛿 13.7, 19.6, 26.1, 26.2, 27.8 (3 equivalent carbons), 28.2, 
28.5, 28.6, 29.0, 29.7 (3 equivalent carbons), 33.2, 38.0, 38.5, 40.0, 41.1, 50.6, 54.9, 55.2, 
55.5, 98.3, 104.4, 106.5, 116.7, 126.9, 147.5, 150.6, 154.0, 157.4, 159.6, 160.4, 176.1. 
HRMS (ESI) calculated for C35H50NaN8O5
+ [M+Na]+ 685.3796 and C70H100N16NaO16
+ 















2.39 (200 mg, 0.39 mmol), DMF (1 mL), DIPEA (152 mg, 1.2 mmol), HATU (149 mg, 
0.39 mmol), and 2-(2-(2-azidoethoxy)ethanamine 3.12 (68 mg, 0.39 mmol) following 
column elution with 100% ethyl acetate. Methanol (3 mL) was added to the product and 
the resulting suspension was filtered and the filtrate was concentrated to give 3.21 (190 
mg, 0.28 mmol, 72%) as a colourless gummy liquid. 1H NMR (400 MHz, DMSO-d6): 𝛿 
0.88 (t, J = 7.4 Hz, 3H), 1.27 (m, 2H), 1.51 (m, 2H), 1.62-1.90 (m, 12H), 3.18 (q, J = 6 
Hz, 2H), 3.36-3.41 (m, 4H), 3.48-3.57 (m, 4H), 3.59 (t, J = 5.0 Hz, 2H), 3.72 (s, 3H), 
3.81 (s, 3H), 3.86 (t, J = 7.4 Hz, 2H), 5.04 (s, 2H), 6.39 (dd, J = 2.4, 8.4 Hz, 1H), 6.57 
(d, J = 2.4 Hz, 1H), 6.70 (d, J = 8.4 Hz, 1H), 7.39 (t, J = 5.8 Hz, 1H), 12.97 (br s, 1H). 
13C NMR (400 MHz, DMSO-d6): 𝛿 13.7, 19.6, 27.8 (3 equivalent carbons), 29.6 (3 
equivalent carbons), 33.2, 38.1, 38.6, 40.3, 41.1, 50.0, 54.9, 55.2, 55.5, 68.9, 69.2, 69.6, 
69.6, 98.3, 104.5, 106.5, 116.7, 126.9, 147.5, 150.6, 154.0, 157.4, 159.6, 160.4, 176.5. 
HRMS (ESI) calculated for C33H46N8NaO7
+ [M+Na]+ 689.3382 and C66H92N16NaO14
+ 













2.39 (200 mg, 0.39 mmol), DMF (1 mL), DIPEA (152 mg, 1.2 mmol), HATU (149 mg, 
0.39 mmol), and 2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethan-1-amine 3.13 (85 mg, 0.39 
mmol) following column elution with ethyl acetate/ methanol (9.5:0.5) gave 3.22 (200 
mg, 0.29 mmol, 75 %) as a colourless gummy liquid. 1H NMR (400 MHz, DMSO-d6): 
𝛿 0.88 (t, J = 7.4 Hz, 3H), 1.27 (m, 2H), 1.50 (m, 2H), 1.64-1.89 (m, 12H), 3.18 (q, J = 
6.2 Hz, 2H), 3.38 (t, J = 5.2 Hz, 4H), 3.45-3.57 (m, 8H), 3.59 (t, J = 4.8 Hz, 2H), 5.04 (s, 
2H), 6.39 (dd, J = 2.1, 8.5 Hz, 1H), 6.57 (d, J = 2.1 Hz, 1H), 6.69 (d, J = 8.5 Hz, 1H), 
7.40 (t, J = 5.6 Hz, 1H), 12.97 (s, 1H). 13C NMR (400 MHz, DMSO-d6): 𝛿 13.7, 19.6, 
27.8 (3 equivalent carbons), 29.7 (3 equivalent carbons), 29.7, 33.2, 35.8, 38.1, 38.6, 
40.1, 40.8, 50.0, 55.2, 55.5, 68.9, 69.3, 69.6, 69.7, 69.8, 69.8, 98.3, 104.4, 116.7, 126.9, 
147.5, 150.6, 154.0, 157.4, 159.6, 162.3, 176.5. HRMS (ESI) calculated for C35H51N8O8
+ 
[M+H]+ 711.3824 and C35H50N8NaO8














2.39 (100 mg, 0.19 mmol), DMF (1 mL), DIPEA (76 mg, 0.59 mmol), HATU (75 mg, 
0.19 mmol), and 5-hexyn-1-amine 3.10 (28 mg, 0.19 mmol) following column elution 
with 100 % ethyl acetate gave 3.19 (58 mg, 0.090 mmol, 50 %) as a colourless gummy 
liquid. 1H NMR (400 MHz, DMSO-d6): 𝛿 0.88 (t, J = 7.4 Hz, 3H), 1.21-1.56 (m, 8H), 
1.66-1.87 (m, 12H), 2.14 (t, J = 6.8 Hz, 2H), 2.74 (t, J = 2.8 Hz, 1H), 3.03 (q, J = 6.3 Hz, 
2H), 3.71 (s, 3H), 3.81 (s, 3H), 3.863 (t, J = 7.4 Hz, 2H), 5.04 (s, 2H), 6.39 (dd, J = 2.4, 
8.4 Hz, 1H), 6.57 (d, J = 2.4 Hz, 1H), 6.70 (d, J = 8.4 Hz, 1H), 7.40 (t, J = 5.8 Hz, 1H), 
12.98 (s, 1H). 13C NMR (400 MHz, DMSO-d6): 𝛿 13.7, 17.4, 19.6, 25.3, 27.9 (3 
equivalent carbons), 28.3, 29.7 (3 equivalent carbons), 33.2, 37.9, 38.1, 40.3, 41.1, 55.2, 
55.5, 71.2, 84.5, 98.3, 104.5, 106.5, 116.7, 126.9, 147.6, 150.6, 154.0, 157.4, 159.6, 
160.4, 162.3, 176.2. HRMS (ESI) calculated for C33H44N5O5
+ [M+H]+ 590.3337, 
C33H43NaN5O5
+ [M+Na]+ 612.3156 and C66H86NaN10O10
+ [2M+Na]+ 1201.6421, found 
m/z 590.3348, 612.3169 and 1201.6451. 
 
General procedure of the synthesis of sulfonyl fluorides 3.2-3.6. The DMB-protected 
carboxamide was dissolved in neat TFA and stirred overnight at 50 °C. The reaction 
mixture was cooled to rt and blown with compressed air for 20 min to evaporate excess 
TFA. CH2Cl2 was added and the organic solution was concentrated in vacuo and then 
dried overnight on high vacuum. The residue was dissolved in DMF then K2CO3 was 
added and the reaction mixture was stirred for 45 min. 4-((3-
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Bromopropyl)carbamoyl)benzenesulfonyl fluoride 2.44 (in a solution of DMF) was 
added drop-wise and the reaction mixture was stirred overnight. The reaction mixture 
was concentrated in vacuo and water was added. The aq. solution was extracted 3 times 
with ethyl acetate. The pooled organic layers were dried with MgSO4, filtered and 
concentrated in vacuo. The crude product was purified by column chromatography and 
underwent subsequent semi-preparative RP-HPLC purification. 
 
4-((3-(8-(4-((4-azidobutyl)carbamoyl)bicyclo[2.2.2]octan-1-yl)-1-butyl-2,6-dioxo-




3.20 (100 mg, 0.16 mmol), TFA (1 mL), DMF (2 mL), K2CO3 (22 mg, 0.16 mmol), 2.44 
(48 mg, 0.15 mmol) (in a solution of 4 mL dimethylformamide) following column elution 
100 % ethyl acetate gave a white solid (58 mg). This white solid was further purified by 
semi-preparative RP-HPLC purification to give 3.2 (20 mg, 0.020 mmol, 19 %) as a white 
solid. 1H NMR (500 MHz, DMSO-d6): 𝛿 0.88 (t, J = 7.3 Hz, 3H), 1.27 (m, 2H), 1.40-
1.55 (m, 6H), 1.60-1.84 (m, 12H), 1.96 (m, 2H), 3.05 (q, J = 6.2 Hz, 2H), 3.34 (q, J = 
overlap, 2H), 3.34 (t, J = overlap, 4H), 3.86 (t, J = 7.3 Hz, 2H), 4.06 (t, J = 7.0 Hz, 2H), 
7.40 (t, J = 5.8 Hz, 1H), 8.16 (d, J = 8.5 Hz, 1H), 8.26 (d, J = 8.5 Hz, 1H), 8.86 (t, J = 
5.8 Hz, 1H), 12.94 (s, 1H). 19F NMR (400 MHz, DMSO-d6): 𝛿 -73.72 (TFA salt), 66.15. 
HRMS (ESI) calculated for C32H42FNaN9O6S











3.23 (80 mg, 0.12 mmol), TFA (1 mL), DMF (2 mL), K2CO3 (17 mg, 0.12 mmol), 2.44 
(35 mg, 0.11 mmol) (in a solution of 4 mL dimethylformamide) following column elution 
with 100 % ethyl acetate gave a white solid (48 mg). This white solid was further purified 
by semi-preparative RP-HPLC purification to give 3.3 (30 mg, 0.039 mmol, 36 %) as a 
white solid. 1H NMR (500 MHz, DMSO-d6): 𝛿 0.88 (t, J = 7.3 Hz, 3H), 1.16-1.41 (m, 
12H), 1.46-1.56 (m, 4H), 1.61-1.81 (m, 12H), 1.96 (m, 2H), 3.00 (q, J = 6.5 Hz, 2H), 
3.31 (q, J = overlap, 2H), 3.31 (t, J = overlap, 2H), 3.85 (t, J = 7.5 Hz, 2H), 4.06 (t, J = 
7.0 Hz, 2H), 7.32 ( t, J = 5.8 Hz, 1H), 8.15 (d, J = 8.5 Hz, 2H), 8.25 (d, J = 8.5 Hz, 2H), 
8.85 (t, J = 5.8 Hz, 1H), 12.93 (s, 1H). 13C NMR (500 MHz, DMSO-d6): 𝛿 13.8, 19.6, 
26.1, 26.2, 27.5, 27.8 (3 equivalent carbons), 28.2, 28.5, 28.6, 29.1, 29.6 (3 equivalent 
carbons), 30.7, 33.2, 37.0, 38.0, 38.6, 40.3, 40.8, 50.7, 128.6 (2 equivalent carbons), 
129.0 (2 equivalent carbons), 133.4 (d), 141.6, 147.3, 150.6, 153.9, 157.9, 158.1, 164.3, 
176.1. 19F NMR (400 MHz, DMSO-d6): 𝛿 -73.75 (TFA salt), 66.18. HRMS (ESI) 
calculated for C36H51FN9O6S
+ [M+H]+ 756.3662 nd C36H50FNaN9O6S
+ [M+Na]+ 














3.21 (43 mg, 0.060 mmol), TFA (1 mL), DMF (2 mL), K2CO3 (9 mg, 0.060 mmol), 2.44 
(19 mg, 0.050 mmol) (in a solution of 4 mL dimethylformamide) following with column 
elution with 100 % ethyl acetate gave a white solid (60 mg). This white solid was further 
purified by semi-preparative RP-HPLC purification to give 3.4 (19 mg, 0.020 mmol, 43 
%) as a white solid. 1H NMR (500 MHz, DMSO-d6): 𝛿 0.88 (t, J = 7.5 Hz, 3H), 1.27 (m, 
2H), 1.50 (m, 2H), 1.62-1.82 (m, 12H), 1.96 (m, 2H), 3.18 (q, J = 6 Hz, 2H), 3.31 (q, J 
= 6.5 Hz, 2H), 3.35-3.62 (m, 8H), 3.60 (t, J = 4.8 Hz, 2H), 3.85 (t, J = 7.5 Hz, 2H), 4.06 
(t, J = 7 Hz, 2H), 7.36 (t, J = 5.8 Hz, 1H), 8.15 (d, J = 8.5 Hz, 2H), 8.25 (d, J = 8.5 Hz, 
2H), 8.85 (t, J = 5.8 Hz, 1H), 12.93 (s, 1H). 13C NMR (500 MHz, DMSO-d6): 𝛿 13.7, 
19.6, 27.5, 27.8 (3 equivalent carbons), 29.6 (3 equivalent carbons), 29.7, 30.7, 33.2, 
37.0, 38.1, 38.6, 40.3, 40.8, 50.0, 68.9, 69.3, 69.6, 106.5, 128.6 (2 equivalent carbons), 
129.0 (2 equivalent carbons), 133.4 (d), 141.6, 150.6, 153.6, 158.2, 160.3, 164.3, 176.5. 
19F NMR (400 MHz, DMSO-d6): 𝛿 -74.41 (TFA salt), 66.18. HRMS (ESI) calculated 
for C34H47FN9O8S
+ [M+H]+ 760.3247 and C34H46FNaN9O8S
+ [M+Na]+ 782.3066, found 














3.22 (69 mg, 0.090 mmol), TFA (1 mL), DMF (2 mL), K2CO3 (14 mg, 0.090 mmol), 
2.44 (28 mg, 0.080 mmol) (in a solution of 4 mL dimethylformamide) following column 
elution with 100 % ethyl acetate gave a white solid (25 mg). This white solid was further 
purified by semi-preparative RP-HPLC purification to give 3.5 (19 mg, 0.023 mmol, 27 
%) as a white solid. 1H NMR (500 MHz, DMSO-d6): 𝛿 0.88 (t, J = 7.5 Hz, 3H), 1.27 (m, 
2H), 1.50 (m, 2H), 1.62-1.83 (m, 12H), 1.96 (m, 2H), 3.18 (q, J = 6 Hz, 2H), 3.31 (q, J 
= 6.5 Hz, 2H), 3.35-3.62 (m, 12H), 3.60 (t, J = 5.0 Hz, 2H), 3.85 (t, J = 7.5 Hz, 2H), 4.06 
(t, J = 7 Hz, 2H),  7.37 (t, J = 5.5 Hz, 1H), 8.15 (d, J = 8.5 Hz, 2H), 8.25 (d, J = 8.5 Hz, 
2H), 8.85 (t, J = 5.8 Hz, 1H), 12.93 (s, 1H). 13C NMR (500 MHz, DMSO-d6): 𝛿 13.7, 
19.6, 27.8 (3 equivalent carbons), 29.6 (3 equivalent carbons), 33.2, 37.0, 38.1, 38.6, 
40.2, 40.8, 50.0, 68.9, 69.3, 69.6, 69.7, 69.8, 69.8, 106.5, 128.6 (2 equivalent carbons), 
129.0 (2 equivalent carbons), 133.4 (d), 141.6, 147.2, 150.6, 153.9, 157.9, 158.1, 160.3, 
164.2, 176.4. 19F NMR (400 MHz, DMSO-d6): 𝛿 -74.10 (TFA salt), 66.16. HRMS (ESI) 
calculated for C36H50FNaN9O9S












3.19 (100 mg, 0.17 mmol), TFA (1 mL), DMF (2 mL), K2CO3 (23 mg, 0.17 mmol), 2.44 
(49 mg, 0.15 mmol) (in a solution of 4 mL dimethylformamide) following column elution 
with 100 % ethyl acetate gave a white solid (67 mg). This white solid was further purified 
by semi-preparative RP-HPLC purification to give 3.6 (35 mg, 0.051 mmol, 33 %) as a 
white solid. 1H NMR (400 MHz, DMSO-d6): 𝛿 0.88 (t, J = 7.4 Hz, 3H), 1.27 (m, 2H), 
1.35-1.54 (m, 8H), 1.61-1.83 (m, 12H), 1.96 (m, 2H), 2.15 (t, J = 6.2 Hz, 2H), 2.74 (t, J 
= 2.4 Hz, 1H), 3.03 (q, J = 6.4 Hz, 2H), 3.31 (q, J = 6.6 Hz, 2H), 3.85 (t, J = 7.5 Hz, 2H), 
4.06 (t, J = 7 Hz, 2H), 7.39 (t, J = 5.8 Hz, 1H), 8.15 (d, 8.5 Hz, 2H), 8.25 (d, J = 8.5 Hz, 
2H), 8.85 (t, J = 5.6 Hz, 1H), 12.94 (s, 1H). 13C NMR (400 MHz, DMSO-d6): 𝛿 13.7, 
17.4, 19.6, 25.3, 27.5, 27.8 (3 equivalent carbons), 28.0, 28.3, 29.6 (3 equivalent 
carbons), 29.7, 38.0, 38.0, 40.2, 40.7, 71.2, 84.5, 106.5, 128.6 (2 equivalent carbons), 
129.0 (2 equivalent carbons), 133.4 (d), 141.5, 147.2, 150.6, 153.9, 160.3, 160.9, 164.2, 
176.2. 19F NMR (400 MHz, DMSO-d6): 𝛿 -69.31, -71.20 (TFA salt), 66.13. HRMS (ESI) 
calculated for C34H44FN6O6S
+ [M+H]+ 683.3022 and C34H43FNaN6O6S
+ [M+Na]+ 












To a stirred suspension of 2.34 (1.1 g, 3.0 mmol) in acetonitrile (3.5 mL) and DMF (2 
mL), Cs2CO3 (1.1 g, 3.3 mmol) and tetra-N-butylammonium bromide (TBAB) (97 mg, 
0.30 mmol) were added. The 1-bromopropane (0.56 g, 0.41 mL, 4.5 mmol) was added 
drop-wise over 15 min and the reaction mixture was stirred for 1 h at rt and then 3 h at 
60 °C. Ice water (30 mL) was added and mixture was stirred for 30 min. The mixture was 
extracted with CH2Cl2 two times (2 x 30 mL) and washed with saturated aq. NaHCO3 
(25 mL) and brine (25 mL). The pooled organic layers were dried with MgSO4, filtered 
and concentrated in vacuo. The solid obtained was recrystallized with 50 % aq. methanol, 
filtered and washed with cold 50 % aq. methanol and air-dried to give 3.24 (0.93 g, 2.4 
mmol, 80 %) as off-white crystals. 1H NMR (400 MHz, DMSO-d6): 𝛿 0.88 (t, J = 7.4 
Hz, 3H), 1.25 (m, 2H), 1.47 (m, 2H), 2.83 (s, 3H), 3.04 (s, 3H), 3.71 (s, 3H), 3.76 (t, J = 
7.2 Hz, 2H), 3.78 (s, 3H), 5.05 (s, 2H), 5.17 (s, 1H), 6.41 (dd, J = 2.4, 8.4 Hz, 1H), 6.53 
(d, J = 2.4 Hz, 1H), 6.64 (d, J = 8.4 Hz, 1H), 8.04 (s, 1H). 13C NMR (400 MHz, DMSO-
d6): 𝛿 13.7, 19.6, 29.6, 34.1, 39.5, 39.7, 39.9, 55.1, 55.4, 81.8, 98.1, 104.4, 118.2, 126.2, 
151.8, 155.8, 157.0, 158.9, 159.2, 162.1. HRMS (ESI) calculated for C20H29N4O4
+ 
[M+H]+ 389.2183 and C20H28N4NaO4














To a stirred suspension of 3.24 (0.92 g, 2.4 mmol) in methanol (7.5 mL) was added 2 M 
aq. KOH (7.4 mL). The suspension was stirred at 50 °C for 1 h. The reaction mixture was 
cooled to rt and neutralised to pH 7 with 2 M aq. HCl. Upon cooling to 5 °C and stirring 
for 2 h a precipitate formed, which was collected by filtration, washed with water and 
air-dried to give 3.25 (0.66 g, 2.0 mmol, 84 %) as colourless fluffy crystals. 1H NMR 
(400  MHz, DMSO-d6): 𝛿 0.80 (t, J = 7.4 Hz, 3H), 1.47 (m, 2H), 3.67 (t, J = 7.4 Hz, 2H), 
3.73 (s, 3H), 3.82 (s, 3H), 4.72 (s, 1H), 4.90 (br s, 2H), 6.49 (dd, J = 2.2, 8.4 Hz), 6.59 
(d, J = 2.2 Hz), 6.67 (br s, 2H), 6.71 (d, J = 8.4 Hz). 13C NMR (400 MHz, DMSO-d6): 𝛿 
11.2, 20.9, 40.3, 41.4, 55.3, 55.5, 75.1, 98.5, 104.7, 116.2, 126.1, 151.4, 154.6, 157.2, 
159.8, 161.2. HRMS (ESI) calculated for C16H21N3NaO4
+ [M+Na]+ 342.1424 and 
C32H42N6NaO8






The aminouracil 3.25 (0.65 g, 2.0 mmol) was dissolved in 50 % aq. acetic acid (15 mL) 
and heated to 70 °C. NaNO2 (0.28 g, 4.1 mmol) was added in 3 batches over 30 min, and 
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the reaction was stirred for 1 h at 70 °C. The mixture was cooled to rt and the precipitate 
that formed was collected by filtration, washed with water and diethyl ether and air-dried 
to give the nitro-intermediate as a pink solid (0.59 g). This nitro intermediate (0.59 g) 
was dissolved in 25 % aq. ammonia (8.4 mL) and methanol (8.4 mL) and heated to 80 °C. 
Na2S2O4 (0.79 g, 4.5 mmol) was added in 3 batches over 30 min and the reaction was 
stirred for 4 h at 80 °C. The mixture was cooled to rt and stirred overnight. The crystals 
that formed were collected by filtration, washed with water and diethyl ether and air-
dried to give 3.26 (0.42 g, 1.3 mmol, 76 %) as grey-green crystals. 3.26 was used 
immediately without further purification due to instability. 
 
4-(3-(2,4-dimethoxybenzyl)-2,6-dioxo-1-propyl-2,3,6,9-tetrahydro-1H-purin-8-




To a suspension of bicyclo[2.2.2]octane-1,4-dicarboxylic acid monomethyl ester 3.27 
(0.30 g, 1.41 mmol) in acetonitrile (5.5 mL) was added Et3N (0.55 g, 5.4 mmol) and the 
reaction stirred for 5 min. HATU (0.54 g, 1.4 mmol) was added and the reaction stirred 
for 15 min. The diaminouracil 3.26 (0.47 g, 1.4 mmol) dissolved in acetonitrile (2 mL), 
was added dropwise and the reaction stirred for 1 h. The mixture was concentrated in 
vacuo and 10 % citric acid (30 mL) was added. The aq. solution was extracted 3 times 
with ethyl acetate (3 x 25 mL) then the pooled organic layers were washed with saturated 
NaHCO3 (20 mL), brine (20 mL) and concentrated in vacuo. Isopropanol (6 mL) and 1 
M aq. KOH (6 mL) were added and the reaction was heated at reflux for 1 h. The mixture 
was cooled, concentrated in vacuo, (10 mL) water was added, and the mixture was 
washed twice with CH2Cl2 (2 x 25 mL), discarding the organic washings. The aq. solution 
was acidified to pH 5 with 12 M aq. HCl. The mixture was refrigerated overnight and the 
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resultant precipitate was collected by filtration, rinsed with water and oven-dried at 80 °C 
to give 3.28 (0.42 g, 0.85 mmol, 59 %) as a white solid. 1H NMR (400 MHz, DMSO-d6): 
𝛿 0.85 (t, J = 7.4 Hz, 3H), 1.54 (m, 2H), 1.68-1.88 (m, 12H), 3.71 (s, 3H), 3.81 (s, 3H), 
3.83 (t, J = 7.2 Hz, 2H), 5.04 (s, 2H), 6.39 (dd, J = 2.4, 8.4 Hz, 1H), 6.57 (d, J = 2.4 Hz, 
1H), 6.69 (d, J = 8.4 Hz, 1H), 12.10 (br s, 1H), 12.98 (s, 1H). 13C NMR (400 MHz, 
DMSO-d6): 𝛿 11.2, 20.8, 27.6 (3 equivalent carbons), 29.4 (3 equivalent carbons), 29.7, 
33.2, 37.7, 41.1, 42.1, 55.2, 55.5, 98.3, 104.4, 106.5, 116.7, 126.9, 147.6, 150.6, 154.0, 
157.4, 159.6, 160.2, 178.4. HRMS (ESI) calculated for C26H31N4O6
- [M-H]- 495.2249; 







The carboxylic acid 3.28 (100 mg, 0.19 mmol) was dissolved in DMF (1 mL), then 
DIPEA (76 mg, 0.59 mmol) was added and the reaction mixture stirred for 5 min. HATU 
(75 mg, 0.19 mmol) was added and the reaction mixture was stirred for 15 min. 3-
Azidopropan-1-amine 2.42 (20 mg, 0.19 mmol) was added dropwise and the reaction 
was stirred for overnight. The mixture was concentrated in vacuo and then ethyl acetate 
(20 mL) and saturated aq. NaHCO3 (10 mL) were added. The aq. layer was washed 2 
times with ethyl acetate and the pooled organic phases were concentrated in vacuo. The 
residue was purified using flash column chromatography on silica gel eluted with 100 % 
ethyl acetate gave 3.29 (82 mg, 0.14 mmol, 70 %) as a yellowish gummy liquid. 1H NMR 
(400 MHz, DMSO-d6): 𝛿 0.85 (t, J = 7.4 Hz, 3H), 1.55 (m, 2H), 1.64 (m, 2H), 1.67-1.88 
(m, 12H), 3.09 (q, J = 6.2 Hz, 2H), 3.30 (t, J = 6.8 Hz, 2H), 3.72 (s, 3H), 3.81 (s, 3H), 
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3.83 (t, J = 7.2 Hz, 2H), 5.04 (s, 2H), 6.39 (dd, J = 2.4, 8.4 Hz, 1H), 6.57 (d, J = 2.4 Hz, 
1H), 6.70 (d, J = 8.4 Hz, 1H), 7.47 (t, J = 5.8 Hz, 1H), 12.98 (s, 1H). 13C NMR (400 MHz, 
DMSO-d6): 𝛿 11.1, 20.8, 27.8 (3 equivalent carbons), 28.4, 29.6 (3 equivalent carbons), 
33.2, 35.8, 36.1, 38.1, 38.2, 41.1, 42.0, 48.5, 55.2, 55.5, 98.3, 104.5, 106.5, 116.7, 126.9, 








The DMB-protected carboxamide 3.28 (50 mg, 0.086 mmol) was dissolved in neat TFA 
(1 mL) and stirred overnight at 50 °C. The reaction mixture was cooled to rt and blown 
with compressed air for 20 min to evaporate excess TFA. CH2Cl2 (15 mL) was added 
and the organic solution was concentrated in vacuo and then dried overnight on high 
vacuum. The residue was dissolved in DMF (2 mL) then K2CO3 (12 mg, 0.080 mmol) 
was added and the reaction mixture was stirred for 45 min. 4-((3-
Bromopropyl)carbamoyl)benzenesulfonyl fluoride 2.44 (in a solution of DMF (2 mL)) 
was added drop-wise and the reaction mixture was stirred overnight. The reaction 
mixture was concentrated in vacuo and water was added. The aq. solution was extracted 
3 times with ethyl acetate (3 x 10 mL). The pooled organic layers were dried with MgSO4, 
filtered and concentrated in vacuo gave a crude white solid (107 mg). Some of this solid 
(39 mg) was purified by semi preparative RP-HPLC purification to give 3.1 (11 mg, 
0.016 mmol, 58 % - yield was scaled up to 2.74 times (107 mg/39 mg) to give an overall 
yield percentage) as white crystals. 1H NMR (500 MHz, DMSO-d6): 𝛿 0.85 (t, J = 7.3 
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Hz, 3H), 1.54 (m, 2H), 1.65 (m, 2H), 1.62-1.81 (m, 12H), 1.96 (m, 2H), 3.09 (q, J = 6.3 
Hz, 2H), 3.31 (t, J = 6.8 Hz, 2H), 3.40 (overlap, 2H), 3.82 (t, J = 7.5 Hz, 2H), 4.06 (t, J 
= 7.0 Hz, 2H), 7.45 (t, J = 5.8 Hz, 2H), 8.16 (d, J = 8.3 Hz, 2H), 8.26 (d, J = 8.3 Hz, 2H), 
8.86 (t, J = 5.5 Hz, 1H), 12.94 (s, 1H). 13C NMR (500 MHz, DMSO-d6): 𝛿 11.2, 20.9, 
27.5, 27.8, 28.4, 29.6, 33.2, 36.1, 37.0, 38.1, 40.8, 42.0, 48.5, 106.5, 128.6, 129.0, 133.4 
(d), 141.6, 147.2, 150.7, 153.9, 157.9, 158.1, 160.3, 164.3, 176.5. 19F NMR (400 MHz, 
DMSO-d6): 𝛿 66.15. HRMS (ESI) calculated for C30H38FNaN9O6S+ [M+Na]+ 694.2542, 
found m/z 694.2537. HPLC 18.17 min. 
 
3.7.3 Computational studies 
The crystal structures of A1AR (PDB ID: 5UEN) and A2AAR (PDB ID: 6PS7) were 
downloaded from the Protein Data Bank.21 The A2BAR homology model (UniProt code: 
P29274) was downloaded from GPCRdb.22 The A3AR homology model (UniProt code: 
P0DMS8) was generated using Modeller 9.2223 based on the antagonist-bound DU172-
A1AR crystal structure (PDB ID: 5UEN).
10 All small molecule three-dimensional 
structures created in this thesis were generated using Avogadro 1.2.024 and minimized 
using the universal force field (UFF). Ligand docking was carried out with GOLD 5.8.1 
(CCDC Software)25 using ChemPLP scoring method with default settings. The docking 
process was centred on residues F171 (A1AR – PDB ID: 5UEN), F168 (A2AAR – PDB 
ID: 6PS7), F173 (A2BAR – Uniprot: P29274) and F168 (A3AR homology model - 
UniProt code: P0DMS8) with a distance extension of 15 Å. Covalent binding mode was 
used and the covalent link was defined between the 4 position of Y2717.36 (A1AR - PDB 
ID: 5UEN or A2AAR – PDB ID: 6PS7) or Y265
7.36 (A3AR homology model - UniProt 
code: P0DMS8) and the oxygen atom of the sulfonyl moiety (-SO3). Non-covalent 
docking was used for the A2BAR homology model (UniProt code: P29274) as there was 
no corresponding tyrosine in this receptor. The highest ranked pose at each receptor are 
presented. The docking results were visualised in PyMOL (The PyMOL Molecular 
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Chapter 4 Design and synthesis of mGluR5 covalent clickable ligands 
 
4.1 Introduction 
mGluR5 has been implicated in many disease pathologies including AD, addiction, pain 
and other CNS disorders.1-7 As discussed in section 1.5.2, there are numerous advantages 
of using fluorescent ligands in studying GPCRs. The synthesis of fluorescent ligands for 
mGluR5 has been sluggish and only recently, a series of fluorescent ligands based on 
NAM 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP, 1.44, Figure 4.1) were 
reported.8 slow progress on the development of mGluR5 fluorescent ligands was due to 
the lipophilic nature of mGluR5 allosteric ligands, in which the derivatisation to 
fluorescent ligands could potentially result in non-specific interactions with cell 
surfaces.8 Bifunctional clickable ligands bearing a photoreactive group were reported by 
Gregory et al. where these ligands underwent a two-step process (covalent binding then 
click to a fluorophore) to label mGluR5 with a fluorophore (the concept described in 
section 1.5.1.1 and 1.5.2.2).9 Upon photoactivation, however, these clickable 
photoaffinity ligands suffered a high degree of non-specific labelling.  
To circumvent undesired non-specificity of clickable ligands binding to the 
mGluR5, the aim of this chapter was to develop a series of covalent clickable ligands 
consisting of a chemoreactive group that can form a covalent bond with mGluR5 and 
subsequently undergo a click reaction with a fluorophore in situ. A suitable linker length 
connecting the mGluR5 ligand scaffold to the reactive click functional group (azide or 
alkyne) were rationalised and chosen in the ligand design. 
 
4.1.1 Scaffold selection 
The ligand design for the covalent clickable mGluR5 ligands started with a scaffold 
selection. Scaffolds relating to the mGluR5 orthosteric site were avoided as mGluR5 
orthosteric ligands were reported to suffer selectivity issues.10 Scaffolds interacting with 
an allosteric site were preferable because it has been shown that mGluR5 selectivity 
against other subtypes in the same class (e.g. mGluR1) was achievable.
11  
 A scaffold favouring negative allosteric modulation of mGluR5 was an attractive 
option for several reasons including rich SARs of ligands, various chemotypes available 
for modification or introduction of a chemoreactive and clickable linker, and the 
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availability of a number of mGluR5 crystal structures that can be used to guide ligand 
design.  
There have been many reported chemotypes of mGluR5 allosteric ligands 
including (but not limited to) alkyne-based NAM MPEP (1.44)12, MTEP (44)13, 
Basimglurant (4.1), VU0403602 (4.2), RO4917523 (4.3), Mavoglurant (1.4) (Figure 
1.9), AFQ056 (4.4) (Figure 4.1)14-17, and non-alkynyl-based mGluR5 ligands, for 
instance, Fenobam (1.9) (Figure 1.12), AZD9272 (4.5), VU0366058 (4.6), PF470 (4.7), 
N-(5-fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (4.8) and 










Figure 4.2. Various non-alkyne-based mGluR5 NAMs. 
 
Following a thorough literature screening for a suitable chemotype for mGluR5 
ligand, an alkyne-based NAM (4-(3-(6-methylpyridin-2-yl)prop-2-yn-1-
ylidene)piperidin-1-yl)(phenyl)methanone (4.10) was identified as a literature compound 
for modification into a covalent clickable ligand for the mGluR5.
20 A library of 
derivatives investigating on the SAR of 4.10 at mGluR5 was reported and substitution 
was tolerated around the benzene ring (Table 4.1).20 Additionally, ligand 4.10 was shown 
to have poor binding at rmGluR1.
20 However, the binding at hmGluR1 was not reported. 
Binding data at other mGluRs (mGluR2, mGluR3, mGluR4, mGluR6, mGluR7 and 
mGluR8) were not reported because of low sequence homology (< 44%) compared to 









Table 4.1. Selected alkyne-based NAM for modification to a covalent clickable ligand 
for the mGluR5. 
 
 
4.1.2 SAR of ligand 4.10 
Anighoro et al. described an extensive SAR study for ligand 4.10 (Figure 4.3).22 
Compound 4.14a (hmGluR5 Ki = 0.5 nM, rmGluR1 Ki = 96.8 nM) was first reported by 
Euro-Celtique. The reduction of the carbonyl amide of 4.14a to 4.14b significantly 
reduced hmGluR5 affinity. However, the introduction of a double bond (compound 
4.14c) recovered the high affinity for hmGluR5 and the sp2 planarity of the compound 
was thought to be important for high binding affinity at mGluR5. The conversion of the 
benzene ring of 4.14c to a pyridine moiety in 4.14d increased the selectivity for hmGluR5 
against rmGluR1. An additional methyl group adjacent to the N of the pyridine moiety 
of 4.14d to give 6-methylpyridine 4.15 resulted in the increased in selectivity for 
hmGluR5 against rmGluR1. The nitrogen atoms on the pyridine ring of 4.16 were 
respectively investigated and it was found that the absence of N pyridine in 4.18 showed 
higher selectivity and affinity for hmGluR5 were not as superior as 4.15. The influence 
of the nitro group in 4.16 was investigated and found that the presence of a hydrogen 
bond acceptor (compared with 4.17 with an absence of the nitro group) at this position 
was essential for good hmGluR5 binding. Following that, the addition of substituents 
around the benzene ring directly attached to the alknyl part of 4.19, 4.20 and 4.21 was 
investigated. The singly-substituted meta and para position of 4.19 and 4.21, 
respectively, were tolerated by hmGluR. However, the disubstituted meta position of 
4.20 showed dramatic loss of hmGluR5 binding. SAR in this region of the molecule 
showed that the cavity around the benzene ring of 4.19, 4.20 and 4.21 is made up of a 
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small volume of space in the mGluR5. Furthermore, the authors explored each end of the 
molecule using bulky substituents shown in compounds 4.22 and 4.23. The addition of a 
bulky azetidinone in 4.22 completely abolished hmGluR5 binding while the addition of 
a bulky benzene ring at the para position of the nicotinitrile ring of 4.23 was tolerated 




Figure 4.3. NAMs of mGluR5 described by Anighoro et al. 
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  Anighoro et al. also described the docking of compound 4.14d into a mGluR5 
homology model (generated based on the mGluR1 crystal structure (PDB ID: 4OR2)) 
(Figure 4.4).22 The binding mode of 4.14d was predicted to be similar to MPEP with 
mGluR5 and near the intracellular region of mGluR5 (Figure 4.4). The nitropyridine ring 
was shown to protrude toward the extracellular surface. This was in agreement with the 
fact that the addition of the bulky benzene substituent on the nitropyridine ring on 4.23 





Figure 4.4. The orientation of compound 4.14d docked in the homology model20 showed 
that the nitropyridine ring protruded towards the extracellular surface. 
 
 Graziani et al. explored derivatisation of compound 4.14d by the replacement of 
the nitro-substituted heteroaryl ring with different linkage groups including amides, 
carbamates, ureas and sulfonamides.20 Various high affinity and selective hmGluR5 
ligands were synthesised. However, literature compounds 4.10-4.13 were selected to be 
used for further modification in this thesis because the derivatisation of compound 4.10 
using the amide linkage involved a convenient amidation reaction. Additionally, the 
tolerance shown by hmGluR5 towards the ortho, meta and para substituted methoxy of 






4.1.2 Selection of linker type and clickable chemistry 
NAM 4.12 was docked into the crystal structures of mGluR5 complexed with 
mavoglurant (PDB ID: 4OO9)23 to inspect for a suitable placement of a clickable linker. 
Figure 4.5 shows the docked ligand 4.12 in mGluR5 (PDB ID: 4OO9). Ligand 4.12 
docked (top ranked pose, cluster 3 of 5) in a similar orientation as mavoglurant (Panel A, 
Figure 4.5). Ligand 4.12 made non-polar interactions with various amino acid residues 
within 4 Å of the binding pocket of mGluR5 (Figure 4.5 B). The conserved triads (Y659, 
T781, S809, discussed in section 1.3.3.3) interacted with the conserved water molecule 
found near the intracellular region (Panel B, Figure 4.5). A tyrosine residue (Y792) was 
identified near the extracellular region of mGluR5 that can be potentially targetable with 
a chemoreactive group to form a covalent linkage (Figure 4.5, Panel B, discussed in 












Figure 4.5. Results of docked ligand 4.12 in crystal structure of mGluR5 (PDB ID: 
4OO9). A) Overlay of ligand 4.12 and mavoglurant (1.4); B) Amino acid residues within 
4 Å from ligand 4.12. Ligand 4.12 in maroon (Panel A) and turquoise sticks (Panel B), 
Mavoglurant in yellow sticks. Amino acid residues in green sticks. Oxygen atoms in red. 
Nitrogen atoms in blue. 
 
 A suitable aliphatic linker was designed for the new ligand series of covalent 
clickable mGluR5 ligands based on docking results shown in panel B of Figure 4.5. The 
introduction of clickable linkers was rationalised based on the SAR discussed in section 
4.1.2 where changes around the benzamide could be tolerated by the hmGluR5. 










B, Figure 4.5) showed butyne or azidobutoxy linkers at the meta or para position to the 
benzamide moiety could have sufficient length to access a ‘clickable’ fluorophore for an 
in situ click reaction near the extracellular surface. The clickable linkers butynyloxy or 
azidobutoxy are expected to undergo CuAAC click reactions with a fluorophore to give 
a 1,2,3-triazole product (concept described in section 1.6).  
 
4.1.3 Selection and introduction of covalent chemoreactive group 
In order to form a covalent bond with mGluR5, a reactive functional group was required 
in the ligand design. The use of a photoreactive group was avoided, because of what was 
previously reported by Gregory et al24 it in that it could demonstrate a high level of non-
specific interactions with the receptor upon UV irradiation.9 Upon close inspection of the 
amino acid residues around the allosteric site of mGluR5 (using the available mGluR5 
crystal structures), a tyrosine residue (Y792, Panel B, Figure 4.5) was identified and 
could be targeted using an electrophilic fluorosulfonylphenyl group. Due to the narrow 
fit of the internal alkyne structure in mGluR5 (discussed for Panel A in Figure 4.5), the 
introduction of a fluorosulfonylphenyl was avoided near the internal alkyne moiety. 
Similar to the placement of the clickable linker, the fluorosulfonyl group was substituted 
from the benzene moiety of ligand 4.12 because of the SAR studies described in section 
4.1.2. The fluorosulfonyl group was therefore placed in the meta or para to the benzamide 
















Table 4.2. Designed compounds to be synthesised in this chapter: a) clickable, with the 
covalent reactive group (4.27, 4.29, 4.30, 4.32 and 4.33), b) clickable, without the 
covalent reactive group (4.24 and 4.25), c) clickable, with the non-covalent reactive 
group (4.35), d) non-clickable, with the covalent reactive group (4.26, 4.28 and 4.31), e) 
non-clickable, with the non-covalent reactive group (4.34) and f) non-clickable, without 





4.1.4 Summary of ligand design 
The ligand design for the covalent clickable mGluR5 ligands incorporated an 
azido/alkyne clickable functional group for click reaction to a fluorophore and a 
chemoreactive fluorosulfonylphenyl group that is proposed to be capable of forming a 
covalent bond with a tyrosine (Y792) of mGluR5. Figure 4.7 shows a library of analogues 
to be synthesised in this chapter. Ligands 4.10 and 4.12 were reported literature 
compounds, serving as the positive controls for the library of mGluR5 ligands to be 
synthesised.20 Ligand 4.24 and 4.25 were designed as clickable ligands without the 
covalent reactive group where the influence of linker addition be investigated. 
Meanwhile, 4.26, 4.28 and 4.31 investigate the tolerance of ligand binding to mGluR5 
upon the addition of the chemoreactive fluorosulfonyl group at different position of the 
benzene ring of the literature compound. Ligands 4.27, 4.29, 4.30, 4.32 and 4.33 are 
bifunctional ligands designed with both clickable and chemoreactive 
fluorosulfonylphenyl group to assess the main goal of this chapter, to bind covalently 
with the mGluR5 and click with a fluorophore. Ligands 4.34 and 4.35 were designed as 
the sulfonic acid derivatives of 4.26 and 4.30, respectively, to investigate the covalent 
property of the bifunctional ligands. Overall, this comprehensive set of ligands could 
shed light on the suitability on the use of the fluorosulfonylphenyl chemoreactive group, 
the length of the linker used, and the optimal positions for the incorporation of the 





4.2 Synthesis of mGluR5 ligands  
4.2.1 Synthesis of core compound 
The synthesis of mGluR5 ligands began with the literature routes
22 to the assembly of 
core compound 4.44 (Scheme 4.1). The propynylpyridinyl 4.39 was prepared by the 
nucleophilic substitution of the anion of diethyl phosphite 4.38 on 3-bromo-1-
trimethylsilyl-1-propyne 4.37. The reaction proceeded efficiently and provided 4.39 with 
good purity without further purification. Compound 4.39 was then treated with the strong 
base LiHMDS to deprotonate the α-hydrogen to the phosphonate group. The resulting 
nucleophile attacked the electrophilic carbonyl carbon of the piperidone 4.36 and 





Scheme 4.1. Synthesis of core ligand 4.44. Reagents and conditions: i. LiHMDS, THF, -
10˚C, then 10˚C for 2 h; ii. LiHMDs, THF, -60˚C, 1 h, then rt, 2 h, ~100%; iii. K2CO3, 
MeOH, rt, 1 h, 90%; iv. Pd(PPh3)4, CuI, NEt3, DCM, rt, overnight, 80%; v. TFA, DCM, 






Figure 4.6. The mechanism for formation of 4.40.25 
   
The silyl group in 4.40 was initially deprotected using TBAF, via a pentavalent 
silicon intermediate, as reported in the literature.22, 26 However, the crude product was a 
viscous liquid that underwent difficult column chromatography purification due to 
overlapping side products. Alternatively, 4.40 was desilylated using potassium carbonate 
in methanol, which resulted in little side products, easy purification by column 
chromatography and a yield of 90%. In this deprotection strategy, a small amount of 
potassium methoxide forms from the acid-base reaction between potassium carbonate 
and methanol,27 which then facilitates deprotection via a pentavalent silicon intermediate 
similar to desilylation using TBAF. 
 Compound 4.41 underwent a Sonogashira coupling reaction with 2-bromo-6-
methylpyridine 4.42 using tetrakis(triohenylphosphine)palladium(0) (Pd(Ph3)4) and a 
catalytic amount of copper (I) iodide to give 4.43. However, following the reported 
Sonogashira coupling reaction conditions utilising neat triethylamine at 80˚C resulted in 
a messy crude product which was difficult to purify. The reaction conditions were later 
optimised by using 3 eq. triethylamine in DCM at rt, which gave a cleaner crude product 
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and a good yield of 80% after purification. Boc-protected 4.43 was deprotected by use of 
TFA in DCM to give 4.44 which was used without further purification.  
 
4.2.2  Assembly of ligands  
4.2.2.1 Ligands with non-clickable group and without covalent reactive group 
Compound 4.44 was coupled efficiently with benzoic acid 4.45 using HATU to give the 
literature ligand 4.10 in a high yield of 92% (Scheme 4.2, HATU-mediated amide 
coupling mechanism same as described in scheme 2.7). Compound 4.44 was coupled 
with 3-hydroxybenzoic acid 4.46 using the same reaction conditions to give 4.47. The 
monitoring process for the synthesis of 4.10 and 4.47 showed the same TLC observation, 
however, there was a considerable difference observed for yield between the two 
products. Compound 4.47 was subsequently underwent methylation using methyl iodide 




Scheme 4.2. The synthesis of 4.10 and 4.12. Reagents and conditions: i. HATU, DIPEA, 
DMF, rt, overnight, 63-92%; ii. methyl iodide, K2CO3, rt, 90%. 
 
  Both synthesised ligands 4.10 and 4.12 (isolated with silica flash column 
chromatography) were stored as a pure compound in the fridge and analysed using 
analytical HPLC approximately 1 month later (94.10% at 13.809 min in Figure 4.7A for 
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4.10, 99.04% at 13.809 min of Figure 4.8A for 4.12). Because of the very high purity 
requirements for biological testing, further purification was carried out by 
semipreparative HPLC.  The HPLC chromatograms of 4.10 and 4.12 during the HPLC 
semipreparative process are shown in Figure 4.7B and Figure 4.8B, respectively. The 
collected HPLC semipreparative fractions of both 4.10 and 4.12 as a solution in the 
HPLC solvent system as collected from the column were kept under -80˚C storage and 
were then concentrated by freeze drying approximately 3 months later. The purity of 
these freeze-dried compounds was analysed using analytical HPLC. Unexpectantly, both 
compounds had degraded, presumably while stored at -80˚C in the HPLC solvent system 
for 3 months (in a solution of HPLC solvent containing 0.05% TFA). Perhaps, the 
degradation could also be due to the acidic condition of the TFA present in the HPLC 
buffers. The purity of the ‘4.10’ and ‘4.12’ isolated using semipreparative HPLC were 
found to have degraded to a purity of 7.55% and 12.40% (at 12.860 min in Figure 4.7C 






Figure 4.7. HPLC chromatograms of 4.10 A) following isolation from ‘normal-phase’ 
silica flash column chromatography, B) during semi-preparative HPLC purification 
12.851 min (94.10%) A) 
B) 10.006 min 
C) 
12.860 min (7.55%) 
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process and C) ‘4.10’ analysed after isolation using semipreparative HPLC, storage at -






Figure 4.8. HPLC chromatograms of 4.12 A) following isolation from ‘normal-phase’ 
silica flash column chromatography, B) during semi-preparative HPLC purification 
process and C) ‘4.12’ analysed after isolation using semipreparative HPLC, storage at -
80˚C for 3 months and then freeze-drying.   
 
 Since 4.10 and 4.12 unexpectantly degraded during storage, the degraded samples 
were analysed using 1H NMR and 2D NMR experiments including HSQC (Appendix 8 
for 4.10, Appendix 9 for 4.12) and COSY (Appendix 10 for 4.10, Appendix 11 for 4.12) 
in an effort to understand what degradation has occurred.  
 The 1H NMR (Figure 4.11) and HPLC analysis (Figure 4.7A) for ‘4.10’ showed 
that the overall ‘4.10’ sample is likely a mixture of compounds. The HSQC spectra of 
the degraded sample of 4.10 (Appendix 8) indicated some likely -CH3s (or -CH) between 
chemical shifts 1.56-2.02 ppm and 3.38-3.59 ppm, while there were some potential CH2s 
at 2.52-3.35 ppm. However, the integration of these overlapping protons could not be 
quantified. The COSY spectra of the degraded 4.10 showed some proton-proton 
13.809 min (99.04%) A) 
B) 9.865 min 
C) 
13.982 min (12.40%) 
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correlations between minor peaks at the aromatic region (6.12-8.36 ppm). A clear 
structure elucidation couldn’t be achieved for the crude degraded sample. While the MS 
analysis of a freshly isolated 4.10 using flash column chromatography showed detection 
of M+1 [M+H]+ and M+23 [M+Na]+ (Figure 4.9), where M describes the mass of 4.10, 
the degraded 4.10 showed additional peaks including those equivalent to M+19, M+41, 
M+59, 2M+59 and 2M+77 (Figure 4.10). The degraded 4.10 still detected the minor 
presence of the desired product 4.10 (M+1 peak). However, potential structures of other 
degraded by-products in the mixture could not be deduced. 
 
 
Figure 4.9. Mass spectrum of the silica gel column chromatography isolated 4.10. 
 
 


















The 1H NMR spectrum (Figure 4.12) and HPLC analysis (Figure 4.8A) for ‘4.12’ 
also showed a mixture of compounds. The HSQC spectra of the degraded sample of 4.12 
showed the presence of a CH (or CH3) signal at 3.82 ppm (overlapped with other signals 
integrations) and CH signals between 6.12-8.37 ppm suggesting the presence of an 
aromatic moiety. In the COSY spectrum of the degraded 4.12, the dd signals at 6.22 and 
6.66 ppm indicated two protons in an ortho-position to each other with a coupling 
constant of 6.4 Hz. The m signals at 6.94 ppm and 7.03 ppm correlated with the t at 7.36 
ppm (in a whole number of integer ratios) which indicated that these three signals 
belonged to a different single aromatic entity. The t signals at 8.24 ppm coupled to both 
7.59 and 7.80 at the ortho-positions of another benzene moiety with coupling constant of 
8.0 Hz. Overall, the COSY experiment showed the presence of 3 aromatic spin systems 
which belonged to the same compound (based on whole number integration value). The 
chemical shift pattern for the 3-methoxybenzamide portion was still observed on 1H 
NMR spectrum, however, not the 1H NMR shift pattern for the methylpyridine ring. 
However, this information was insufficient to work out the entire structures of the 
compounds in the degraded sample. The MS analysis of a freshly isolated 4.12 using 
flash column chromatography showed detection of the M+1 [M+H]+ while the degraded 











 In an attempt to understand the degradation observed for 4.10 and 4.12 and 
because for biological testing newly made (and desired product) material was required, 
ligands 4.10 and 4.12 were re-synthesised. This time the crude product immediately 
following reaction work-up and before any column purification was analysed by 1H NMR 
spectroscopy (Appendix 12 for 4.10, Appendix 13 for 4.12). The crude of both repeated 
reactions showed major presence of 4.10 and 4.12. Purification by normal-phase silica 
gel flash column chromatography was carried out and the isolated 4.10 and 4.12 were 
analysed by 1H NMR spectroscopy (Figure 4.13 for 4.10, Figure 4.14 for 4.12). Both the 
1H NMR spectra of the freshly purified 4.10 and 4.12 showed good purity with expected 
signals. Analytical HPLC analysis was carried out on the freshly synthesised and normal 
phase column purified 4.10 and 4.12, and showed excellent purities (~100%) at similar 
retention times (Figure 4.15 for 4.10, Figure 4.16 for 4.12). It was therefore clear that the 
normal phase silica column chromatography isolation process did not contribute to any 



























Figure 4.16. The HPLC chromatogram of the column-isolated 4.12 (re-synthesised).
12.447 min (100%) 
13.212 min (100%) 
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Since the purity of the newly synthesised 4.10 and 4.12 following normal-phase 
column chromatography was high and suitable for biological testing, instead of HPLC 
purifying these samples the previous degradation of 4.10 and 4.12 was investigated by 
subjecting these freshly synthesised and purified (and confirmed as ‘pure’) 4.10 and 4.12 
to mimicking storage conditions for the previously synthesised (and then degraded) 4.10 
and 4.12. Due to time constraints regarding the submission of this PhD, compounds were 
stored for 3 weeks at various temperatures in the same HPLC solvent system as previous 
degradation occurred in (Table 4.3).  
 
Table 4.3. The storage conditions used to investigate the stability of 4.10 and 4.12. 
Samples Storage conditions 
 
4.10 and 4.12 
i. Stored in MeOH at rt 
ii. Stored in HPLC mobile phases (A:B 
1:1)a in a concentration of 1 mg/ mL at -
20˚C 
iii. Stored in HPLC mobile phases (A:B 
1:1) in a concentration of 1 mg/ mL at rt 
aThe mobile phases used were A: H2O (0.05% TFA) and B: 9:1 ACN/H2O (0.05% TFA). 
 
Each storage solution was analysed using analytical HPLC 2.5 weeks after the 
solution was prepared. Compounds 4.10 which was stored in MeOH at rt (storage 
condition i, table 4.3) remained one peak at a retention time of 12.475 min in high purity 
of 99.48% (Figure 4.17A). However, compound 4.10 showed a small amount of 
degradation (purity 91.62%) with storage conditions of -20˚C in HPLC mobile phase 
containing TFA (storage condition ii, table 4.3, Figure 4.17B). Condition iii, which 
involved storage of compound 4.10 at rt in HPLC mobile phases containing TFA, 
resulted in major degradation (Figure 4.17C). Here the assumed 4.10 was still present at 
12.699 min but only as 27.63% of the sample. The small peak at retention time of 9.246 
min in Figure 4.17B, however, disappeared while a new peak at 10.413 min was observed 









Figure 4.17. Analytical HPLC chromatograms of 4.10 analysed after 2.5 weeks being 
stored in A) MeOH at rt, B) HPLC mobile phases (A:B 1:1) at -20˚C, and C) HPLC 
mobile phases (A:B 1:1) at rt. The mobile phases were A: H2O (0.05% TFA) and B: 9:1 
ACN/H2O (0.05% TFA). 
   
Degradation was also observed when the ‘freshly synthesised’ 4.12 was subjected 
to the same test storage condition in table 4.3. Stored compound 4.12 in MeOH at rt 
showed one peak at 13.005 min in high purity of 99.22% (storage condition i, table 4.3, 
Figure 4.18A). In storage condition ii (in HPLC mobile phases containing TFA at -20˚C, 
table 4.3), a small peak was observed at retention time 11.101 min that amounted for 
2.52% of the sample while the peak at 13.000 min of 4.12 degraded to a HPLC purity of 
96.92% (Figure 4.18B). In storage conditions iii (in HPLC mobile phases containing TFA 
at rt, Table 4.3), a peak at 11.041 min accounted for 32.81% of the sample and a peak at 
13.150 min accounted for 66.69% of the sample. The HPLC peaks that emerged at 
retention times of 11.101 min (Figure 4.18B) and 11.041 min (Figure 4.18C) were 




99.48%, 12.475 min 
91.93%, 12.367 min 
27.63%, 12.699 min 
7.76%, 9.246 min 
69.72%, 10.413 min 
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retention time 13.005, 13.000 and 13.150 appeared to be compound 4.12 because it 
matches the analytical HPLC retention times of 4.12 that was analysed on HPLC before 






Figure 4.18. HPLC chromatograms of 4.12 analysed after 2.5 weeks being stored in A) 
MeOH at rt, B) HPLC mobile phases (A:B 1:1) at -20˚C, and C) HPLC mobile phases 
(A:B 1:1) at rt. The mobile phases used were A: H2O (0.05% TFA) and B: 9:1 ACN/H2O 
(0.05% TFA). 
 
The HPLC analysis of compound 4.10 and 4.12 which have been stored for 2.5 
weeks in storage condition shown in table 4.3 showed that both compounds can remain 
stable in a solution of methanol without TFA at rt. The gradual degradation of compounds 
4.10 and 4.12 were suggested to occur due to the TFA-catalysed (found in the HPLC 
mobile phases) hydration reaction (proposed mechanism is described in Figure 4.19). 
The degradation analysed on HPLC (Figure 4.8C) showed that there was more than one 
99.22%, 13.005 min 
96.92%, 13.000 min 
66.69%, 13.150 min 
2.52%, 11.101 min 






degraded compound in the mixture, which could correspond to the potential hydration on 
both the alkene and alkyne part of 4.10 and 4.12.  
Since final compounds 4.10 and 4.12 can be synthesised in excellent purity 
(Figure 4.15 and 4.16), either a purification only via silica gel column chromatography 
(to a purity level acceptable for testing) or a timely evaporation following HPLC 
semipreparative isolation is predicted to prevent compounds 4.10 and 4.12 undergoing 
degradation.  
 
Figure 4.19. Proposed TFA-catalysed hydration of final compound 4.12. 
 
4.2.2.2 Ligands with clickable group but not the covalent reactive group 
The successful methylation of 4.47 to give 4.12 was followed with the effort to alkylate 
4.47 with a longer alkyl chain. The longer alkyl chains (azidobutyl or butyne) included 
the clickable linkers to make clickable analogues of 4.10. 
 The alkylation of phenol 4.47 with 1.1 eq. of 4-bromo-1-butyne 4.47i was 
attempted (Scheme 4.4), however product 4.24 was not detected and the starting material 
4.47 remained unreacted. Several different reaction conditions were trialled including 
heating to 60˚C, using up to 5 eq. of K2CO3, running the reaction for up to 3 days and the 
use of sodium hydride instead of K2CO3 as a stronger base. The reaction was monitored 
236 
 
by TLC and a faint more non-polar spot was observed on TLC which was suspected to 





Scheme 4.4. The attempted alkylation of 4.47 with 4-bromo-1-butyne 4.47i. Reagents 
and conditions: i. various conditions and attempts - 1.1-5 eq. of 4-bromo-1-butyne 4.47i, 
K2CO3, DMF, rt (up to 60˚C), overnight (to up to 3 days). 
 
 Alternatively, the alkylation of phenol 4.47 with 4-bromo-1-butyne 4.47i was 
carried out prior to amide coupling reaction with 4.44. Compound 4.46 underwent 
esterification in excess MeOH at reflux to give 4.48 in good yield and purity without 
silica gel flash column chromatography. Alkylation of methyl 3-hydroxybenzoate 4.48 
with 4-bromo-1-butyne 4.47i was carried out multiple times on under various reaction 
conditions (Scheme 4.5, Table 4.2) Unfortunately, the alkylation was still unsuccessful 




Scheme 4.5. The attempted alkylation of 4.48 with 4-bromo-1-butyne 4.47i. Reagents 
and conditions: i. H2SO4, MeOH, reflux, ~100%; ii. reaction conditions and outcomes 





Table 4.4. Reaction conditions trialled for the alkylation of 4.48. 
No. Reaction conditions Observations 
1 1.5-5 eq. of K2CO3, 1.5-5 eq. of 4-
bromo-1-butyne 4.47i, DMF or 
acetone, rt 
Quantitative amount of starting 
material 4.48 was recovered, product 
4.49 was not observed.   
2 1.3 eq. of Cs2CO3, 1.3 eq. 4-bromo-1-
butyne 4.47i, DMF, rt or 90˚C 
Quantitative amount of starting 
material 4.48 was recovered, product 
4.49 was not observed. 
3 1.2 eq. of NaH (60%), 1.3 eq. 4-
bromo-1-butyne 4.47i, THF,  
A prominent spot on baseline of TLC 
on the baseline was observed and it 
could be the hydrolysed product of 
methyl ester 4.48. Product 4.49 was 
not observed. 
 
 To investigate if the failed alkylation was due to the 4-bromo-1-butyne 4.47i 
specifically rather than some fault with the alkylation reaction in general a ‘model 
system’ of alkylation on phenol 4.51 was carried out using propargyl bromide (Scheme 
4.6). Compound 4.50 underwent esterification in excess MeOH at reflux to give 4.51 in 
good yield and purity without silica gel flash column chromatography. The alkylation of 
4.51 using propargyl bromide took place smoothly to give 4.52 in 90% yield. However, 
it was unknown to why the alkylation with 4-bromo-1-butyne 4.47i was unsuccessful. 
The efficient alkylation involving propargyl bromide could be due to the higher 
electrophilicity induced by the electron withdrawing group of the terminal alkyne on the 
carbon adjacent to bromine. The presence of bromine atom para to the hydroxy group of 










Scheme 4.6. The synthesis of 4.52 as a model system for alkylation. Reagents and 
conditions: i. H2SO4, MeOH, reflux, 8 h, 91%; ii. propargyl bromide, K2CO3, DMF, rt, 
overnight, 90%.  
 
 Moving forward, a different phenol alkylation strategy was devised to install the 
butyne substituent. 4-Buty-1-ol 4.53 was reacted with trifluoromethanoic anhydride 4.54 
to give 4.55 that was used without silica gel flash column purification (Scheme 4.7). 
Alkylation of phenol 4.48 was carried out with triflate 4.55, which successfully gave the 
alkylated product 4.49 in 54% yield. The methyl ester of 4.49 was hydrolysed using 1 M 
NaOH (in MeOH) to give benzoic acid 4.56. Subsequently, the amide coupling of 4.56 
and core compound 4.44 gave product 4.24 following silica gel column chromatography 
isolation in a mass of 48 mg. 
    
 
Scheme 4.7. The synthesis of 4.24. Reagents and conditions: i. trifluoromethanoic 
anhydride 4.54, pyridine, DCM, 0˚C, 1 h, ~100%; ii. K2CO3, DMF, rt, overnight, 54%; 
iii. 1 M NaOH (in MeOH), rt, 1 h, 67%; iv. HATU, DIPEA, DMF, rt, overnight, 90%. 
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 The normal phase column purified 4.24 was subjected to analytical HPLC 
analysis to check purity as per standard biological testing requirements. Unexpectantly, 
the analytical HPLC showed desired compound 4.24 was present as 77.43% of the 
sample and there were several minor peaks present. (Appendix 14). Following that and 
in order to meet the very high purity requirements for biological testing, 4.24 was further 
purified using semipreparative HPLC and the HPLC chromatogram during the isolation 
process is shown in Appendix 15. The collected fractions from the semi-prep HPLC 
experiment were stored at -80˚C for 3 months (in a solution of HPLC solvent containing 
0.05% TFA), in a similar storage fashion to that as 4.10 and 4.12 when first synthesised. 
3 months later when the semi-prep fractions were freeze dried and the product then 
analysed - degradation of ligand 4.24 was observed (Appendix 16) (as these reactions 
were carried out at the same time and followed the same storage time as the first synthesis 
of 4.10 and 4.12). Due to thesis submission time constraints, investigations into what 
4.24 degraded into were not carried out. However, the 1H NMR spectrum of the degraded 
4.24 is highly similar to the 1H NMR spectrum of the degraded 4.12 which indicated 
similar degradation products (Appendix 17). Also due to thesis submission time 
constraints, ligand 4.24 was not re-synthesised. It is likely that if 4.24 was to be re-
synthesised, careful storage and timely evaporation of HPLC buffers (if compound is 
being purify using semipreparative HPLC) can be carried out to prevent degradation. 
The synthesis of target test ligand 4.25 was designed using an analogous strategy 
as described for the optimised synthesis of 4.24, thus the triflate ‘linker’ was required. 4-
Chloro-1-butanol 4.57 underwent nucleophilic substitution by an azide ion (generated 
from sodium azide) to give 4-azido-1-butanol 4.58 which was isolated in 82% yield 
(Scheme 4.8). Subsequently, alcohol 4.58 was treated with trifluoromethanoic anhydride 
4.54. Upon reaction work-up, the 1H NMR spectrum of the crude indicated several major 
compounds present in the crude mass. Silica gel column chromatography purification of 
the crude mass was not carried out to prevent potential degradation if triflate 4.59 was 






Scheme 4.8. The attempted synthesis of 4.59. Reagents and conditions: i. NaN3, DMF, 
80˚C, overnight, 82%; ii. trifluoromethanoic anhydride 4.54, pyridine, DCM, 0˚C, 1 h.  
 
 Alternatively, 4.58 was treated with 4-toluenesulfonyl chloride 4.60 (Scheme 4.9, 
reaction mechanism same as described in scheme 3.2) to generate tosylate 4.61 which 
was isolated in 35% yield. Subsequently, the alkylation of 4.62 with tosylate 4.61 was 
carried out to give the azide-containing benzoate 4.63 in 98% yield. Unlike the 
unsuccessful alkylation of 4.48 with 4-bromo-1-butyne 4.47i, the alkylation of 4.62 with 
4.61 was efficient. The methyl ester para to the hydroxy group of 4.62 is able to stabilise 
the phenoxide through delocalisation, however, did not prevent the completion of the 
reaction. The basic hydrolysis of the methyl ester of 4.63 with 1 M NaOH solution gave 
4.64. The amide coupling between 4.64 and 4.44 successfully gave 4.25, which was 










Scheme 4.9. The synthesis of 4.25. Reagents and conditions: i. 4-toluenesulfonyl 
chloride, NEt3, DMAP, DCM, rt, overnight, 35%; ii. K2CO3, DMF, rt, overnight, 98%; 
iii. 1 M NaOH (in MeOH), rt, 1 h, 63%; iv. HATU, DIPEA, DMF, rt, overnight, 54%. 
 
Compound 4.25 was then subjected to analytical HPLC analysis (Figure 4.20A). 
Following that and in order to meet the very high purity requirements for biological 
testing, 4.25 was further purified using semipreparative HPLC and the HPLC 
chromatogram during the isolation process is shown in Figure 4.20B. The fractions 
collected from the semi-prep HPLC experiment were stored at the same time and under 
the same conditions as for the HPLC fractions for 4.10, 4.12 and 4.24 (-80˚C for 3 
months, in a solution of HPLC solvent containing 0.05% TFA). Three months later, the 
stored fractions of 4.25 was freeze dried and the product was analysed with analytical 
HPLC (Figure 4.20C). This analytical HPLC procedure was carried out on a different 
HPLC and a different method was utilised.  Unexpectedly, more than one major peak 
was observed, and it was suggested that 4.25 might have underwent partial degradation. 
LCMS analysis was carried out to identify the mass of the peaks at retention time of 
21.752 min and 24.761 min and respective masses of M+1 and M+19, where M describes 
the mass of 4.25, were found (Figure 4.20C). The M+1 [M+H] peak at 21.752 min was 
confirmed to be the remaining product 4.25 and matched with the retention time at 17.158 










Figure 4.20. HPLC chromatograms of 4.25 A) following isolation from ‘normal-phase’ 
silica flash column chromatography, B) HPLC semi-prep chromatogram C) analytical 
HPLC chromatogram of pooled semi prep HPLC fractions of ‘4.25’ after storage at -
80˚C for 3 months in the HPLC fraction solution and then freeze-drying. Analytical 
HPLC methods used for Panel A and C were different. Analytical HPLC method for 
Panel A - 5% B for 1 min, linear gradient from 5-95% B from 1-27 min (followed by 1 
min hold at 95% B, then 2 min linear gradient from 95-5% B and 4 min re-equilibration 
at 5% B). Analytical HPLC method for Panel C - 5% B for 1 min, linear gradient from 
5-95% B from 1-33 min (followed by 7 min hold at 95% B, then 3 min linear gradient 
from 95-5% B and 7 min re-equilibration at 5% B).  
 
To investigate if the peak at retention time 24.761 (Figure 4.20, C) was a non-
covalent adduct of the same compound 4.25, an analytical HPLC analysis with variable 
temperatures were carried out to see if the peak ratio of the suggested masses [M+1]+ and 







[M+19]+, where M describes the mass of 4.25, altered with temperature. However, the 
analytical HPLC analysis at 15˚C and 40˚C (Appendix 18) did not change the ratio of the 
two peaks at retention times 21.752 min and 24.761 min.  
1H NMR spectroscopy was carried out to compare the 1H NMR spectra of 4.25 
before (Figure 4.21) and after semipreparative HPLC isolation (where the collected 
HPLC fractions was stored in -80˚C for 3 months, in a solution of HPLC solvent 
containing 0.05% TFA and then freeze-drying) (Figure 4.22). Surprisingly, the 1H NMR 
spectrum of the 4.25 after semipreparative and freeze-drying processes showed excellent 
purity with no traces of degradation. Therefore, the mass of [M+19]+, where M describes 
the mass of 4.25, shown on LCMS was suggested to be the non-covalent adduct 
[M+NH4]
+ of 4.25. 
Due to thesis submission time constraints, ligand 4.25 was not re-synthesised. As 
future work, it is expected that successful synthesis and purification of 4.25 could be 
achieved with careful storage and immediate evaporation of HPLC buffers (if compound 





















Figure 4.22. The 1H NMR spectrum of 4.25 after semipreparative HPLC isolation (where the collected HPLC fractions was stored in -80˚C for 3 





4.2.2.3 Ligands with non-clickable and covalent reactive group 
With the synthetic route to ligands 4.10, 4.12, 4.24 and 4.25 established (albeit it with a 
final product degradation issue due to storage conditions), ligands containing the 
clickable and covalent reactive groups were then synthesised. The synthesis of the 
chemoreactive fluorosulfonylphenyl group was carried out by applying a reported 
literature procedure.28 The first step (ii, Scheme 4.10) requires a bromo starting material, 
the charge-transfer complex 1,4-diazabicyclo[2.2.2]octane bis(sulfur dioxide) adduct 
(DABSO), NEt3 and PdCl2(amphos) in IPA while the subsequent step (iii, Scheme 4.10) 
involves the addition of electrophilic fluorinating agent N-fluorobenzenesulfonimide 
(NFSI). The synthesis of the fluorosulfonylphenyl functional group from a halogenated 
starting material was first trialled in model system, before using ‘ligand’ starting material. 
Compound 4.65 was first methylated using methyl iodide and K2CO3 in DMF to give 
4.66 which was isolated in 93% yield. Both bromo 4.66 and iodo 4.69 were treated with 
the DABSO, NEt3, PdCl2(amphos) in IPA and treated with NFSI. The trialled reaction 
initially did not give 4.67 and 4.69. However, it was found that degassing IPA and NEt3 
with nitrogen was crucial and the reaction successfully gave 4.67 and 4.69 in 34% and 
25% yield. Apart from the desired product observed on TLC, there was another spot seen 
on the baseline of TLC which was suspected to be the carboxylic acid or sulfonic acid 
by-products derived from the starting or desired product. The baseline spot on TLC, 
however, was not isolated. Longer reaction time did not result in higher yield. The 










Scheme 4.10. Model system for the synthesis of fluorosulfonylphenyl derivatives. 
Reagents and conditions: i. methyl iodide, K2CO3, DMF, rt, overnight, 93%; ii. DABSO, 
NEt3, 5% PdCl2(amphos), IPA, 75˚C, 24 h; iii. NFSI, rt, 3 h, 25-34% (yield over 2 steps). 
 
The mechanism for the formation of the fluorosulfonylphenyl group has been 
proposed by Bajohr et al. (Figure 4.23).29 The inactive Pd(II)Cl2(Amphos)2 is first 
reduced to the active Pd(0)(Amphos)2 by IPA. The Pd(0) catalyst then undergoes 
oxidative addition with an aryl bromide. The SO2 generated from DABSO undergoes 
insertion into the intermediate and followed by the reduction elimination by  isopropyl 
alcohol to produce ammonium sulfinate and ammonium bromide. The ammonium 






Figure 4.23. Proposed general mechanism for the conversion of aryl bromide to 
fluorosulfonylphenyl compounds via the generation of ammonium sulfinate.   
 
 Since the introduction of the fluorosulfonyl group worked in the model reactions, 
the synthesis was carried out in the reactions for the desired ligands. The introduction of 
the fluorosulfonyl group was initially designed as the final step of the multistep synthesis 
to minimise the chance of undesired changes to the fluorosulfonyl group including 
hydrolysis. Compound 4.70 was prepared accordingly via an amide coupling between 
4.75 and 4.44. The unprotected hydroxy group in 4.75 was unaffected during the amide 
coupling process. Subsequently, the methylation of 4.70 gave 4.71 which was isolated in 
46% yield. Bromo 4.71 was subjected to the same reaction conditions to synthesise the 
fluorosulfonyl functional group as used in the model system (Scheme 4.10). However, 
changes were not observed by TLC on the first step of the reaction (ii, scheme 4.10) and 
close to quantitative amount of starting material 4.71 was recovered upon silica gel flash 
column chromatography purification of the crude reaction mixture following work-up. 
The reaction was repeated and left to react for 3 days but again the starting material 4.71 
remained unreacted. Higher amount of PdCl2(Amphos)2 (15% mol) was used but did not 
affect reaction outcome. Increasing the mol equivalent of PdCl2(Amphos)2 was not 
considered as a sustainable option as with all the analogues this would use a large amount 
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of the expensive catalyst. Additionally, activated molecular sieves were used to remove 
traces of moisture in NEt3 and IPA, however, did not improve the reaction. It was 
suggested that the unsuccessful synthesis fluorosulfonyl group in 4.71 to 4.28 could be 
due to the steric hindrance that the adjacent methoxy group to the bromo group or the 
synthesis potentially suffered from the interaction between the PdCl2(Amphos)2 and the 




Scheme 4.11. Attempted synthesis of fluorosulfonylphenyl derivative 4.28. Reagents and 
conditions: i. HATU, DIPEA, DMF, rt, overnight, 40%; ii. methyl iodide, K2CO3, rt, 
50%; iii. DABSO, NEt3, 5% PdCl2(amphos), IPA, 75˚C, 24 h; iv. NFSI, rt, 3 h – 3 days. 
  
Since the attempted conversion of bromo 4.71 to fluorosulfonyl 4.28 failed, an 
alternative synthetic procedure where a bromo starting material with less steric hindrance 
and without an alkyne group was utilised (4.72, Scheme 4.12). Therefore, the 
fluorosulfonyl group was designed to be introduced earlier in the multistep synthesis 
before coupling with the core ligand 4.44 to give the final ligands. Compound 4.72 was 
treated with the same reagents as the introduction of fluorosulfonyl group in the model 
reaction in scheme 4.10 (Scheme 4.12) to give 4.73 in 22% yield which was similar to 
the yield observed in the model reaction. The characteristic 19F NMR spectra chemical 
shift, along with the 1H NMR and 13C NMR spectra confirmed the structure of 4.73, 
however HRMS (ESI) analysis of 4.73 did not show the presence of the desired parent 
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ion (most likely because the low molecular weight compound was sub-optimal for the 
HRMS set-up).  
  
 
Scheme 4.12. i. DABSO, NEt3, 5% PdCl2(amphos), IPA, 75˚C, 24 h; iv. NFSI, rt, 3 h, 
22%. 
 
4.2.2.4 Ligands with clickable and covalent reactive group 
Since the NMR spectra of 4.73 were in agreement to the desired sulfonyl fluoride 
product, further analogues were synthesised (Scheme 4.13). Bromohydroxybenzoic acids 
4.50, 4.74 and 4.75 were esterified in excess MeOH to give bromohydroxy benzoate 4.51, 
4.66 and 4.76 in good yields between 82-98% without silica gel column chromatography 
purification. The hydroxy group of 4.51, 4.66 and 4.76 were either methylated or 
alkylated with a clickable linker (azidobutyl or butyne) using K2CO3 in DMF to give 
4.66, 4.77-4.83 which were isolated in yields between 61-99%. Subsequently, the 
installation of the fluorosulfonyl groups from bromo 4.66, 4.77-4.83 was carried out. 
Surprisingly, only bromomethoxybenzoate 4.66, 4.77 and 4.81 showed successful 
transformations to fluorosulfonyl derivatives 4.73, 4.84 and 4.85. The conversion of all 
the azide or alkyne containing compounds (4.78, 4.79, 4.80, 4.82 and 4.83) to a sulfonyl 
fluoride were unsuccessful and the starting material was recovered. One explanation for 
this is that the palladium catalyst (PdCl2(Amphos)2) was interacting with both azide and 







Scheme 4.13. The synthesis of fluorosulfonylphenyl derivatives 4.73, 4.84, 4.85 and 
attempted synthesis of 4.86, 4.87, 4.88, 4.89, 4.90. Reagents and conditions: i. H2SO4, 
MeOH, reflux, 8 h, 82-98%; ii. methyl iodide or 4.55 or 4.61, K2CO3, DMF, rt, overnight, 
61-99%; iii. DABSO, NEt3, 5% PdCl2(amphos), IPA, 75˚C, 24 h; iv. NFSI, rt, 3 h, 22-
42%. 
 
To circumvent the potential problematic interaction between the azide and alkyne 
groups with palladium catalyst observed in the attempted synthesis of fluorosulfonyl 
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4.86, 4.87, 4.88, 4.89 and 4.90 an alternative route to the synthesis of fluorosulfonyl 
containing compounds was designed. The synthesis of fluorosulfonyl group was 
designed to be carried out before the alkylation of the phenol with a clickable (azide or 
alkyne containing) linker (Scheme 4.14).  
The hydroxy group of 4.76 could not be methylated since it was the future site of 
clickable linker 4.55, therefore a protecting group was required. Phenol 4.76 was 
protected with a tert-butyldimethylsilyl (TBDMS) group using tert-butyldimethylsilyl 
chloride (TBDMSCl) and imidazole in DCM to give 4.91 in 95% yield. The synthesis of 
4.92 containing a fluorosulfonyl group was then attempted but was unsuccessful. This 
could be due to the steric hindrance of TBDMS which prevented the interaction of the 
aryl-bromide with the PdCl2(Amphos)2 catalyst. Due to time constraint for the 
submission of the PhD thesis, the synthesis of fluorosulfonyl analogues containing the 
clickable handles 4.27, 4.29, 4.30, 4.32, 4.34 and 4.35 (Table 4.2) was therefore not 







Scheme 4.14. Alternative synthetic route for the synthesis of fluorosulfonylphenyl 
derivatives where the addition of linker takes place after the synthesis of the 
fluorosulfonyl group. Reagent and conditions: i. imidazole, TBDMSCl, DCM, rt, 24 h, 
95%; ii. DABSO, NEt3, 5% PdCl2(amphos), IPA, 75˚C, 24 h; iii. NFSI, rt, 3 h; iv. K2CO3, 
MeOH, rt; v. 4.55, K2CO3, DMF, rt; vi. 1 M NaOH (in MeOH), rt; vii. HATU, DIPEA, 
DMF, rt. 
 
4.2.2.5 Coupling of fluorosulfonylbenzoic acid 4.87, 4.88 and 4.89 with core ligand 
4.44  
Despite the unsuccessful synthesis of fluorosulfonyl analogues containing the clickable 
handles 4.27, 4.29, 4.30, 4.32, 4.34 and 4.35 (Table 4.2), the fluorosulfonyl analogues 
4.26, 4.28 and 4.31 were pursued.  
The hydrolysis of the methyl benzoate of 4.73, 4.84 and 4.85 was carried out 
using trimethyltin hydroxide in DCE at 80˚C to give 4.93, 4.94 and 4.95 which were 
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isolated in quantitative yield (Scheme 4.15). The mild hydrolysis using trimethyltin 
hydroxide on benzoate 4.73, 4.84 and 4.85 was to prevent the hydrolysis of the 
fluorosulfonyl group.32 Coupling of the benzoic acids 4.93, 4.94 and 4.95 to core ligand 
4.44 was then attempted to synthesise 4.26, 4.28 and 4.31. The silica gel column 
chromatography isolated product showed the presence of what looked like the desired 
signals in the 1H NMR spectrum. However, the expected and distinctive 19F chemical 
shift was not observed in the 19F NMR spectrum, indicating the absence of the 
fluorosulfonyl group. HRMS (ESI) analysis was then carried out and the detection of 
masses of [M+83] and [M+105], where M describes the mass of 4.26, 4.28 and 4.31, 
were found. However, a common ionised mass correlating to the structure could not be 
identified. Additionally, the negative mode in HRMS did not indicate a sulfonic acid – 
the hydrolysed version of the fluorosulfonyl of 4.26, 4.28 or 4.31. The structure of the 








Scheme 4.15. The attempted synthesis of a fluorosulfonylphenyl derivatives by coupling 
with 4.44. Reagents and conditions: i. trimethyltin hydroxide, DCE, 80˚C, overnight, 
~100%; ii. HATU, DIPEA, DMF, rt, overnight. 
 
The effort in introducing the fluorosulfonyl group from a bromo starting material 
using DABSO, NEt3, PdCl2(Amphos)2 in IPA has been carried out and found to be 
challenging for alkyne/azide-based compounds in this chapter. As a future work, a 
different synthetic procedure on the synthesis of fluorosulfonyl group should be 
attempted, for instance, a one-pot chemical conversion from an aryl amine to a sulfonyl 





Scheme 4.16. Proposed synthesis of fluorosulfonyl group. Reaction conditions: i. Boc-
anhydride, dioxane/H2O, rt; ii. Bromo-alkylating agent, K2CO3, DMF, rt, 16 h; iii. 1 M 
NaOH/ MeOH, rt; iv. HATU, DIPEA, DMF, rt, 16 h; v. TFA/DCM, rt, vi. HBF4 (aq. 
48%), t-BuONO, EtOH, 0 oC - rt, 1 h; vii. Na2S2O5, Selectfluor, MeOH, 70 
oC, 9 h.
  
4.3 Summary, conclusions and future directions. 
This chapter aimed to develop high affinity clickable mGluR5 ligands. A thorough 
literature review of mGluR5 ligands resulted in the identification of an alkyne-based 
NAM 4.10 and 4.12 as the lead compounds that were used as inspiration to develop 
covalent, clickable mGluR5 ligands. A library of ligands was designed, including a) 
clickable, with the covalent reactive group, b) clickable, without the covalent reactive 
group, c) clickable, with the non-covalent reactive group, d) non-clickable, with the 
covalent reactive group, e) non-clickable, with the non-covalent reactive group and f) 
non-clickable, without the covalent reactive group. 
   Out of the 14 ligands in the designed library of mGluR5 ligands (Table 4.2), 
literature compounds 4.10 and 4.12 and clickable analogues 4.24 and 4.25 (without the 
sulfonyl fluoride group) were successfully synthesised and isolated in pure form. 
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Compounds 4.10, 4.12, 4.24 and 4.25 were fully characterised and can be sent to Monash 
University for pharmacological evaluation by collaborators.  
The synthesis of fluorosulfonyl group has been attempted in this chapter, 
however, only successful in the synthesis of model compounds 4.67, 4.69 and benzoate 
4.73, 4.84 and 4.85. It is suggested that the Pd catalyst (in PdCl2(Amphos)2) might 
interact with the alkyne and/or azide group found in the clickable linker or core ligand 
4.44. As a future work, a different synthetic procedure for the introduction of 
fluorosulfonyl group should be employed to prepare analogues 4.26-4.35, avoiding the 





























4.4.1 Methods and material (Chemistry) 
The general methods and materials are as described in section 2.6.1. 
 
4.4.2 Experimental procedure and data for compounds as described in chapter 4 
Compounds 4.39, 4.40 and 4.44 were synthesised according to the literature.22 
 




To a solution of 1 M lithium bis(trimethylsilyl)amide (LiHMDS) (3.9 mL, 3.9 mmol) in 
THF (10 mL) stirred at -10 ˚C under nitrogen atmosphere, diethyl phosphite 4.38 (0.5 
mL, 3.9 mmol) was added dropwise. The reaction mixture was stirred for 20 min before 
the dropwise addition of 3-bromo-1-trimethylsilyly-1-propyne 4.37 (0.63 mL, 3.9 mmol) 
and reaction mixture was stirred at 10 ˚C for 2 h. The reaction mixture was quenched 
with water and extracted 3 times with ethyl acetate (3 x 50 mL). The pooled organic layer 
was washed with brine (30 mL), dried with MgSO4, filtered and concentrated in vacuo 
to give 4.39 (0.94 g, 3.8 mmol, 97 %) as a white solid. 1H NMR (400 MHz, CDCl3): 𝛿 
0.12 (m, 9H), 1.32 (t, J = 7.2 Hz, 6H), 2.74 (m, 1H), 2.80 (m, 1H), 4.16 (m, 4H). 13C 
NMR (400 MHz, CDCl3): 𝛿 -0.01 (3 equivalent carbons), 2.0, 16.5 (d), 18.7, 20.1, 63.1 
(d), 88.0 (d), 95.8 (d). HRMS (ESI) calculated for C10H22O3PSi
+ [M+H]+ 249.1070, 
C10H21NaO3PSi
+ [M+Na]+ 271.0890 and C20H42Na2O6P2Si2
+ [2M+Na]+ 519.1887; found 
m/z 249.1062, 271.0884 and 519.1876. The experimental data is in agreement with the 














To a solution of 4.39 (0.97 g, 3.9 mmol) in THF (12 mL) stirred at -60 ˚C under nitrogen 
atmosphere, LiHMDS (in THF/ethylbenzene) (3.9 mL, 3.9 mmol) was added dropwise 
and the resulting mixture was stirred for 1 h. A solution of tert-butyl-4-oxopiperidine-1-
carboxylate 4.36 (in 4 mL of dry THF) (0.78 g, 3.9 mmol) was added dropwise and the 
mixture was stirred for 20 min. The reaction was allowed to warm to rt for 2 h and the 
reaction mixture was quenched with water and the mixture was extracted 3 times with 
ethyl acetate (3 x 50 mL). The pooled organic layer was washed with brine(30 mL), dried 
with MgSO4, filtered and concentrated in-vacuo. The residue was purified using flash 
column chromatography on silica gel with n-hexane/ ethyl acetate (9:1) to give 4.40 (0.67 
g, 2.3 mmol, 59 %) as white crystals. 1H NMR (400 MHz, CDCl3): 𝛿 0.19 (s, 9H), 1.47 
(s, 9H), 2.22 (t, J = 6.4 Hz, 2H), 2.48 (t, J = 6.6 Hz, 2H), 3.43 (m, 4H), 5.37 (s, 1H). 13C 
NMR (400 MHz, CDCl3): 𝛿 0.2 (3 equivalent carbons), 28.6 (3 equivalent carbons), 31.3, 
35.0, 79.9 (2 equivalent carbons), 97.6, 102.2, 104.4 (2 equivalent carbons), 152.3, 154.8. 
HRMS (ESI) calculated for C16H27NNaO2Si
+ [M+Na]+ 316.1703; found m/z 316.1698. 
The experimental data is in agreement with the literature reported compound.22 
 




To a solution of 4.40 (0.35 g, 1.2 mmol) in MeOH (5 mL), K2CO3 (165 mg, 1.2 mmol) 
was added and the reaction mixture was stirred for 1 h. The reaction mixture was 
concentrated in vacuo. The residue was purified using flash column chromatography on 
silica gel with n-hexane/ ethyl acetate (9.5:0.5) to give 4.41 (0.24 g, 1.1 mmol, 90 %) as 
a pale-yellow liquid. 1H NMR (400 MHz, CDCl3): 𝛿 1.46 (s, 9H), 2.23 (t, J = 5.8 Hz, 
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2H), 2.49 (t, J = 6.0 Hz, 2H), 3.00 (d, J = 2.4 Hz, 1 H), 3.44 (m, 4H), 5.32 (s, 1H). 13C 
NMR (400 MHz, CDCl3): 𝛿 28.6 (3 equivalent carbons), 31.2, 35.0, 80.0, 80.3 (2 
equivalent carbons), 80.6, 95.9, 103.2 (2 equivalent carbons), 152.9, 154.8.  HRMS (ESI) 
calculated for C13H19NNaO2







Compound 4.41 (0.43 g, 1.5 mmol), 2-bromo-6-methylpyridine 4.42 (0.28 g, 1.6 mmol), 
tetrakis(triphenylphosphine)palladium(0) (0.12 g, 0.10 mmol) and copper (I) iodide (28 
mg, 0.15 mmol) were added into a two-necked round bottom flask equipped with a 
condenser. The round bottom flask was evacuated and back-filled with nitrogen gas (3 
times). DCM (5 mL) and NEt3 (anhydrous and degassed) (0.62 mL, 4.5 mmol), were 
respectively added and the reaction mixture was stirred for 2 h. The reaction mixture was 
concentrated and ethyl acetate was added. The mixture was filtered under celite and the 
filtrate was washed with water (2 times). The organic layer was dried with MgSO4, 
filtered and concentrated in vacuo. The residue was purified using flash column 
chromatography on silica gel with n-hexane/ ethyl acetate (7:3) to give 4.43 (0.28 g, 0.89 
mmol, 62 %) as white crystals. 1H NMR (400 MHz, CDCl3): 𝛿 1.47 (s, 9H), 2.29 (t, J = 
6.0 Hz, 2H), 2.57 (s, 3H), 2.59 (t, J = 6.0 Hz, 2H), 3.47 (m, 4H), 5.57 (s, 1H), 7.08 (d, J 
= 7.6 Hz, 1H), 7.24 (d, J = 7.6 Hz, 1H), 7.55 (t, J = 7.6 Hz, 1H). 13C NMR (400 MHz, 
CDCl3): 𝛿 24.6, 28.5 (3 equivalent carbons), 31.6, 35.1, 79.9 (2 equivalent carbons), 
103.8 (2 equivalent carbons), 122.4, 124.1, 128.7, 132.1, 136.5, 142.9, 153.0, 154.7, 
158.9. . HRMS (ESI) calculated for C19H25N2O2
+ [M+H]+ 313.1911 and C19H24N2NaO2
+ 












To a solution of 4.43 (1.1 g, 3.7 mmol) in CHCl3 (60 mL), TFA (4 mL) was added and 
the reaction mixture was refluxed for 15 min. The reaction mixture was cooled to rt and 
water was added. The mixture was basified to pH 12 with 2 M NaOH. The aq. phase was 
extracted 2 times with DCM (50 mL). The pooled organic layer was washed with brine 
(50 mL), dried with MgSO4, filtered and concentrated in-vacuo to give 4.44 (quantitative) 
as pale-yellow liquid. 1H NMR (400 MHz, CDCl3): 𝛿 2.40 (t, J = 5.2 Hz, 2H), 2.55 (s, 
3H), 2.69 (t, J = 6.0 Hz, 2H), 3.01 (m, 4H), 3.69 (br s, 1H), 5.55 (s, 1H), 7.06 (d, J = 7.8 
Hz, 1H), 7.22 (d, J = 7.8 Hz, 1H), 7.52 (t, J = 7.8 Hz, 1H). 13C NMR (400 MHz, CDCl3): 
𝛿 24.7, 32.0, 35.5, 46.9, 47.4, 86.0, 92.2, 103.7, 122.4, 124.1, 136.4, 143.1, 152.3, 159.0. 
HRMS (ESI) calculated for C14H17N2
+ [M+H]+ 212.1313; found m/z 213.1385. The 
experimental data is in agreement with the literature reported compound.22 
 
General procedure (A) for the synthesis of carboxamides 4.10, 4.47, 4.12, 4.24, 4.25. 
The carboxylic acid (1.3 eq.) was dissolved in DMF, then N,N-diisopropylethylamine 
(DIPEA) (3 eq.) was added and the reaction mixture stirred for 5 min. HATU (1.3 eq.) 
was added and the reaction mixture was stirred for 15 min. 4.44 (in a solution of DMF, 
1 eq.) was added dropwise and the reaction was stirred overnight. The mixture was 
concentrated in vacuo and then ethyl acetate and saturated aq. NaHCO3 were added. The 
aq. layer was washed 2 times with ethyl acetate and the pooled organic phases were 
















This procedure only reports the synthesis to make 4.10 described for Figure 4.13.    
Benzoic acid 4.45 (25 mg, 0.20 mmol), DMF (1 mL), DIPEA (80 mg, 0.62 mmol), 
HATU (79 mg, 0.20 mmol) and 4.44 (44 mg, 0.20 mmol) following column elution with 
n-hexane/ ethyl acetate (5:5) to give 4.10 (45 mg, 0.14 mmol, 90 %) as a pale-yellow 
liquid. 1H NMR (400 MHz, MeOD): 𝛿 2.28-2.84 (m, 4H, 11-H and 13-H), 2.50 (s, 3H, 
24-H), 3.49 (m, 2H, 10-H), 3.80 (m, 2H, 14-H), 5.70 (s, 1H, 15-H), 7.25 (m, 1H, 21-H), 
7.33 (m, 1H, 22-H), 7.42-7.52 (m, 5H, 4-H, 5-H, 6-H, 7-H, 8-H), 7.70 (m, 1H, 23-H). 
13C NMR (400 MHz, MeOD): 𝛿 23.6, 38.9 (2 equivalent carbons), 87.9, 92.2, 105.0, 
124.3, 125.7, 127.9 (2 equivalent carbons), 129.8 (2 equivalent carbons), 131.1 (2 
equivalent carbons), 137.0, 139.0, 143.3, 154.2, 159.9, 164.8, 172.7. HRMS (ESI) 
calculated for C21H21N2O








Benzoic acid 4.46 (138 mg, 1.00 mmol), DMF (5 mL), DIPEA (299 mg, 2.3 mmol), 
HATU (293 mg, 1.0 mmol) and 4.44 (164 mg, 0.63 mmol) following column elution 
with n-hexane/ ethyl acetate (5:5) to give 4.47 (188 mg, 0.57 mmol, 90 %) as a pale-
yellow liquid. 1H NMR (400 MHz, MeOD): 𝛿 2.20-2.76 (m, 4H), 2.56 (s, 3H), 3.21-3.86 
(m, 4H), 5.59 (s, 1H), 6.85 (d, J = 7.6 Hz, 1H), 6.93 (m, 2H), 7.13 (d, J = 7.6 Hz, 1H), 
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7.18-7.35 (m, 2H), 7.61 (t, J = 7.6 Hz, 1H), 9.70 (s, 1H). HRMS (ESI) calculated for 
C21H21N2O2
+ [M+H]+ 333.1598 and C21H20NaN2O2
+ [M+Na]+ 355.1417; found m/z 
333.1596 and 355.1402. 
 
General procedure (B) for the synthesis of 4.12, 4.49, 4.52, 4.63, 4.66, 4.77-4.83 
Starting material phenol (1 eq.) and K2CO3 (1.5 eq.) were added in the round bottom 
flask. DMF was added and the reaction mixture was stirred for 1 h. Methyl iodide (1.3 
eq), triflate 4.55 (4 eq.) or tosylate 4.61 (1.1 eq.) was then added drop-wise and the 
reaction mixture was stirred overnight. Water was added and the reaction mixture was 
extracted 3 times with ethyl acetate. The pooled organic solution was dried over MgSO4, 
filtered and concentrated. The residue was purified using flash column chromatography 
on silica gel 
 
2‐{3‐[1‐(3‐methoxybenzoyl)piperidin‐4‐ylidene]prop‐1‐ 




This reaction was carried out according to general procedure A. Compound 4.47 (100 
mg, 0.30 mmol), K2CO3 (62 mg, 0.45 mmol), DMF (5 mL) and methyl iodide (56 mg, 
0.39 mmol) following column elution with n-hexane/ ethyl acetate (5:5) to give 4.12 (94 
mg, 0.27 mmol, 90 %) as a pale-yellow liquid. 1H NMR (400 MHz, MeOD): 𝛿 2.30-2.84 
(m, 4H, 11-H and 13-H), 2.50 (s, 3H, 24-H), 3.50 (m, 2H, 10-H), 3.81 (m, 2H, 14-H), 
3.83 (s, 3H, 26-H), 5.70 (s, 1H, 15-H), 6.95-7.07 (m, 3H, 4-H, 5-H, 6-H), 7.17-7.42 (m, 
3H, 8-H, 21-H, 22-H), 7.67-7.72 (m, 1H, 23-H). 13C NMR (400 MHz, MeOD): 𝛿 23.8, 
32.3 (d), 35.8 (d), 38.9, 44.3 (d), 49.3 (d), 55.9, 87.4, 92.5, 105.0, 113.3, 116.7, 119.8, 
124.2, 125.6, 131.0, 138.2, 138.7, 143.6, 154.0, 161.3, 172.4. HRMS (ESI) calculated for 
C22H23N2O2











This reaction was carried out according to general procedure B. Compound 4.47 (123 
mg, 0.37 mmol), K2CO3 (77 mg, 0.56 mmol), DMF (5 mL), 4-bromo-1-butyne (64 mg, 
0.48 mmol) (up to 5 eq.) The reaction mixture was stirred and monitored after overnight 
to up to 3 days. However, quantitative amount of starting material was recovered.  
 
General procedure (C) for the synthesis of hydroxybenzoate 4.48, 4.51, 4.65 and 
4.76. 
The benzoic acid was dissolved in excess MeOH (50 mL for 1 g of benzoic acid). A few 
drops of H2SO4 were added and the reaction mixture was stirred and heated to reflux. 
Upon reaction completion, MeOH was removed in vacuo and saturated sodium 
bicarbonate solution was added. The aq. solution was extracted 3 times with ethyl acetate. 
The pooled organic solution was dried over MgSO4, filtered and concentrated to give 
desired carboxylic acid. 
 




This reaction was carried out according to general procedure C. 3-Hydroxybenzoic acid 
4.46 (1.3 g, 9.6 mmol) was used to give 4.48 (1.4 g, 9.3 mmol, 97 %) as a white solid. 1H 
NMR (400 MHz, MeOD): 𝛿 3.87 (s, 3H), 7.01 (ddd, J = 1.2, 2.8, 8.2 Hz, 1H), 7.27 (t, J 
= 8.2 Hz, 1H), 7.41 (m, 1H), 7.47 (m, 1H). The chemical shift for OH was not detected. 
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13C NMR (400 MHz, MeOD): 𝛿 52.6, 117.0, 121.2, 121.6, 130.6, 132.6, 158.8, 168.6. 
HRMS data not available because the MS was uncalibrated for low molecular weight 
compound. 
 




i) This reaction was carried out according to general procedure B. Compound 
4.48 (100 mg, 0.66 mmol), K2CO3 (136 mg, 0.99 mmol) (up to 5 eq.), DMF 
(5 mL) (or acetone), 4-bromo-1-butyne 4.47i (135 mg, 0.99 mmol) (up to 5 
eq.). However, quantitative amount of starting material was recovered while 
product 4.49 was not observed. 
ii) This reaction was again carried out according to general procedure B, 
however, replacing K2CO3 with Cs2CO3. Compound 4.48 (100 mg, 0.66 
mmol), Cs2CO3 (278 mg, 0.85 mmol), DMF (5 mL), 4-bromo-1-butyne 4.47i 
(118 mg, 0.86 mmol). However, quantitative amount of starting material was 
recovered while product 4.49 was not observed. 
iii) In a solution of 4.48 (100 mg, 0.66 mmol) in THF (5 mL) at 0˚C, NaH (182 
mg, 0.79 mmol) was added slowly under nitrogen. The reaction mixture was 
stirred at 0˚C for 30 mins. 4-Bromo-1-butyne 4.47i (135 mg, 0.99 mmol) was 
added drop-wise and the reaction was stirred while allowing the reaction 
mixture to warm to rt. A prominent spot on the baseline of TLC was observed 
and suspected to be the hydrolysed product of methyl ester 4.48. Product 4.49 












This reaction was carried out according to general procedure C. 3-Bromo-5-
hydroxybenzoic acid 4.50 (1.3 g, 5.3 mmol) was used to give 4.51 (1.1 g, 4.8 mmol, 91 
%) as a white solid. 1H NMR (400 MHz, MeOD): 𝛿 3.86 (s, 3H), 7.16 (dd, J = 1.8, 2.4 
Hz, 1H), 7.36 (t, J = 1.8, 2.4 Hz, 1H), 7.57 (t, J = 1.8 Hz, 1H). 13C NMR (400 MHz, 
MeOD): 𝛿 54.7, 117.5, 124.9, 125.4, 126.9, 134.5, 158.7, 168.1. HRMS data not 
available because the MS was uncalibrated for low molecular weight compound. 
 




This reaction was carried out according to general procedure B. 4.51 (500 mg, 2.2 mmol), 
K2CO3 (448 mg, 3.2 mmol), DMF (5 mL) and propargyl bromide (334 mg, 2.8 mmol) 
following column elution with n-hexane/ ethyl acetate (8:2) to give 4.52 (524 mg, 2.0 
mmol, 90 %) as a pale-yellow liquid. 1H NMR (400 MHz, CDCl3): 𝛿 2.56 (t, J = 2.6 Hz, 
1H), 3.92 (s, 3H), 4.73 (d, J = 2.6 Hz, 2H), 7.32 (dd, J = 2.6, 1.8 Hz, 1H), 7.57 (dd, J = 
2.6, 1.2 Hz, 1H), 7.81 (dd, J = 1.8, 1.2 Hz, 1H). 13C NMR (400 MHz, CDCl3): 𝛿 52.7, 
56.4, 76.6, 77.6, 114.6, 122.9, 123.3, 126.0, 132.9, 158.2, 165.7. HRMS data not 











To a solution of trifluoromethanoic anhydride 4.54 (2.2 mL, 12.9 mmol) (in 10 mL DCM) 
at 0 ˚C under nitrogen, butyn-1-ol 4.53 (900 mg, 12.9 mmol) and pyridine (1.1 mL, 13.5 
mmol) were added. The reaction mixture was stirred for 1 h before warming to rt. Water 
(30 mL) was added to quench the reaction and the reaction mixture was extracted 2 times 
with DCM (2 x 50 mL). The pooled organic solution was dried with MgSO4, filtered and 
concentrated at 300 mbar and rt to give 4.55 in a mass of 2.5 g. The crude 4.55 was used 
without further purification. 1H NMR (400 MHz, CDCl3): 2.11 (t, J = 2.4 Hz, 1H), 2.74 
(td, J = 6.8, 2.4 Hz, 2H), 4.58 (t, J = 6.8 Hz, 2H). 13C NMR (400 MHz, CDCl3): 20.2, 
71.9, 73.7, 77.0. HRMS data not available because the MS was uncalibrated for low 
molecular weight compound. 
 




This reaction was carried out according to general procedure B. 4.48 (0.11 g, 0.72 mmol), 
K2CO3 (0.15 g, 1.1 mmol), DMF (5 mL) and 4.55 (0.60 g, 3.0 mmol) following column 
elution with n-hexane/ ethyl acetate (7:3) to give 4.49 (82 mg, 0.40 mmol, 56 %) as a 
colorless liquid. 1H NMR (400 MHz, CDCl3): 𝛿 2.05 (t, J = 2.8 Hz, 1H), 2.70 (td, J = 
7.0, 2.8 Hz, 2H), 4.15 (t, J = 7.0 Hz, 2H), 7.12 (ddd, J = 8.0, 2.6, 1.0 Hz, 1H), 7.35 (t, J 
= 8.0, 1H), 7.57 (dd, J = 2.6, 1.0 Hz, 1H), 7.65 (ddd, J = 8.0, 1.6, 1.0 Hz, 1H). 13C NMR 
(400 MHz, CDCl3): 𝛿 19.7, 52.3, 66.3, 70.1, 80.4, 114.9, 120.2, 122.6, 129.6, 131.7, 
158.6, 167.0. HRMS data not available because the MS was uncalibrated for low 




General procedure (D) for the synthesis of alkoxybenzoic acid 4.56 and 4.64. The 
methyl benzoate was dissolved in 1 N NaOH (in MeOH) and the reaction solution was 
stirred for 1 h. Methanol was removed in-vacuo and a small amount of water was added. 
The mixture was acidified to pH 4 with 37 % HCl. The resulting precipitates was filtered, 
washed with water and air-dried. 
 




This reaction was carried out according to general procedure D. 4.49 (302 mg, 2.0 mmol) 
and 1 N NaOH (in MeOH) (5 mL) to give 4.56 (293 mg, 1.8 mmol, 89 %) as a white 
solid. 1H NMR (400 MHz, MeOD): 2.33 (t, J = 2.8 Hz, 1H), 2.67 (td, J = 6.4, 2.4 Hz, 
2H), 4.12 (t, J = 6.4 Hz, 2H), 7.16 (dd, J = 8.4, 2.8 Hz, 1H), 7.36 (t, J = 8.0 Hz, 1H), 7.55 
(dd, J = 1.2, 2.4 Hz, 1H), 7.60 (m, 1H). The chemical shift for OH was not detected. 13C 
NMR (400 MHz, MeOD): 𝛿 20.2, 67.6, 70.9, 81.3, 116.3 (t), 120.6, 123.4, 130.6, 133.4, 
160.1, 169.6. HRMS (ESI) calculated for C11H9O3








This reaction was carried out according to general procedure A. This experimental 
information refers to the synthesis of 4.24 in scheme 4.7. 4.56 (36 mg, 0.19 mmol), DMF 
(2 mL), DIPEA (56 mg, 0.43 mmol), HATU (72 mg, 0.19 mmol) and 4.44 (31 mg, 0.14 
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mmol) following column elution with n-hexane/ ethyl acetate (6:4) to give 4.24 in a mass 
of 48 mg as a pale-yellow liquid. 1H NMR (400 MHz, MeOD): 𝛿 2.25-2.81 (m, 4H, 11-
H and 13-H), 2.34 (m, 1H, 29-H), 2.48 (s, 3H, 24-H), 2.64 (m, 2H, 27-H), 3.39-3.86 (m, 
4H, 10-H and 14-H), 4.12 (t, J = 6.4 Hz, 2H, 26-H), 5.68 (br s, 1H, 15-H), 6.93-7.09 (m, 
3H, 4-H, 5-H, 6-H), 7.16-7.42 (m, 3H, 8-H, 21-H, 22-H), 7.61-7.74 (m, 1H, 23-H). 
HRMS (ESI) calculated for C25H25N2O2
+ [M+H]+ 385.1911; found m/z 385.1904. 






To a solution of 4-chloro-1-butanol 4.57 (1.4 g, 12.5 mmol) in DMF (20 mL), sodium 
azide (1.6 g, 25.1 mmol) was added and the reaction mixture was heated to 50 ˚C 
overnight. The reaction mixture was then cooled to rt and DMF was removed by rotary 
evaporation. Water (50 mL) was added and the mixture was extracted two times with 
ethyl acetate (2 x 50 mL). The pooled organic solution was washed with water (30 mL), 
brine (30 mL) and dried with MgSO4, filtered and concentrated at 160 mbar and 40˚C. 
The residue was purified using flash column chromatography on silica gel with n-hexane/ 
ethyl acetate (8:2) to give 4.58 (1.2 g, 10.3 mmol, 82 %) as a pale-yellow liquid. 1H NMR 
(400 MHz, CDCl3): 𝛿 1.59-1.74 (m, 4H), 3.32 (t, J = 6.4 Hz, 2H), 3.68 (t, J = 5.8 Hz, 
2H). The chemical shift of OH was not detected. 13C NMR (400 MHz, CDCl3): 𝛿 25.6, 
29.9, 51.4, 62.4. HRMS data not available because the MS was uncalibrated for low 
molecular weight compound. The experimental data is in agreement with the literature 















To a solution of trifluoromethanoic anhydride 4.54 ( 2.2 g, 7.7 mmol) (in 10 mL DCM) 
at 0 ˚C under nitrogen, 4.58 (884 mg, 7.7 mmol) and pyridine (638 mg, 8.1 mmol) were 
added. The reaction mixture was stirred for 1 h before warming to rt. Water (50 mL) was 
added to quench the reaction and the reaction mixture was extracted 2 times with DCM 
(2 x 50 mL). The pooled organic solution was dried with MgSO4, filtered and 
concentrated at 300 mbar and rt. However, product 4.59 was not observed. 
 




To a solution of 4.58 (1.2 g, 10.3 mmol), DMAP (63 mg, 0.52 mmol) and triethylamine 
(2.1 g, 20.6 mmol) in DCM (25 mL), a 4-toluenesulfonyl chloride 4.60 (3.9 g, 20.5 mmol) 
solution (in 20 mL DCM) was added drop-wise (over 1 h) and the solution was stirred 
overnight. The reaction mixture was then quenched using water (50 mL) and stirred for 
10 mins. The reaction mixture was extracted 2 times with DCM (2 x 50 mL). The pooled 
organic solution was washed with water (30 mL), dried over MgSO4, filtered and 
concentrated. The residue was purified using flash column chromatography on silica gel 
with n-hexane/ ethyl acetate (8:2) to give 4.61 (0.96 g, 3.6 mmol, 35 %) as a yellow 
liquid. 1H NMR (400 MHz, CDCl3): 𝛿 1.55-1.78 (m, 4H), 2.45 (s, 3H), 3.26 (t, J = 6.6 
Hz, 2H), 4.05 (t, J = 6.2 Hz, 2H), 7.35 (d, J = 8.2 Hz, 2H), 7.79 (d, J = 8.2 Hz, 2H). 13C 
NMR (400 MHz, CDCl3): 𝛿 22.0, 26.0, 26.3, 27.0, 51.1, 51.5, 70.3, 127.2, 130.4, 141.9, 
146.9. HRMS (ESI) calculated for C11H16N3O3
+ [M+H]+ 270.0907; found m/z 270.0709. 









This reaction was carried out according to general procedure C. 4-Hydroxybenzoic acid 
(1.5 g, 10.0 mmol), methanol (50 mL) to give 4.62 (1.5 g, 9.9 mmol, 99 %) as white 
crystals. 1H NMR (400 MHz, CDCl3): 𝛿 3.90 (s, 3H), 6.88 (d, J = 8.8 Hz, 2H), 7.96 (d, J 
= 8.8 Hz, 2H). The chemical shift for OH was not detected. 13C NMR (400 MHz, CDCl3): 
𝛿 52.2, 115.4 (2 equivalent carbons), 122.6, 132.1 (2 equivalent carbons), 160.2, 167.4. 
HRMS data not available because the MS was uncalibrated for low molecular weight 
compound. 
 




This reaction was carried out according to general procedure B. 4.62 (0.10 g, 0.72 mmol), 
K2CO3 (0.15 g, 1.1 mmol), DMF (5 mL) and 4.61 (0.23 g, 0.85 mmol) following column 
elution with n-hexane/ ethyl acetate (9:1) to give 4.63 (0.16 g, 0.64 mmol, 98 %) as a 
















This reaction was carried out according to general procedure D. 4.63 (160 mg, 0.64 
mmol) and 1 N NaOH (in MeOH) (5 mL) to give 4.64 (95 mg, 0.40 mmol, 63 %) as a 
white solid. 1H NMR (400 MHz, MeOD): 1.83 (m, 4H), 3.39 (t, J = 6.8 Hz, 2H), 4.08 (t, 
J = 6.0 Hz, 2H), 6.97 (d, J = 9.0 Hz, 2H), 7.96 (d, J = 9.0 Hz, 2H). The chemical shift for 
OH was not detected. 13C NMR (400 MHz, MeOD): 𝛿 26.7, 27.5, 52.2, 68.7, 115.2 (2 
equivalent carbons), 124.1, 132.8 (2 equivalent carbons), 164.4, 169.9. HRMS data not 
available because the MS was uncalibrated for low molecular weight compound. 
 
2‐(3‐{1‐[3‐(4‐azidobutoxy)benzoyl]piperidin‐4‐ 




This reaction was carried out according to general procedure A. 4.64 (31 mg, 0.13 mmol), 
DMF (2 mL), DIPEA (40 mg, 0.31 mmol), HATU (51 mg, 0.13 mmol) and 4.44 (22 mg, 
0.10 mmol) following column elution with n-hexane/ ethyl acetate (5:5) to give 4.25 (30 
mg, 0.070 mmol, 54 %) as a pale-yellow liquid. 1H NMR (400 MHz, MeOD: 𝛿 1.73-1.93 
(m, 4H), 2.43 (m, 2H), 2.50 (s, 3H), 2.72 (m, 2H), 3.39 (t, J = 6.6 Hz, 2H),  3.47-3.87 
(m, 4H), 4.07 (t, J = 6.0 Hz, 2H), 5.70 (s, 1H), 7.00 (d, J = 8.8 Hz, 2H), 7.23 (d, J = 7.6 
Hz, 1H), 7.31 (d, J = 8.0 Hz, 1H), 7.42 (d, J = 8.8 Hz, 2H), 7.68 (t, J = 8.0 Hz, 1H). 13C 
NMR (400 MHz, MeOD): 𝛿 23.7, 26.7, 27.6, 52.2, 68.6, 87.5, 92.5, 104.9, 115.5, 124.2, 









This reaction was carried out according to general procedure C. 3-Bromo-4-
hydroxybenzoic acid 4.75 (4.8 g, 22.1 mmol), methanol (50 mL) to give 4.65 (4.20 g, 
18.2 mmol, 82 %) as a white solid. 1H NMR (400 MHz, CDCl3): 𝛿 3.91 (s, 3H), 5.71 (s, 
1H), 7.48 (dd, J = 8.24, 1.8 Hz, 1H), 7.54 (d, J = 8.2 Hz, 1H), 7.68 (d, J = 1.8 Hz, 1H). 
The chemical shift for OH was not detected. 13C NMR (400 MHz, CDCl3): 𝛿 52.5, 115.7, 
117.2, 122.9, 131.5, 132.3, 152.5, 166.3. HRMS (ESI) calculated for C8H6BrO3
- [M-H]- 
228.9506; found m/z 228.9492. 
 




This reaction was carried out according to general procedure B. 4.65 (1.4 g, 6.2 mmol), 
K2CO3 (1.3 g, 9.3 mmol), DMF (25 mL) and methyl iodide (1.1 g, 8.1 mmol) following 
column elution with n-hexane/ ethyl acetate (9:1) to give 4.66 (1.41 mg, 5.8 mmol, 93 
%) as a white solid. 1H NMR (400 MHz, CDCl3): 3.89 (s, 3H), 3.96 (s, 3H), 6.92 (d, J = 
8.6 Hz, 1H), 7.98 (dd, J = 8.6, 2.2 Hz, 1H), 8.23 (d, J = 2.2 Hz, 1H). 13C NMR (400 MHz, 
CDCl3): 𝛿 52.3, 56.6, 111.2, 111.6, 123.9, 130.8, 135.0, 159.6, 165.9. HRMS data not 
available because the MS was uncalibrated for low molecular weight compound. 
 
General procedure (E) for the synthesis of fluorosulfonyl derivatives 4.67, 4.69, 4.73 
and 4.84. A round bottom flask was filled with bromobenzoate, DABSO, 
PdCl2(Amphos)2 and sealed with a rubber septum. The reaction flask was evacuated and 
filled with nitrogen (4 cycles). IPA (degassed) and triethylamine (degassed) were added 
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sequentially and the reaction mixture was stirred at 75 ˚C for 24 h. The reaction mixture 
was then cooled to rt. NFSI was added and the reaction mixture was concentrated in-
vacuo and ethyl acetate was added. The suspension was filtered through celite and the 
filtrate was washed with saturated solution of aq. Na2S2O3 and brine. The pooled organic 
layer was dried with MgSO4, filtered and concentrated in-vacuo. The residue was purified 
using flash column chromatography on silica gel. 
 




This reaction was carried out according to general procedure E. 4.66 (800 mg, 3.3 mmol), 
DABSO (470 mg, 2.0 mmol), IPA (25 mL), triethylamine (0.99 g, 9.8 mmol), 
PdCl2(Amphos)2 (115 mg, 0.16 mmol) and NFSI (1.5 g, 4.9 mmol) following column 
elution with n-hexane/ ethyl acetate (9:1) to give 4.67 (202 mg, 0.81 mmol, 25 %) as a 
yellow solid. 1H NMR (400 MHz, CDCl3): 3.82 (s, 3H), 3.88 (s, 3H), 6.99 (d, J = 8.8 Hz, 
1H), 7.92 (d, J = 2.2 Hz, 1H), 8.06 (dd, J = 8.8, 2.2 Hz, 1H). 13C NMR (400 MHz, CDCl3): 
𝛿 52.0, 56.0, 110.5, 122.5, 127.0, 131.4, 133.1, 161.0, 167.0. 19F NMR (400 MHz, 
CDCl3): 𝛿 58.65. HRMS data not available because the MS was uncalibrated for low 
molecular weight compound. 
 




This reaction was carried out according to general procedure E. 4-Iodoanisole 4.68 (130 
mg, 0.56 mmol), DABSO (80 mg, 0.33 mmol), IPA (3 mL), triethylamine (168 mg, 1.7 
mmol), PdCl2(Amphos)2 (20 mg, 0.028 mmol) and NFSI (525 mg, 1.7 mmol) following 
column elution with n-hexane/ ethyl acetate (8:2) to give 4.69 (36 mg, 0.19 mmol, 34 %) 
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as a yellow liquid. 1H NMR (400 MHz, CDCl3): 3.9 (s, 3H), 7.1 (d, J = 9.0 Hz, 2H), 7.9 
(d, J = 9.0 Hz, 2H). 19F NMR (400 MHz, CDCl3): 𝛿 67.22. HRMS data not available 







This reaction was carried out according to general procedure A. 3-Bromo-4-
hydroxybenzoic acid 4.75 (540 mg, 2.5 mmol), DMF (5 mL), DIPEA (743 mg, 5.8 
mmol), HATU (947 mg, 2.5 mmol) and 4.44 (317 mg, 1.5 mmol) following column 
elution with n-hexane/ ethyl acetate (5:5) to give 4.70 (247 mg, 0.60 mmol, 40 %) as a 
pale-yellow liquid. 1H NMR (400 MHz, MeOD): 𝛿 2.43 (m, 2H), 2.50 (s, 3H), 2.72 (m, 
2H), 3.67 (m, 4H), 5.70 (s, 1H), 6.96 (d, J = 8.4 Hz, 1H), 7.23 (d, J = 7.6 Hz, 1H), 7.28-
7.34 (m, 2H), 7.62 (d, J = 2.4 Hz, 1H), 7.69 (t, J = 7.6 Hz, 1H). The chemical shift for 
OH was not detected. HRMS (ESI) calculated for C21H20BrN2O2
+ [M+H]+ 411.0703; 







This reaction was carried out according to general procedure B. 4.70 (34 mg, 0.10 mmol), 
K2CO3 (21 mg, 0.15 mmol), DMF (5 mL) and methyl iodide (21 mg, 0.15 mmol) 
following column elution with 100 % ethyl acetate to give 4.71 (18 mg, 0.050 mmol, 50 
%) as a pale-yellow liquid. 1H NMR (400 MHz, MeOD): 𝛿 2.49 (m, 2H), 2.72 (s, 3H), 
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2.75 (m, 2H), 3.70 (m, 4H), 5.83 (s, 3H), 6.96 (d, J = 8.4 Hz, 1H), 7.32 (dd, J = 2.2, 8.4 
Hz, 1H), 7.62 (d, J = 2.2 Hz, 1H), 7.70 (d, J = 8.0 Hz, 1H), 7.80 (d, J = 8.0 Hz, 1H), 8.27 
(t, J = 8.0 Hz, 1H). HRMS (ESI) calculated for C22H21BrN2O2
+ [M+H]+ 424.0786; found 
m/z 424.0795.    
 
Attempted synthesis of 4.28 
This reaction was carried out according to general procedure E. 4.71 (94 mg, 0.22 mmol), 
DABSO (32 mg, 0.13 mmol), PdCl2(Amphos)2 (8 mg, 0.011 mmol), IPA (2 mL), NEt3 
(65 mg, 0.64 mmol) and NFSI (105 mg, 0.33 mmol). The reaction was allowed to stirred 
up to 3 days. However, starting material 4.71 was recovered in quantitative amount. 
Product 4.28 was not observed. 
 




This reaction was carried out according to general procedure E. This reaction was carried 
out according to general procedure E. 4.72 (750 mg, 3.1 mmol), DABSO (441 mg, 1.8 
mmol), PdCl2(Amphos)2 (108 mg, 0.15 mmol), IPA (20 mL), NEt3 (928 mg, 9.2 mmol) 
and NFSI (1.4 g, 4.6 mmol) following column elution with n-hexane/ ethyl acetate (8:2) 
to give 4.73 (170 mg, 0.68 mmol, 22 %) as a pale-yellow liquid. 1H NMR (400 MHz, 
CDCl3): 3.95 (s, 3H), 3.98 (s, 3H), 7.65 (dd, J = 2.8, 1.6 Hz, 1H), 7.92 (m, 1H), 8.24 (m, 
1H). 13C NMR (400 MHz, CDCl3): 𝛿 53.1, 56.4, 117.6, 121.5, 122.2, 133.4, 134.7 (d), 
160.5, 164.8. 19F NMR (400 MHz, CDCl3): 𝛿 65.60. HRMS data not available because 












This reaction was carried out according to general procedure C. 3-Bromo-5-
hydroxybenzoic acid 4.50 (1.2 g, 5.3 mmol), methanol (50 mL) to give 4.51 (1.2 g, 5.1 
mmol, 96 %) as a white solid. 1H NMR (400 MHz, MeOD): 𝛿 3.89 (s, 3H), 4.86 (s, 1H), 
7.16 (dd, J = 2.4, 1.8 Hz, 1H), 7.36 (dd, J = 2.4, 1.8 Hz, 1H), 7.57 (t, J = 1.8 Hz, 1H). 
13C NMR (400 MHz, MeOD): 𝛿 52.8, 115.6, 123.0, 123.6, 125.0, 132.7, 156.8, 166.3. 
HRMS data not available because the MS was uncalibrated for low molecular weight 
compound. 
 




This reaction was carried out according to general procedure C. 4-Bromo-3-
hydroxybenzoic acid 4.74 (1.5 g, 7.1 mmol), methanol (50 mL) to give 4.76 (1.6 g, 6.8 
mmol, 97 %) as white crystals. 1H NMR (400 MHz, CDCl3): 𝛿 3.89 (s, 3H), 5.95 (s, 1H), 
7.05 (d, J = 8.4 Hz, 1H), 7.92 (dd, J = 8.4, 2.0 Hz, 1H), 8.19 (d, J = 2.0 Hz, 1H). 13C 
NMR (400 MHz, CDCl3): 𝛿 52.4, 110.2, 115.9, 124.2, 131.2, 134.1, 156.3, 165.7. HRMS 













This reaction was carried out according to general procedure B. 4.76 (0.35 g, 1.5 mmol), 
K2CO3 (0.31 g, 2.2 mmol), DMF (5 mL) and methyl iodide (0.28 g, 1.9 mmol) following 
column elution with n-hexane/ ethyl acetate (9:1) to give 4.77 (0.31 g, 1.3 mmol, 83 %) 
as a white solid. 1H NMR (400 MHz, CDCl3): 𝛿 3.92 (s, 3H), 3.96 (s, 3H), 7.51 (dd, J = 
8.4, 1.8 Hz, 1H), 7.55 (d, J = 1.8 Hz, 1H), 7.61 (d, J = 8.4 Hz, 1H). 13C NMR (400 MHz, 
CDCl3): 𝛿 52.5 (d), 56.5 (d), 112.6 (t), 117.6, 123.0, 130.7, 133.5, 156.1, 166.6. HRMS 
data not available because the MS was uncalibrated for low molecular weight compound. 
 




This reaction was carried out according to general procedure B. 4.76 (150 mg, 0.65 
mmol), K2CO3 (134 mg, 0.97 mmol), DMF (5 mL) and 4.59 (227 mg, 0.84 mmol) 
following column elution with n-hexane/ ethyl acetate (9:1) to give 4.78 (191 mg, 0.58 
mmol, 89 %) as a pale-yellow liquid. 1H NMR (400 MHz, CDCl3): 1.80-2.00 (m, 4H), 
3.41 (t, J = 6.8 Hz, 2H), 3.91 (s, 3H), 4.12 (t, J = 5.6 Hz, 2H), 7.49 (m, 1H), 7.52 (m, 
1H), 7.61 (d, J = 8 Hz, 1H). 13C NMR (400 MHz, CDCl3): 𝛿 25.5, 26.4, 51.3, 52.5, 68.7, 
113.6, 118.1, 123.1, 130.6, 133.5, 155.3, 166.5. HRMS data not available because the 











This reaction was carried out according to general procedure B. 4.75 (320 mg, 1.4 mmol), 
K2CO3 (383 mg, 2.8 mmol), DMF (5 mL) and 4.55 (1.1 g, 5.4 mmol) following column 
elution with n-hexane/ ethyl acetate (9:1) to give 4.79 (326 mg, 1.2 mmol, 83 %) as a 
white solid. 1H NMR (400 MHz, CDCl3): 2.05 (t, J = 2.8 Hz, 1H), 2.69 (dt, J = 6.8, 2.4 
Hz, 2H), 4.12 (t, J = 4.12, 2H), 3.89 (s, 3H), 6.92 (d, J = 8.4 Hz, 1H), 7.98 (dd, J = 8.8, 
2.2 Hz, 1H), 8.23 (d, J = 2.2 Hz, 1H). 13C NMR (400 MHz, CDCl3): 19.6, 52.6, 66.6, 
70.3, 80.1, 114.2, 122.9, 123.1, 125.5, 132.9, 159.2, 165.7. HRMS data not available 
because the MS was uncalibrated for low molecular weight compound. 
 




This reaction was carried out according to general procedure B. 4.66 (200 mg, 0.87 
mmol), K2CO3 (179 mg, 1.30 mmol), DMF (5 mL) and 4.59 (303 mg, 1.1 mmol) 
following column elution with n-hexane/ ethyl acetate (9:1) to give 4.80 (284 mg, 0.86 
mmol, 99 %) as a pale-yellow liquid. 1H NMR (400 MHz, CDCl3): 1.80-2.01 (m, 4H), 
3.42 (t, J = 6.8 Hz, 2H), 3.89 (s, 3H), 4.12 (t, J = 5.6 Hz, 2H), 6.88 (d, J = 8.6 Hz, 1H), 
7.96 (dd, J = 8.6, 2.0 Hz, 1H), 8.23 (d, J = 2.0 Hz, 1H). 13C NMR (400 MHz, CDCl3): 
25.7, 26.2, 51.1, 52.1, 68.6, 111.8, 123.7, 127.0, 129.6, 130.5, 134.8, 165.7. HRMS data 










This reaction was carried out according to general procedure B. 4.51 (775 mg, 3.4 mmol), 
K2CO3 (695 mg, 5.0 mmol), DMF (10 mL) and methyl iodide (617 mg, 4.4 mmol) 
following column elution with n-hexane/ ethyl acetate (9:1) to give 4.81 (753 mg, 3.1 
mmol, 92 %) as a pale-yellow liquid. The NMR data was generated on the following 
product 4.82. HRMS data not available because the MS was not calibrated for low 
molecular weight compound. 
 




This reaction was carried out according to general procedure B. 4.51 (320 mg, 1.4 mmol), 
K2CO3 (383 mg, 2.8 mmol), DMF (5 mL) and 4.55 (1.1 g, 5.4 mmol) following column 
elution with n-hexane/ ethyl acetate (9:1) to give 4.82 (239 mg, 0.84 mmol, 60 %) as a 
pale-yellow liquid. 1H NMR (400 MHz, CDCl3): 2.05 (t, J = 2.8 Hz, 1H), 2.69 (m, 2H), 
3.91 (s, 3H), 4.12 (t, J = 6.8 Hz, 2H), 7.62 (dd, J = 2.0, 2.6 Hz, 1H), 7.50 (dd, J = 1.6, 
2.6 Hz, 1H), 7.78 (t, J = 2.0 Hz, 1H). 13C NMR (400 MHz, CDCl3): 𝛿 19.6, 52.6, 66.6, 
70.3, 80.1, 114.2, 122.9, 123.0, 125.5, 132.9, 159.2, 165.7. HRMS (ESI) calculated for 
C12H12BrO3












This reaction was carried out according to general procedure B. 4.51 (150 mg, 0.65 
mmol), K2CO3 (134 mg, 0.97 mmol), DMF (5 mL) and 4.59 (227 mg, 0.84 mmol) 
following column elution with n-hexane/ ethyl acetate (9:1) to give 4.83 (170 mg, 0.52 
mmol, 80 %) as a pale-yellow liquid. 1H NMR (400 MHz, CDCl3): 1.74-1.94 (m, 4H), 
3.37 (t, J = 6.8 Hz, 2H), 3.92 (s, 3H), 4.02 (t, J = 6.0 Hz, 2H), 7.23 (t, J = 2.4 Hz, 1H), 
7.48 (dd, J = 2.4, 1.6 Hz, 1H), 7.58 (t, J = 1.6 Hz, 1H). 13C NMR (400 MHz, CDCl3): 𝛿 
25.8, 26.5, 51.2, 52.6, 68.0, 114.1, 122.8, 122.9, 125.1, 132.9, 159.7, 165.8. HRMS data 
not available because the MS was uncalibrated for low molecular weight compound. 
 




This reaction was carried out according to general procedure E. 4.77 (1.5 g, 6.6 mmol), 
DABSO (0.95 g, 4.0 mmol), IPA (45 mL), triethylamine (2.0 g, 19.8 mmol), 
PdCl2(Amphos)2 (233 mg, 0.33 mmol) and NFSI (3.1 g, 9.9 mmol) following column 
elution with n-hexane/ ethyl acetate (8:2) to give 4.84 (0.68 g, 2.7 mmol, 42 %) as a 
yellow solid. 1H NMR (400 MHz, CDCl3): 3.83 (s, 3H), 3.94 (s, 3H), 7.30 (d, J = 7.8 Hz, 
1H), 7.64 (d, J = 1.6 Hz, 1H), 7.70 (dd, J = 7.8, 1.6 Hz, 1H). 13C NMR (400 MHz, CDCl3): 
𝛿 52.4 (d), 56.0 (d), 112.0 (d), 121.9, 131.0, 131.3, 131.9, 157.0, 167.1. 19F NMR (400 
MHz, CDCl3): 𝛿 58.57. HRMS data not available because the MS was uncalibrated for 









This reaction was carried out according to general procedure E. 4.77 (800 mg, 3.3 mmol), 
DABSO (470 mg, 2.0 mmol), IPA (25 mL), triethylamine (987 mg, 9.8 mmol), 
PdCl2(Amphos)2 (115 mg, 0.16 mmol) and NFSI (1.5 g, 4.9 mmol) following column 
elution with n-hexane/ ethyl acetate (8:2) to give 4.84 (202 g, 0.81 mmol, 25 %) as a 
yellow solid. 1H NMR (400 MHz, CDCl3): 3.82 (s, 3H), 3.88 (s, 3H), 6.98 (d, J = 8.8 Hz, 
1H), 7.92 (d, J = 2.4 Hz, 1H), 8.06 (dd, J = 2.2, 8.8 Hz, 1H). 13C NMR (400 MHz, CDCl3): 
𝛿 52.0, 56.0, 110.5, 122.5, 127.0, 131.4, 133.1, 161.0, 167.0. HRMS data not available 
because the MS was uncalibrated for low molecular weight compound. 
 




To a solution of 4.76 (300 mg, 1.3 mmol) in DCM (5 mL), imidazole (177 mg, 2.6 mmol) 
and tetra-butyl-dimethyl silyl chloride (TBDMSCl) (215 mg, 1.4 mmol) were added 
sequentially and the reaction was stirred for 4 h. Brine (30 mL) was poured into the 
reaction mixture and the organic layer was extracted 2 times with ethyl acetate (2 x 30 
mL). The pooled organic solution was dried with MgSO4, filtered and concentrated. The 
residue was purified using flash column chromatography on silica gel with n-hexane/ 
ethyl acetate (9:1) to give 4.91 (425 mg, 1.2 mmol, 95 %) as white crystals. 1H NMR 
(400 MHz, CDCl3): 𝛿 0.28 (s, 6H), 1.05 (s, 9H), 3.90 (s, 3H), 7.49 (m, 2H), 7.59 (d, J = 
8.4 Hz, 1H). 13C NMR (400 MHz, CDCl3): 𝛿 4.1 (3 equivalent carbons), 18.5 (2 
equivalent carbons), 25.8, 52.5, 120.9, 121.4, 123.4, 130.6, 133.6, 152.9, 166.5. HRMS 
data not available because the MS was uncalibrated for low molecular weight compound. 
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Attempted synthesis of 4.92 
This reaction was carried out according to general procedure E. 4.91 (1.5 g, 6.6 mmol), 
DABSO (0.95 g, 4.0 mmol), IPA (45 mL), triethylamine (2.0 g, 19.8 mmol), 
PdCl2(Amphos)2 (233 mg, 0.33 mmol) and NFSI (3.1 g, 9.9 mmol). However, starting 
material remain unchanged after the first step of reaction and product 4.92 was not 
observed after NFSI was added on the second step. 
 
General procedure (F) for the synthesis of fluorosulfonylbenzoic acids 4.93, 4.94 and 
4.95 
The fluorosulfonylbenzoate starting material (1 eq.) was dissolved in dichloroethane 
(DCE) (5 mL for 100 mg of fluorosulfonylbenzoate starting material). Trimethyltin 
hydroxide (8 eq.) was added and the reaction mixture was stirred at 80 ˚C overnight. The 
reaction mixture was cooled to rt and 1 M aq. HCl was added to the mixture. The solution 
was extracted 3 times with ethyl acetate and the pooled organic solutions was dried over 
MgSO4, filtered and concentrated. The residue was purified using flash column 
chromatography on silica gel to give product 4.92, 4.94 and 4.95. 
 




This reaction was carried out according to general procedure F. 4.84 (100 mg, 0.40 
mmol), trimethyltin hydroxide (319 mg, 3.2 mmol) and DCE (5 mL) following column 
elution with DCM/ MeOH (9.5:0.5) to give 4.93 (93 mg, 0.40 mmol, 99 %) as an off-
white solid. 1H NMR (400 MHz, MeOD): 3.78 (d, J = 2.0 Hz, 3H), 7.24 (m, 1H), 7.61-
7.68 (m, 2H). The chemical shift for OH was not detected. 19F NMR (400 MHz, MeOD): 











This reaction was carried out according to general procedure F. 4.85 (110 mg, 0.44 
mmol), trimethyltin hydroxide (644 mg, 3.5 mmol) and DCE (5 mL) following column 
elution with DCM/ MeOH (9.5:0.5) to give 4.94 (101 mg, 0.43 mmol, 98 %) as a white 
solid. 1H NMR (400 MHz, MeOD): 3.82 (d, J = 1.6 Hz, 3H), 7.13 (dd, J = 8.4, 2.8 Hz, 
1H), 7.80 (m, 1H), 8.04 (m, 1H). The chemical shift of OH was not detected. 13C NMR 
(400 MHz, MeOD): 𝛿 56.4 (d), 111.6, 111.7, 132.2, 132.3, 133.7, 134.1, 162.6. 19F NMR 
(400 MHz, MeOD): 𝛿 56.81. HRMS data not available because the MS was uncalibrated 
for low molecular weight compound. 
 




This reaction was carried out according to general procedure F. 4.73 (80 mg, 0.32 mmol), 
trimethyltin hydroxide (468 mg, 2.6 mmol) and DCE (5 mL) following column elution 
with DCM/ MeOH (9.5:0.5) to give 4.95 (74 mg, 0.32 mmol, 99 %) as an off-white solid. 
1H NMR (400 MHz, MeOD): 3.97 (d, J = 3.6 Hz, 3H), 7.74 (m, 1H), 7.97 (m, 1H), 8.16 
(d, J = 1.6 Hz, 1H). The chemical shift of OH was not detected. 13C NMR (400 MHz, 
MeOD): 𝛿 20.48, 56.9 (d), 117.8, 118.3, 121.8, 123.2, 123.4, 162.6. 19F NMR (400 MHz, 
MeOD): 𝛿 63.50. HRMS data not available because the MS was uncalibrated for low 






Attempted synthesis of 4.26 
This reaction was carried out according to general procedure A. Benzoic acid 4.87 (94 
mg, 0.40 mmol), DMF (2 mL), DIPEA (119 mg, 0.92 mmol), HATU (152 mg, 0.40 
mmol) and 4.44 (66 mg, 0.31 mmol). However, product 4.26 was not observed. 
 
Attempted synthesis of 4.28 
This reaction was carried out according to general procedure A. Benzoic acid 4.88 (105 
mg, 0.45 mmol), DMF (2 mL), DIPEA (134 mg, 1.0 mmol), HATU (171 mg, 0.45 mmol) 
and 4.44 (73 mg, 0.35 mmol). However, product 4.28 was not observed. 
 
Attempted synthesis of 4.31 
This reaction was carried out according to general procedure A. Benzoic acid 4.89 (82 
mg, 0.35 mmol), DMF (2 mL), DIPEA (105 mg, 0.81 mmol), HATU (133 mg, 0.35 
mmol) and 4.44 (57 mg, 0.27 mmol). However, product 4.31 was not observed. 
 
4.4.3 Computational studies 
The crystal structures of mGluR5 (PDB ID: 4OO9) was downloaded from the Protein 
Data Bank.37 All three-dimensional structure created in this thesis were generated using 
Avogadro 1.2.038 and minimised using the universal force field (UFF). Ligand docking 
was carried out with GOLD 5.8.1 (CCDC Software)39 using ChemPLP scoring method 
with default settings. The docking process was centred on residues P655 (mGluR5 – PDB 
ID: 4OO9) with a distance extension of 10 Å. Non-covalent binding mode was used. The 
highest ranked pose at each receptor are presented. The docking results were visualised 
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Chapter 5 Executive Conclusions 
 
The aim of this PhD research was to develop high affinity and selective covalent, 
clickable chemical tools for the A1AR and mGluR5. Chapter 2 of this thesis described the 
synthesis and pharmacological evaluation of a library of A1AR ligands. Highlights of this 
chapter included the development of bifunctional ligands 2.24 and 2.27 (Figure 5.1), 
which consisted of a clickable linker (azidopropyl or propargyl linker) and the 
chemoreactive fluorosulfonylphenyl group. Both covalent clickable ligands 2.24 and 
2.27 demonstrated high affinity at hA1AR (pKi 8.17 ± 0.14 (6.7 nM) and 7.58 ± 0.11 
(26.1 nM), respectively) and showed irreversible binding at hA1AR. Molecular docking 
was carried out and suggested that additional hydrogen bond interactions shown by 2.24 
at hA1AR could be the reason for higher hA1AR affinity. However, both ligands 2.24 and 
2.27 were found to be not selective among the other adenosine receptor subtypes. Out of 
these two ligands, only ligand 2.24 displayed a successful in situ click reaction to a Cy5.5 
fluorophore. It was suggested that a longer linker than the clickable butyne linker of 2.27 




Figure 5.1. Highlighted covalent, clickable ligands 2.24, 2.27 and 3.6 developed in 
chapters 2 and 3. 
 
 In chapter 3, the modification of covalent clickable ligands 2.24 and 2.27 was 
carried out using different composition linkers and length. Out of the 6 covalent clickable 
A1AR analogues made in chapter 3, 3.6 (hA1AR pKi = 8.81 ± 0.24 (1.6 nM), Figure 5.1) 
containing a longer hexyne linker showed the most improved hA1AR affinity. Ligand 3.6 
also demonstrated the best hA1AR selectivity (18-fold, 9-fold and 11-fold against 
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hA2AAR, hA2BAR and hA3AR, respectively) among all A1AR ligands synthesised in 
chapters 2 and 3. It was shown that the extension from a propargyl linker to a hexyne 
linker resulted in a successful click reaction to the Cy5.5 fluorophore. Despite the 
improvement in hA1AR selectivity of 3.6 compared to other A1AR ligands synthesised 
in chapters 2 and 3, the selectivity profile could still be improved upon as many biological 
applications still require A1AR ligands with hA1AR selectivity of >100-fold. Despite this, 
ligand 3.6 will be useful in probing cells that have a high expression of A1AR while co-
expressing known low or no levels of A2AAR, A2BAR or A3AR.   
 Chapter 4 described the design and synthesis of covalent clickable mGluR5 
ligands. This chapter aimed to develop mGluR5 ligands consisting of a clickable linker 
(azidobutyl or butyne linker) and a chemoreactive fluorosulfonyl group. Out of the 14 
compounds designed, literature compounds (4.10 and 4.12, Figure 5.2), and clickable 
compounds, without the chemoreactive group compounds (4.24 and 4.25, Figure 5.2) 
were successfully synthesised and will be sent for pharmacological evaluation by 
collaborators at Monash University. The synthesis of the fluorosulfonyl chemoreactive 
group was successfully carried out for compounds 4.73, 4.84 and 4.85 while the synthesis 
of the fluorosulfonyl-containing biological test ligands 4.26-4.35 was unsuccessful. As 




















































































Aryl protons at 
C29,30,32 and 33.  
A quarternary carbon that is not correlated to any 
proton. Based on the relative intensity, it is C31 
because it is split by fluorine coupling. It has a 2J 





Appendix 4. HSQC of isolated 2.30; a) 0-9 ppm (1H NMR) and 0-170 ppm (13C NMR), b) 8.0-8.4ppm (1H NMR) and 123-135 ppm (13C NMR), 








to C23  
Color indication 
Blue = CH3 and CH 
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Appendix 5. The 13C NMR spectrum of isolated 2.30.
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5UEN_A     SISAFQAAYIGIEVLIALVSVPGNVLVIWAVKVNQALRDATFCFIVSLAVADVAVGA 
P0DMS8     ALSLANVTYITMEIFIGLCAIVGNVLVICVVKLNPSLQTTTFYFIVSLALADIAVGV 
            :*  :.:** :*::*.* :: ****** .**:* :*: :** ******:**:***. 
 
5UEN_A    
LVIPLAILINIGPQTYFHTCLMVACPVLILTQSSILALLAIAVDRYLRVKIPLRYKMVVTPRR 
P0DMS8    
LVMPLAIVVSLGITIHFYSCLFMTCLLLIFTHASIMSLLAIAVDRYLRVKLTVRYKRVTTHRR 
          **:****::.:*   :*::**:::* :**:*::**::*************:.:*** *.* 
** 
 
5UEN_A    
AAVAIAGCWILSFVVGLTPMFGWNNLSAVERAWAAAGSMGEPVIKCEFEKVISMEYMVYFNFF 
P0DMS8    IWLALGLCWLVSFLVGLTPMFGWNMKLTSEY------
HRNVTFLSCQFVSVMRMDYMVYFSFL 
            :*:. **::**:**********   : *         . ..:.*:* .*: 
*:*****.*: 
 
5UEN_A    VWVLPPLLLMVLIYLEVFYLIRKQL.../ 
P0DMS8    TWIFIPLVVMCAIYLDIFYIIRNKL.../  
          .*:: **::*  ***::**:**::*    
 
5UEN_A    ERARSTLQKELKIAKSLALILFLFALSWLPLHILNCITLFCPSCHKPSILTYIAIFLT 
P0DMS8    KETGAFYGREFKTAKSLFLVLFLFALSWLPLSIINCIIYF--NGEVPQLVLYMGILLS 
          :.: :   :*:* **** *:*********** *:***  *  . . *.:: *:.*:*: 
 
5UEN_A     HGNSAMNPIVYAFRIQKFRVTFLKIWNDHFRCQPLEVLF 
P0DMS8     HANSMMNPIVYAYKIKKFKETYLLILKACVVCHPSDSLD 
           *.** *******::*:**: *:* * :  . *:* : *  
 
Appendix 6. Sequence alignment from T-Coffee using the adenosine A1AR crystal 
structure (PDB ID: 5UEN) and the adenosine A3AR amino acid sequence (UniProt code: 
P0DMS8). * - conserved amino acids,: - conservative differences, . - semi-conservative 









Appendix 7. Design of synthetic route for clickable covalent ligands with clickable linker 
attached to the benzene sulfonyl fluoride moiety. Reagents and   conditions: i. TFA, 50˚C; 












Appendix 8. HSQC experiment of the degraded 4.10 following isolation with semipreparative HPLC. 
Color indication 
Blue = CH3 and CH 






Appendix 9. HSQC experiment of the degraded 4.12 following isolation with semipreparative HPLC. 
Color indication 
Blue = CH3 and CH 












































Appendix 15. HPLC chromatograms of 4.24, during semipreparative HPLC isolation process.   
 
10.903 min 



























Appendix 18. The analytical HPLC chromatogram of 4.25 at A) 15˚C and B) 40˚C.
A) 
B) 









Biological assays performed by PhD candidate Phuc Nguyen (Monash) 
Cell Culture and Membrane Preparation. Nontransfected HEK293 adherent (NT-
HEK293A) and nontransfected FlpIn Chinese hamster ovary (NT-FlpInCHO) cells were 
maintained in DMEM supplemented with 5% FBS and 16 mM HEPES. FlpInCHO cells 
stably transfected with the human A1, A2A, A2B, or A3 adenosine receptor (A1R-
FlpInCHO, A2AR-FlpInCHO, A2BR-FlpInCHO, or A3R-FlpInCHO, respectively) were 
grown in DMEM supplemented with 5% FBS, 16 mM HEPES, and hygromycin B (500 
μg/mL). All cells were maintained at 37 °C in a 5% CO2 humidified incubator, grown to 
confluence, and then seeded in 96-well culture plates at assay-specific densities. 
Membrane preparation was performed as previously described. The protein content was 
determined using a Pierce BCA protein assay kit according to the manufacturer’s 
instructions. 
 
cAMP Accumulation. The A1R-, A2AR-, A2BR-, and A3R-FlpInCHO cells were seeded 
into 96-well culture plates at a density of 30000 cells/well and incubated overnight at 37 
°C in a 5% CO2 incubator. The cAMP assays were performed as described previously. 
Ligand concentration−response curves were normalized to the baseline response (0%) 
mediated by 3 μM forskolin (A1R- and A3R-FlpInCHO) or buffer (A2AR- and A2BR-
FlpInCHO) and the maximal response (100%) mediated by buffer (A1R- and A3R-
FlpInCHO) or 3 μM forskolin (A2AR- and A2BR-FlpInCHO). [
3H]DPCPX Binding Assay 
Using A1R-FlpInCHO Membranes and Whole Cells. Radioligand binding experiments 
were performed in binding buffer [10 mM HEPES, 10 mM D-glucose, 145 mM NaCl, 5 
mM KCl, 1 mM MgSO4, 1.5 mM NaHCO3, 2 mM CaCl2, and 1 unit/ mL ADA (pH 7.4)]. 
Membrane homogenates of A1AR-FlpInCHO (15 μg) were incubated with different 
concentrations of competing ligands in the presence of approximately 1 nM [3H]DPCPX 
(precise concentrations in each experiment were determined by β-counting) for 4 h at 25 
°C. Incubation was terminated by rapid filtration through UniFilter-96 GF/C (Whatman) 
microplates using a Filtermate 96 harvester (Packard). Filter plates were washed three 
times with ice-cold 0.9% NaCl, dried overnight before the addition of MicroScint-O 
scintillation cocktail (40 μL/well), and allowed to stand for at least 1 h before 
radioactivity was determined by β-counting using a MicroBeta 2 LumiJET microplate 
counter (PerkinElmer). To assess the irreversible binding of selected clickable probes, 
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A1R-FlpInCHO cells were plated in 96-well poly-D-lysine isoplates at a density of 40000 
cells/well and incubated overnight at 37 °C in a 5% CO2 incubator. After removal of cell 
media, cells were incubated with increasing concentrations of competing ligands for 3 h 
in binding buffer, followed by extensive washing steps (6 × 20 min, total of 2 h) at room 
temperature. Cells were incubated with approximately 1 nM [3H]DPCPX (precise 
concentrations in each experiment were determined by β-counting) for 4 h at 4 °C. Upon 
removal of the radioligand, cells were washed five times with ice-cold phosphate 
buffered saline (PBS) (10 mM Na2HPO4, 1.8 mM KH2PO4, 137 mM NaCl, and 2.7 mM 
KCl) and dissolved in Ultima Gold scintillation liquid (100 μL/well). Isoplates were 
sealed and allowed to incubate for at least 1 h before radioactivity was determined by β-
counting using a MicroBeta 2 LumiJET microplate counter (PerkinElmer). For all 
radioligand binding experiments, nonspecific binding was assessed using 1 μM SLV320, 
a selective A1R antagonist. After subtraction of the nonspecific binding, competition 
binding data were normalized to radioligand binding values in the absence of competitors 
and fitted to the one-site competition binding equation in Prism 8.0 (GraphPad) to derive 
log Ki values. 
 
NanoBRET Binding Displacement Assay. Nontransfected HEK293A cells were 
transiently transfected with 3 μg of cDNA of N-terminal NanoLuc (Nluc)-tagged A3R 
using polyethylenimine (PEI) at a 4:1 ratio in 10 cm dishes. Twenty-four hours post-
transfection, cells were seeded into 96-well poly-D-lysine solid white bottom plates at a 
density of 40000 cells/well and incubated overnight at 37 °C in a 5% CO2 incubator in 
serum-free DMEM. On the day of the assay, 48 h post-transfection, cells were incubated 
with increasing concentrations of competing ligands for 3 h, prepared in a binding buffer. 
After ligand incubation, 5 nM CA200645 was added for 60 min at room temperature and 
then the NLuc substrate furimazine was added to a final concentration of 10 μM. 
Sequential emission measurements were taken using a PHERAStar Omega plate reader 
(BMG Labtech) using 460 nm (80 nm bandpass, donor NLuc emission) and 610 nm 
(longpass filter, fluorescent ligand emission) filters at 25 °C. Raw BRET ratios were 
calculated by dividing the 610 nm emission (acceptor) by the 460 nm emission (donor). 
To assess irreversible binding of selected clickable probes, 6 × 20 min (total of 2 h) 
extensive washing steps were added before the addition of a fluorescent antagonist and 
furimazine. In all NanoBRET binding experiments, nonspecific binding was assessed 
using 1 μM MRS1220, a selective A3R antagonist. After subtraction of the nonspecific 
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binding, competition binding data were normalized to total binding values in the presence 
of a vehicle and fitted to the one-site competition binding equation in Prism 8.0 
(GraphPad) yielding log Ki values.  
 
Whole Cell Affinity Labeling and SDS−PAGE. Nontransfected FlpInCHO cells and 
A1R-FlpInCHO cells were incubated with clickable probes at indicated concentrations 
(0.1, 1, and 10 μM) or a vehicle control (0.1% DMSO) in a binding buffer for 90 min. 
Cells were washed twice with PBS (10 min/wash, gentle shaking), lifted from the plate, 
and centrifuged (300g for 5 min at rt). Then, cell pellets were resuspended in a click 
chemistry conjugation reaction mixture for 1 h at rt with intermittent vortexing. The click 
reagents were added in the following sequence: 1 μM fluorescent Cy5.5 azide or Cy5.5 
alkyne (Lumiprobe), 1 mM ascorbic acid (made immediately prior to use), TBTA/tert-
butanol, and 1 mM CuSO4. Following click chemistry, unbound click reagents were 
washed off by centrifugation of the samples (300g for 5 min at rt) and resuspending the 
material in PBS once before resuspending the cells in a radioimmunoprecipitation assay 
(RIPA) lysis buffer (10 mM Tris, 2 mM EDTA, 20 mM β-glycerophosphate, 0.1% NP40, 
100 mM NaCl, and 12 mM sodium deoxycholate) for 10 min at 4 °C. Cell lysates were 
then centrifuged (16000g for 10 min at 4 °C), and the protein concentration of the 
supernatant was determined by the Pierce BCA protein assay. After normalization of the 
protein concentration, 4× SDS loading buffer was added and the protein material 
denatured for 30 min at 37 °C. Proteins were separated by SDS−PAGE on 10% 
polyacrylamide gels (200 V for 50 min at rt). In-gel fluorescence was detected using a 
Typhoon system (Amersham). Proteins were subsequently transferred to nitrocellulose 
membranes (20 V overnight at 4 °C), and membranes were blocked with Odyssey 
blocking buffer and incubated with the anti-V5 (1:2500, mouse monoclonal, Sigma) or 
anti-β-actin (1:2500, rabbit polyclonal, Abcam) antibody overnight at 4 °C. Thereafter, 
membranes were washed three times (20 min/wash) with PBS-T (PBS with 0.1% Tween 
20) and incubated with the donkey anti-mouse 488 (1:10000, Abcam) or donkey anti-
rabbit 488 (1:10000, Abcam) antibody for 2 h at rt. Following three washes with PBST, 
membranes were imaged using the Typhoon system (Amersham). The signal intensities 
of the Cy5.5 click tag and secondary antibodies were quantified using ImageStudio 
(LiCOR). The Cy5.5 fluorescence was normalized to the relative V5 level (for A1R-
FlpInCHO cells) or β-actin level (for nontransfected FlpIn CHO cells) in each sample. 
To assess nonspecific protein labeling, prior to the two-step labeling experiment, A1R-
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FlpInCHO cells were preincubated with 10 μM 2.38 or a vehicle control (0.1% DMSO) 
for 90 min, followed by labeling with either 1 or 10 μM clickable probes for an additional 
90 min. Samples were then subjected to the click chemistry procedure using the protocol 
described above.  
 
Data Analysis. Nonlinear regression curve fitting and statistical analyses were 
performed using Prism 8.0 (GraphPad Software Inc., San Diego, CA). To derive potency 
estimates, agonist concentration− response data were fitted to a three-parameter Hill 
equation as described previously.10 Radioligand inhibition binding data with 
competitive ligands were fitted to a one-site inhibition mass action curve. Resulting IC50 
values were converted to dissociation constants (Ki values) using the Cheng−Prusoff 
equation.38 To estimate antagonist affinity values, functional interaction studies between 
NECA and multiple concentrations of each antagonist in the cAMP assays were fitted to 
the competitive model as described previously.22 All results were expressed as means ± 
SEM. 
 
